

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Flurandrenolide		1524-88-5			
Flurazepam		17617-23-1			
flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro- Alpha-methyl- [CAS]	5104-49-4	US 3793457	Anti-inflammatory	
flurithromycin	Erythromycin, 8-fluoro-mono(ethyl butanedioate) (ester)- [CAS]	82730-23-2	EP 56291	Macrolide antibiotic	Infection, respiratory tract, lower
Fluogestone		2529-45-5			
Flurothyl		333-36-8			
Fluoxetine		406-90-6			
Fluspirilene		1841-19-6			
flutamide	Propanamide, 2-methyl-N-[4-nitro-3- (trifluoromethyl)phenyl]- [CAS]	13311-84-7	US 4329364	Anticancer, hormonal	
	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)- one, 10-chloro-11b-(2-fluorophenyl)- 2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS]	27060-91-9	US 3905956	Anxiolytic	
flutazolam	Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3- oxo-, S-(fluoromethyl) ester, (6Alpha, 11β, 16Alpha, 17Alpha)- [CAS]	80474-14-2 90566-53-3		Formulation, inhalable, solution	Asthma
fluticasone	2H-1,4-Benzodiazepin-2-one, 7-chloro-1- (cyclopropylmethyl)-5-(2-fluorophenyl)-1,3- dihydro- [CAS]	25967-29-7	GB 1253368	Anxiolytic	Psychosis, general
flutoprazepam	1H-Imidazole, 1-[(2-fluorophenyl)(4- fluorophenyl)phenylmethyl]- [CAS]	119006-77-8	EP 352352	Antifungal	Infection, dermatological
Flutropium Bromide		63516-07-4			
	6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1- (1-methylethyl)-1H-indol-2-yl]-3,5- dihydroxy-, monosodium salt, [R*, S*-(E)]- (±)- [CAS]	93957-55-2 93957-54-1	EP 114027	Hypolipaeamic/Antiatherosclerosis	Hypercholesterolaemia
fluvastatin	1-Pentanone, 5-methoxy-1-[4- (trifluoromethyl)phenyl]-O-(2- aminoethyl)oxime, (E)- [CAS]	54739-18-3 61718-82-9	GB 1535226	Antidepressant	Depression, general, Obsessive-compulsive disorder
fluvoxamine		59-30-3			
Folic Acid		58-05-9			
Folinic Acid		7554-65-6			
Fomepizole					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fomivoben	Benzamide, N-[3-chloro-2-[[methyl(2-(4-morpholinyl)-2-oxoethyl]amino)methyl]phenyl]- [CAS]	18053-31-1 24600-36-0	US 3661903	Respiratory stimulant	Eczema, general
Fomivirsen		144245-52-3			
Fomocaine		17692-39-6			
Fonazine		7456-24-8			
fondaparinux	Alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-6-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-Alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate) [CAS]	104993-28-4 114870-03-0		Anticoagulant	Thrombosis, venous
Formebolone		2454117			
formestane	Androst-4-ene-3,17-dione, 4-hydroxy- [CAS]	566-48-3	EP 346953	Anticancer, hormonal	Cancer, breast
Formocortol		2825-60-7			
formoterol	Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*, R*)-(+/-)- [CAS]	43229-80-7 73573-87-2	GB 1415256	Antiasthma	Asthma
fosamprenavir	Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonoxy)propyl)- C-((3S)-tetrahydro-3-furanyl ester, [CAS]	226700-81-8		Antiviral, anti-HIV	Infection, HIV/AIDS
foscarnet	Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt [CAS]	34156-56-4 4428-95-9 63585-09-1	US 4839445	Antiviral, other	Infection, cytomegalovirus
Fosfestrol		522-40-7			
fosfluconazole	2,4-difluoro-Alpha,Alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester)	194798-83-9		Antifungal	Infection, fungal, general
fosfomycin	Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)- [CAS]	23155-02-4 26016-98-8	GB 1223923	Antibiotic, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fosfomycin trometamol	Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)- [CAS]	78964-85-9	EP 27597	Antibiotic, other	Infection, urinary tract
Fosfosal	L-Proline, 4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphinyl]acetyl]-, (2Alpha,4Beta)- [CAS]	6064-83-1			
fosinopril	2,4-Imidazolidinedione, 5,5-diphenyl-3-[[phosphonoxy)methyl]- [CAS]	88889-14-9 98048-97-6	EP 63896	Antihypertensive, renin system	Hypertension, general
fosphenytoin	Phosphonic acid, [1-[[[2-chloroethyl]nitrosoamino]carbonyl]amino]ethyl]-, diethyl ester [CAS]	92134-98-0 93390-81-9	US 4260769	Antiepileptic	Epilepsy, generalized, tonic-clonic
fosfomustine		92118-27-9	EP 117959	Anticancer, alkylating	Cancer, melanoma
Frophenem		106560-14-9			
frovatriptan	1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)- [CAS]	158747-02-5	WO 9922730	Antimigraine	Migraine
Fructose		57-48-7			
Fructose-1,6-diphosphate		488-69-7			
FTC	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)- (4R)			Antiviral, anti-HIV	Infection, HIV/AIDS
FTY-720	1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride [CAS]	162359-56-0	WO 9408943	Immunosuppressant	Transplant rejection, general
fudosteine	Alanine, 3-((3-hydroxypropyl)thio)- [CAS]	13189-98-5	US 5047428	Antitussive	Cough
fulvestrant	Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[[[4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7Alpha,17Beta)- [CAS]	129453-61-8	EP 346014	Anticancer, hormonal	Cancer, breast
fumagiline	2,4,6,8-Decatetraenedioic acid, mono[5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, [3R-[3Alpha,4Alpha(2R*,3R*),5S,6S(all-E)]]- [CAS]	23110-15-8		Protozoacide	Infection, GI tract

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Fumagillin		23110-15-8			
Furaltadone		139-91-3			
Furazabol		1239-29-8			
Furazolidone		67-45-8			
Furazolum Chloride		5118-17-2			
Furonazide		3460-67-1			
furosemide	Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]- [CAS]	54-31-9		Formulation, modified-release, other	Hypertension, general
Fursultiamine		804-30-8			
Furtrethonium		7618-86-2			
Fusidic Acid		06/03/6990			
G1, YM BioSciences	1-(5-bromofur-2-yl)-2-bromo-2-nitroethene			Antifungal	Infection, gynaecological
G25			WO 9804252	Antimalarial	Infection, malaria
GABA-A Alpha5 inverse agonist, Mer			WO 0206285	Cognition enhancer	Alzheimer's disease
gabapentin	Cyclohexanecarboxylic acid, 1-(aminomethyl)- [CAS]	60142-96-3	US 4152326	Antiepileptic	Epilepsy, general
gabexate	Benzoic acid, 4-[[6-[(aminomethyl)amino]-1-oxohexyl]oxy]-, ethyl ester, monomethanesulfonate [CAS]	39492-01-8 56974-61-9	US 3751447	GI inflammatory/bowel disorders	Pancreatitis
gaboxadol	Isoxazolo[5,4-c]pyridin-3(2H)-one, 4,5,6,7-tetrahydro- [CAS]	64603-91-4	CA 1125288	Hypnotic/Sedative	Sleep disorder, general
Gadobenate		127000-20-8			
Dimeglumine					
Gadobutrol		138071-82-6			
Gadodiamide		131410-48-5			
Gadopentetic Acid		80529-93-7			
Gadoteridol		120066-54-8			
Gadoversetamide		131069-91-5			
Gadoxetic Acid		135326-11-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
galantamine	(4aS,6R,8aS)-6-Hydroxy-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4H-benzofuro[3a,3,2-e,f][2]benzazepine			Formulation, modified-release, other	Alzheimer's disease
Galanthamine		357-70-0			
galarubicin	β -Alanine, 2-[4-[(2,6-dideoxy-2-fluoro-Alpha-L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthaceny]-2-oxoethyl ester, [CAS]	140637-82-7 140637-86-1	EP 424899	Anticancer, antibiotic	Cancer, breast
Gallamine Triethiodide		65-29-2			
Gallic Acid		149-91-7			
gallium maltolate	4H-Pyran-4-one, 3-hydroxy-2-methyl-, gallium complex			Anticancer, other	Cancer, myeloma
gallium nitrate	Nitric acid, gallium salt [CAS]	13494-90-1	US 4529593	Osteoporosis treatment	Hypercalcaemia of malignancy
gallopamil	Benzenecetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4,5-trimethoxy-Alpha-(1-methylethyl)-[CAS]	16662-47-8	GB 1367677	Antianginal	Angina, general
γ-Aminobutyric Acid		56-12-2			
Ganaxolone		38398-32-2			
ganciclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-[CAS]	107910-75-8 82410-32-0	EP 49072	Antiviral, other	Infection, cytomegalovirus
ganirelix	[N-Ac-D-Nal,D-pCl-Phe,D-Pal,D-hArg(Et)2,hArg(Et)2,D-Ala]GnRH-[CAS]	124904-93-4	EP 312052	Releasing hormones	Infertility, female
ganstigmine	Carbamic acid, (2-ethylphenyl)-, (3aS,8aS)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester,	223585-99-7	EP 1023297	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
gantofiban	1-Piperazineacetic acid, 4-[[[(5R)-3-[4-[imino[(methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-ethyl]ester [CAS]	183547-57-1	EP 741133	Antithrombotic	Thrombosis, general
garenoxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isindol-5-yl]-1,4-dihydro-4-oxo-1,4-dihydro-2H-pyridine-2-sulfonate [CAS]	223652-82-2		Quinolone antibacterial	Infection, respiratory tract, lower
gamocestim	5-73-macrophage inflammatory protein 2Alpha (human gene gro2)- [CAS]	246861-96-1		Radio/chemoprotective	Chemotherapy-induced injury, bone marrow, neutropenia
gatifloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-, (+/-)- [CAS]	112811-59-3	EP 230295	Quinolone antibacterial	Infection, respiratory tract, general
Gefarnate		51-77-4			
gefitinib	4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy) [CAS]	184475-35-2	WO 9633980	Anticancer, other	Cancer, lung, non-small cell
gemcabene	6,6'-oxybis(2,2-dimethylhexanoate)	209789-08-2		Hypolipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
gemcitabine	Cytidine, 2'-deoxy-2', 2'-difluoro-, [CAS]	122111-03-9 95058-81-4	GB 2136425	Anticancer, antimetabolite	Cancer, pancreatic
gemeprost	Prosta-2,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, methyl ester, (2E,11Alpha,13E,15R)- [CAS]	64318-79-2	GB 1540427	Prostaglandin	
gemfibrozil	Pentanoic acid, 5-(2,5-dimethylphenoxyl)-2,2-dimethyl-, [CAS]	25812-30-0	US 3674836	Hypolipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
gemifloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxymino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, [CAS]	175463-14-6	US 5869670	Quinolone antibacterial	Infection, respiratory tract, general
gentamicin	Gentamicin [CAS]	1403-66-3		Formulation, implant	Infection, general
Gentian Violet		548-62-9			
Gentipicrin		20831-76-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Gentisic Acid		490-79-9			
Gepefrine		18840-47-6			
gepirone	2,6-Piperidinedione, 4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- [CAS]			Formulation, modified-release, other	Depression, general
gestodene	18,19-Dinorepregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha)- [CAS]	109852-02-0 60282-87-3	GB 1569135	Formulation, fixed-dose combinations	Contraceptive, female
gestodene + ethinyloest	18,19-Dinorepregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha) mixt with 19-Norepregna-1,3,5(10)-trien-20-yne-13,17-diol (17Alpha)			Formulation, modified-release, >24hr	Contraceptive, female
Gestonorone Caproate		1253-28-7			
Gestrinone		16320-04-0			
γ-Hydroxybutyrate		591-81-1			
gimatecan	(4S)-1-[(E)-(1,1-dimethylethoxy)imino]methyl-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione	292618-32-7		Anticancer, other	Cancer, brain
Giractide		24870-04-0			
Gitoxin		4562-36-1			
GL-406349	N,N'-Bis[2-[N-[2-(N2,N5-dimethyl-DL-lysylamino)-ethyl]carbamoyl]1H-indol-6-yl]-1H-indole-2,5-dicarboxamide			Antifungal	Infection, fungal, general
Glafenine		3820-67-5			
glatiramer	L-Glutamic acid, polymer with L-alanine, L-lysine and L-tyrosine, [CAS]	147245-92-9 28704-27-0	WO 5800808	Multiple sclerosis treatment	Multiple sclerosis, relapsing-remitting
Glibornuride		26944-48-9			
gliclazide	Benzenesulfonamide, N-[[[hexahydrocyclopenta[c]pyrrol-2(1H)-yl]amino]carbonyl]-4-methyl- [CAS]	21187-98-4	GB 1153982	Antidiabetic	Diabetes, Type II

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
glimepiride	1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[4-methyl(cyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo- [CAS]	93479-97-1	WO 9303724	Antidiabetic	Diabetes, Type II
γ-Linolenic Acid		506-26-3			
glipizide	Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	29094-61-9	US 3669966	Antidiabetic	
glitazone	Benzenesulfonamide, N-[[cyclohexylamino)carbonyl]-4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinoliny]ethyl]- [CAS]	33342-05-1	GB 1277847	Antidiabetic	Diabetes, general
glisolanide	3-Isoxazolecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	24477-37-0		Antidiabetic	Diabetes, general
Glisoxepid		25046-79-1			
Glucametacin		52443-21-7			
Glucoheptonic Acid		87-74-1			
Gluconic Acid		526-95-4			
glucosamine	D-Glucose, 2-amino-2-deoxy-, [CAS]	29031-19-4	DE 1953689	Antiarthritic, other	Arthritis, osteo
Glucosulfone		3416-24-8			
		554-18-7			
glufosfamide	β -D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate)- [CAS]	132682-98-5	DE 3835772	Anticancer, alkylating	Cancer, general
Glutamic Acid		56-86-0			
Glutaraldehyde		111-30-8			
Glutethimide		77-21-4			
Glyburide		10238-21-8			
Glybutthiazol(e)		535-65-9			
Glybuzole		1492-02-0			
Glycerol		56-81-5			
Glycocycamine		352-97-6			
Glycol Salicylate		87-28-5			
Glyconiazide		3691-74-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Glycopyrrolate		596-51-0			
Glyhexamide		451-71-8			
Glymidine		339-44-6			
Glypinamide		1228-19-9			
GMDP	N-acetylglucosaminyl-N-acetylmuramyl dipeptide			Anti-infective, other	Infection, general
Gold Sodium Thiomalate		12244-57-4			
Gold Sodium Thiosulfate		10233-88-2			
goserelin	Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-10-deglycinamide-, 2-(aminocarbonyl)hydrazide [CAS]	65807-02-5	US 4100274	Releasing hormones	Cancer, prostate
GPI-1485	L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester [CAS]	186452-09-5		Antiparkinsonian	Parkinson's disease
GPI-5693	2-(Phosphonomethyl)pentanedioic acid		US 5672592	Analgesic, other	Pain, neuropathic
<i>Graftskin</i>					
granisetron	1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, endo- [CAS]	107007-99-8 109889-09-0	EP 200444	Antiemetic	Chemotherapy-induced nausea and vomiting
Grepafloxacin		119914-60-2			
griseofulvin	Spiro[benzofuran-2(3H),1'-[2]cyclohexane]-3,4'-dione, 7-chloro-2',4,6-trimeth-oxy-6-methyl-, (1'S-trans)- [CAS]	126-07-8		Formulation, dermal, topical	Infection, dermatological
Guaiacol		90-05-1			
Guaiapate		852-42-6			
Guaiazulene		489-84-9			
Guaiifenesin		93-14-1			
guaimesal	4H-1,3-Benzodioxin-4-one, 2-(2-methoxyphenoxy)-2-methyl- [CAS]	81674-79-5	GB 2098201	Anti-inflammatory	
Guamecycline		16545-11-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Guanabenz		5051-62-7			
Guanadrel		40580-59-4			
Guanethidine		55-65-2			
Guanfacine		29110-47-2			
Guanoxabenz		24047-25-4			
Guanoxan		2165-19-7			
gugulipid	Pregna-4,17(20)-diene-3,16-dione [CAS]	95975-55-6	EP 447706	Hypolipaeic/Antiatherosclerosis	
Gusperimus		104317-84-2			
GW-280430A	(Z)-2-Chlorofumaric acid 1-[3-{[6,7-dimethoxy-2(S)-methyl-1(R)-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium-2-yl]propyl}]			Muscle relaxant	Anaesthesia, adjunct
GW-320659	[2S,3S,5R]-2-[3,5-difluorophenyl]-3,5-dimethyl-2-morpholinol			Anorectic/Antiobesity	Obesity
GYKI-16084	(+)-R-2-[3-[N-(2-Benzof[1,4]dioxanylmethyl)amino]-1-propyl]-3(2H)-pyridazinone hydrochloride		US 6194411	Prostate disorders	Benign prostatic hyperplasia
Hachimycin		1394-02-1			
Halazepam		23092-17-3			
Halcinonide		3093-35-4			
halobetasol	Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6Alpha,11beta,16beta)- [CAS]	68852-54-8	US 4619921	Antipsoriasis	Psoriasis
halofantrine	9-Phenanthrenemethanol, 1,3-dichloro-Alpha-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)- [CAS]	36167-63-2 69756-53-2	EP 138374	Antimalarial	Infection, malaria
halometasone	Pregna-1,4-diene-3,20-dione, 2-chloro-6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6Alpha,11beta,16Alpha)- [CAS]	50629-82-8	US 4076737	Antipruritic/Inflamm, allergic	
Haloperidol		52-86-8			
Halopredone		57781-14-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Haloproglin		777-11-7			
Halopropane		679-84-5			
Halothane		151-67-7			
Haloxazolam		59128-97-1			
harkoseride	2(R)-Acetamido-N-benzyl-3-methoxypropionamide		WO 9733861	Antiepileptic	Epilepsy, general
HE-2000	16Alpha-Bromo-3β-hydroxy-5Alpha-androstane-17-one			Antiviral, anti-HIV	Infection, HIV/AIDS
Healos			WO 9714376	Musculoskeletal	Regeneration, bone
Hematoporphyrin		14459-29-1			
Hepronicate		7237-81-2			
Heptabarbital		509-86-4			
Heptaminol		372-66-7			
Hetacillin		3511-16-8			
Hetastarch		9004-62-0			
Hexachlorophene		70-30-4			
Hexadimethrine Bromide		28728-55-4			
Hexafluorenium Bromide		317-52-2			
Hexamethonium		60-26-4			
Hexamidine		3811-75-4			
Hexapropymate		358-52-1			
Hexedine		5980-31-4			
Hexestrol		84-16-2			
Hexestrol Bis(β-diethylaminoethyl ether)		2691-45-4			
Hexethal		144-00-3			
Hexetidine		141-94-6			
Hexobarbital		56-29-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Hexobendine		54-03-5			
Hexocyclium Methyl Sulfate		115-63-9			
Hexoprenaline		3215-70-1			
Hexfend	Hexfend [CAS]	235746-51-7	US 5407428	Plasma substitute	Surgery adjunct
Hexylcaine		532-76-3			
HF-0299	11b-hydroxy androstenedione			Osteoporosis treatment	Osteoporosis
HGP-2	Benzeneacetic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 2-tricyclo[3.3.1.1 ^{3,7} dec-1-yl]ethyl ester, (2Z)-2-butenedioate (1:1) [CAS]	121009-31-2		Antiglaucoma	Glaucoma
HGP-6 ^a	8-Azoniabicyclo[3.2.1]octane, 3-(3-ethoxy-1,3-dioxo-2-phenylpropoxy)-8,8-dimethyl-, (3-endo)-, methyl sulfate [CAS]	113932-41-5		Antiepileptic	Epilepsy, general
Hydrosmim	Hydrosmim- [CAS]	120250-44-4		Vasoprotective, systemic	
histamine	histamine	51-45-6	EP 0493468	Anticancer, immunological	Cancer, melanoma
Histapyrrodine		493-80-1			
histrelin	Luteinizing hormone-releasing factor (pig), 6-[1-(phenylmethyl)-D-histidine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	76712-82-8	EP 217659	Releasing hormones	Precocious puberty
HM-101	HM 101 [CAS]	217311-70-1		Osteoporosis treatment	Osteoporosis
HMN-214	(E)-4-[2-[2-(p-methoxybenzenesulfonamide)-phenyl]ethenyl]pyridine-1-oxide			Anticancer, other	Cancer, general
Homatropine		87-00-3			
Homocamfin		535-86-4			
Homochlorcyclizine		848-53-3			
Hopantenic Acid		18679-90-8			
HP-228	Glycinamide, N-acetyl-L-norleucyl-L-glutamyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tryptophyl- [CAS]	172617-89-9	EP 759770	Analgesic, other	Pain, post-operative

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Hyperzine A		102518-79-6			
hyaluronan	Hyaluronic acid [CAS]	9004-61-9		Formulation, other	Restenosis
Hycanthone		3105-97-3			
Hydnocarpic Acid		459-67-6			
Hydralazine		86-54-4			
Hydrastine		118-08-1			
Hydrastinine		6592-85-4			
Hydrochlorothiazide		58-93-5			
hydrocodone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5Alpha)- [CAS]	125-29-1			
Hydrocortamate		76-47-1		Formulation, modified-release, other	Pain, general
hydrocortisone	Pregn-4-ene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-(1-oxopropoxy)-, (11β)-[CAS]	74050-20-7	DE 2826257	Dermatological	Unspecified
hydrocortisone butyrate propio	Pregn-4-ene-3,20-dione, 11-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)-, (11β)-[CAS]	72590-77-3	DE 2910899	Antipruritic/inflam, allergic	
Hydroflumethiazide		135-09-1			
hydromorphone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5Alpha)-, mixt with acetamide, N-(4-hydroxyphenyl)-, mixt with morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5Alpha)-	103-90-2 16590-41-3 466-99-9			
Hydroquinidine		1435-55-8		Formulation, fixed-dose combinations	Pain, general
Hydroquinine		522-66-7			
Hydroquinone		123-31-9			
Hydroxocobalamin		13422-51-0			
Hydroxyamphetamine		1518-86-1			
Hydroxychloroquine		118-42-3			
Hydroxydione		53-10-1			
Hydroxypethidine		468-56-4			
Hydroxyphenamate		50-19-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Hydroxypropyl Cellulose		9004-64-2			
Hydroxystilbamidine		495-99-8			
Hydroxytetracaine		490-98-2			
Hydroxyzine		68-88-2			
<i>HyLan G-F 20</i>					
Hymecromone		90-33-5			
hyosciamine	benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1]oct-3-yl ester, [3(S)-endo],	101-31-5		Formulation, oral, orally-disintegrating	Ulcer, GI, general
hypericin	Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl- [CAS]	548-04-9		Anticancer, other	Cancer, brain
IACFT		180468-34-2			
ibandronic acid	Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene] bis- [CAS]	114084-78-5	EP 252504	Osteoporosis treatment	Hypercalcaemia of malignancy
ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1	GB 1551661	Cardiostimulant	Heart failure
ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1		Formulation, mucosal, topical	Surgery adjunct
Ibritumomab Tiuxetan		206181-63-7			
ibuprofen	Phosphonic acid, [[4-[[[4-bromo-2-cyanophenyl]amino]carbonyl]phenyl]methyl], -, diethyl ester [CAS]	133208-93-2	EP 402033	Hypolipaeic/Antiatherosclerosis	Hypertriglyceridaemia
ibudilast	1-Propanone, 2-methyl-1-[2-(1-methyl-1-ethyl-1,5-pyridin-3-yl)- [CAS]	50847-11-5	EP 215438	Antiasthma	Asthma
Ibufenac		1553-60-2			
ibuprofen piconol	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-pyridinylmethyl ester [CAS]	64622-45-3	DE 2658610	Antipruritic/inflam, non-allergic	Eczema, contact

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)- [CAS]	15687-27-1		Formulation, modified-release, other	Inflammation, general
Ibuproxam		53648-05-8			
Ibutilide	Methanesulfonamide, N-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl-, (+)-, [CAS]	122647-31-8 122647-32-9	JP 60239458	Antiarrhythmic	Fibrillation, atrial
ICA-17043			US 6288122	Antisickling	Anaemia, sickle cell
Icodextrin	Dextrin- [CAS]	9004-53-9		Urological	Renal failure
Idarubicin	5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)- [CAS]	58957-92-9 86189-66-4	US 4471052	Anticancer, antibiotic	Cancer, leukaemia, acute lymphocytic
Idazoxan		79944-58-4			
IdB-1016	2-(2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one phosphatidylcholine complex	134499-06-2	EP 209038	Anticancer, hormonal	Cancer, ovarian
Idobenone	2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl- [CAS]	58186-27-9	EP 58057	Neuroprotective	Ischaemia, cerebral
IDN-5109	4-Hexenoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (3aS,4R,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis(acetyloxy)-13-(benzoyloxy)-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-methanocyclodeca [2",3",5",6"] benzo[1,2:4,5] cyclodeca [1,2-d] dioxyl-4-yl ester, 2R,3S) [CAS]	186348-05-0	US 5264591	Anticancer, other	Cancer, colorectal
Idoxifene		116057-75-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
idaraparinux	Alpha-D-Glucopyranoside, methyl O-2,3,4-tri-O-methyl-6-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-β-D-glucopyranuronosyl-(1-4)-O-2,3,6-tri-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-Alpha-L-idopyranuronosyl-(1-4)-, tris(hydrogen sulfate) nonasodium salt [CAS]	149920-56-9	AU 698456	Antithrombotic	Thrombosis, venous
idroclamide	2-Propenamide, N-(2-hydroxyethyl)-3-phenyl- [CAS]	6961-46-2	US 3659014	Anti-inflammatory, topical	
ifenprodil	(7)-2-(4-benzyl piperidino)-1-p-hydroxyphenylpropanol tartrate	23210-58-4 23210-56-2	US 3509164	Neuroprotective	
ifostamide	2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrathio-2-oxide [CAS]	3778-73-2	US 3732340	Anticancer, alkylating	Cancer, lung, general
iguratimod	N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl] methanesulfonamide	123663-49-0	DE 3834204	Antiarthritic, other	Arthritis, rheumatoid
ilaprazole	1H-Benzimidazole, 2-((4-methoxy-3-methyl-2-pyridinyl) methyl)sulfinyl)-5-(1H-pyrrol-1-yl)- [CAS]	172152-36-2	US 5703097	Antiulcer	Ulcer, GI, general
ilomastat	Butanediamide, N4-hydroxy-N1-(1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (S-(R*, S*))-[CAS]	142880-36-2	US 5892112	COPD treatment	Emphysema, smoking-related
iloperidone	Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- [CAS]	133454-47-4	US 5776963	Neuroleptic	Schizophrenia
iloprost trometamol	Pentanoic acid, 5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]- [CAS]	78919-13-8	DE 3417638	Prostaglandin	Peripheral vascular disease
ILX23-7553	1Alpha,25-Hydroxy-16-yne vitamin D3			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
imatinib	4-((Methyl-1-piperazinyl)methyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate	152459-95-5	US 5521184	Anticancer, other	Cancer, leukaemia, chronic myelogenous
imidapril	4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3(R*(R*),4R*)]- [CAS]	89371-37-9 89396-94-1	EP 95163	Antihypertensive, renin system, Musculoskeletal	Hypertension, general, Cachexia
imidazole salicylate	Benzoic acid, 2-hydroxy-, compd. with 1H-imidazole (1:1) [CAS]	36364-49-5	US 4329340	Anti-inflammatory	Pain, general
imipenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1'-hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-, [5R,7R,4S,1S,2S,3S]- [CAS]	64221-86-9 74431-23-5 81129-83-1	GB 1570990	Beta-lactam antibiotic	Infection, general
Imipramine		50-49-7			
Imipramine N-Oxide		6829-98-7			
imiquimod	1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- [CAS]	99011-02-6	EP 145340	Antiviral, other	Infection, human papilloma virus
Imolamine		318-23-0			
implitapide	Benzeneacetamide, Alpha-cyclopentyl-4-((2,4-dimethyl-9H-pyrido(2,3-b)indol-9-yl)methyl)-N-((1R)-2-hydroxy-1-phenylethyl)- (AlphaS)- [CAS]	177469-96-4	EP 705831	Hypolipaeic/Antiatherosclerosis	Atherosclerosis
Improsulfan		13425-98-4			
Inaperisone		99323-21-4			
incadronate	Phosphonic acid, [(cycloheptylamino)methylene]bis-, [CAS]	138330-18-4		Musculoskeletal	Hypercalcaemia of malignancy
Incadronic Acid		124351-85-5			
Indalpine		63758-79-2			
Indanazoline		40507-78-6			
indapamide	4-chloro-N-(2-methylindolin-1-yl)-3-sulfamoylbenzamide	26807-65-8	GB 1203691	Antihypertensive, diuretic	Hypertension, general
Indecainide		74517-78-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
indoxazine	Morpholine, 2-[(1H-inden-7-yloxy)methyl]- [CAS]	60929-23-9 65043-22-3	JP 52083773	Cognition enhancer	Alzheimer's disease
Indeloxazine		65043-22-3			
		30190-87-5			
indanolol	2-Propanol, 1-[1H-inden-4(or 7)-yloxy]-3-[(1-methylethyl)amino]- [CAS]	60607-68-3 68906-88-7	GB 1290343	Antihypertensive, adrenergic	
	D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-{2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R*),2Alpha]], [CAS]	150378-17-9 157810-81-6	EP 0541168	Antiviral, anti-HIV	Infection, HIV/AIDS
indinavir					
	Acetamide, N-methyl-N-(3-(3-(2-thienylcarbonyl)pyrazolo(1,5-a) pyrimidin-7-yl)phenyl)- [CAS]	325715-02-4	US 6399621	Hypnotic/Sedative	Insomnia
indiplon					
	1H-Indazole-3-carboxamide, N-(3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, diendo- [CAS]	160472-97-9		Antiemetic	Nausea and vomiting, general
indiseron					
	1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- [CAS]	165668-41-7		Anticancer, other	Cancer, lung, non-small cell
indisulam					
Indobufen		63610-08-2			
Indocyanine Green		3599-32-4			
indometacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- [CAS]	53-86-1		Formulation, modified-release, other	Inflammation, general
Indoprofen		31842-01-0			
		26844-12-2			
indoramin	Benzamide, N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl]- [CAS]	38821-52-2	GB 1218570	Antihypertensive, adrenergic	
Inducterm			US 5993810	Labour inducer	Labour, induction
Infliximab		170277-31-3			
Inosine Pranobex		36703-88-5			
Inositol		87-89-8			
Inositol Niacinate		6556112			
Iobenguane		80663-95-2			
Iobenzamic Acid		3115057			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Iobitridol		136949-58-1			
Iocarmic Acid		10397-75-8			
Iocetamic Acid		16034-77-8			
Iodamide		440-58-4			
Iodine	Iodine [CAS]	7553-56-2		Formulation, oral, other	Fibrocystic breast disorder
Iodipamide		606-17-7			
Iodixanol		92339-11-2			
Iodoalphonic Acid		577-91-3			
Iodochlorhydroxyquin	5-Chloro-7-Iodo-8-quinolinol	130-26-7		Cognition enhancer	Alzheimer's disease
Iodoform		75-47-8			
Iodopyracet		300-37-8			
Iodopyrrole		87-58-1			
Iodoquinol		83-73-8			
Iofetamine ¹²³ I		75917-92-9			
Ioglycamic Acid		2618-25-9			
Iohexol		66108-95-0			
Iomeglamic Acid		25827-76-3			
Iomeprol		78649-41-9			
Iopamidol		60166-93-0			
Iopanoic Acid		96-83-3			
Iopentol		89797-00-2			
Iophendylate		99-79-6			
Iophenoxic Acid		96-84-4			
Iopromide		73334-07-3			
Iopronic Acid		41473-08-9			
Iopydol		5579-92-0			
Iopydone		5579-93-1			
Iothalamic Acid		2276-90-6			
Iotrolan		79770-24-4			
Ioversol		87771-40-2			
Ioxaglic Acid		59017-64-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
loxilan	(3R,4R)-(delta6)-THC-DMH-11-oic acid	107793-72-6	WO 9401429	Analgesic, other	Pain, neuropathic
IP-751					
Ipidacrine		62732-44-9			
	Stigmaster-15-one, 22,29-epoxy-3,4,6,7,29-pentahydroxy-, (3Alpha,4beta,5Alpha,6Alpha,7beta,14beta,22S)-[CAS]				
IPL-576092		137571-30-3	US 6046185	Antiasthma	Asthma
Ipodate		5587-89-3			
		66985-17-9			
ipratropium bromide		22254-24-6		Formulation, inhalable, solution	Chronic obstructive pulmonary disease
	(endo, syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azontabicyclo[3.2.1]octane				
ipratropium				Formulation, inhalable, topical	Asthma
	Hydrazinecarboxamide, 2-[1,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5H-indol-5-ylidene]- [CAS]	7248-21-7		Haemostatic	
iprazochrome					
ipriflavone	4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl- [CAS]	35212-22-7	EP 214647	Osteoporosis treatment	Osteoporosis
Iprindole		5560-72-5			
Iproclozide		3544-35-2			
Iproniazid		54-92-2			
Ipsapirone		95847-70-4			
	2-n-butyl-4-spirocyclopentane-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolyl-5-one				
irbesartan		138402-11-6	WO 9114679	Antihypertensive, renin system	Hypertension, general
	Butanedioic acid, mono[2-[2-(acetylthio)ethyl]-2,3-dihydro-4,6,7-trimethyl-5-benzofuranyl] ester, (+/-)-[CAS]				
IRFI-042		134867-62-2	US 5114966	Cardiovascular	Atherosclerosis
	N-Cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine				
IRFI-165		191349-26-5	EP 865442	Antidepressant	Depression, general
Iridomyrmecin		485-43-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
irindalone	-Imidazolidinone, 1-[2-[4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-piperazinyl]ethyl]-, (1R-trans)- [CAS]	104113-57-7 96478-43-2	EP 183349	Antidepressant	Depression, general
Irinotecan	Spiro[cyclopropane-1,5'-[5H]inden]-7'(6H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]	97682-44-5			
irofulven		125392-76-9	US 5563176	Anticancer, other	Cancer, prostate
Iron Sorbitex		1338-16-5			
irsogladine	1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- [CAS]	57381-26-7 57381-28-9 57381-33-6	US 4657907	Antihypertensive, diuretic	Hypertension, general
IS-741	Cyclohexanecarboxamide, N-[2-((ethylsulfonyl)amino)-5-(trifluoromethyl)-3-pyridinyl]- [CAS]	141283-87-6	EP 465913	GI inflammatory/bowel disorders	Pancreatitis
isaglitazone	2,4-Thiazolidinedione, 5-[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-[CAS]	161600-01-7	US 5594016	Antidiabetic	Diabetes, Type II
ISAtx-247			NZ 502362	Immunosuppressant	Transplant rejection, general
Isbogrel		89667-40-3			
isepamicin	D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]	58152-01-5 58152-03-7	US 4029882	Aminoglycoside antibiotic	Infection, dermatological
Isoaminile		77-51-0			
Isobutyl p-Aminobenzoate		94-14-4			
Isocarboxazid		59-63-2			
isiconazole	1-[2-(2,6-dichlorobenzoyloxy)-2-(2,4-dichlorophenyl)ethyl]	24168-96-5 27523-40-6	GB 1244530	Antifungal	Infection, fungal, general
Isoetharine		530-08-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
isofluroxypipin	1-Piperazineethanol, 4-[3-fluoro-10,11-dihydro-8-(1-methylethyl)dibenzo[b,f]thiopin-10-yl]-[CAS]	106819-39-0 106819-41-4 70931-18-9	GB 2010843	Neuroleptic	
isoflurane	Ethane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro- [CAS]	26675-46-7	US 3535388	Anaesthetic, inhalation	Anaesthesia
Isoflurophate		55-91-4			
Isoladol		530-34-7			
Isomethadone		466-40-0			
Isometheptene		503-01-5			
Isoniazid		54-85-3			
Isonixin		57021-61-1			
Isopromethazine		303-14-0			
Isopropamide Iodide		71-81-8			
Isopropyl Alcohol		67-63-0			
	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)-, 1-methylethylester, (1R-(1Alpha(Z), 2S,3Alpha,5Alpha))- [CAS]	120373-24-2	EP 289349	Prostaglandin	Glaucoma
Isoproterenol		7683-59-2			
Isosorbide		652-67-5			
isosorbide dinitrate	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, modified-release, other	Angina, general
isosorbide mononitrate	D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate [CAS]	16051-77-7		Formulation, modified-release, other	Angina, general
Isothipendyl		482-15-5			
isotretinoin	Retinoic acid, 13-cis- [CAS]	4759-48-2	US 4843096	Antiacne	Acne
Isovaleryl Diethylamide		533-32-4			
Isoxepac		55453-87-7			
Isoxicam		34552-84-6			
Isoxsuprine		395-28-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
isradipine	3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazan-1-yl)-4-dihydro-2,6-dimethyl-1-methyl ester [CAS]	75695-93-1	GB 2037766	Antihypertensive, other	Hypertension, general
israpafant	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-(4-(2-methylpropyl)phenyl)ethyl]-[CAS]	117279-73-9	EP 268242	Antiasthma	Asthma
ISV-403			US 5447926	Formulation, mucosal, topical	Conjunctivitis
Itasetron		123258-84-4			
ITF-282	ITF 282 [CAS]	93615-44-2	GB 2115821	Antianaemic	Anaemia, general
itopride	Benzamide, N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxy-, monohydrochloride [CAS]	122892-31-3	EP 306827	Gastroprokinetic	Gastritis
itraconazole	3H-1,2,4-Triazol-3-one, 4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-(1-methylpropyl)- [CAS]	84625-61-6	EP 6711	Antifungal	Infection, fungal, general
Ittramin		13445-63-1			
itriglumide	1-Naphthalenepropanoic acid, β-[2-[2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6-dimethylphenylamino]-2-oxoethyl]-, (8R)-[CAS]	201605-51-8	WO 9800404	Anxiolytic	Anxiety, general
itirelix	D-Alaninamide N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methyl-2-ethyl)-L-lysyl-L-prolyl- [CAS]	112568-12-4	WO 8901944	Fertility enhancer	Infertility, female
ivabradine	7,8-dimethoxy-3-[[[1S](4,5-dimethoxybenzocyclobutan-1-yl)methyl]methylamino]propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one			Antianginal	Angina, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ixabepilone	17-Oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethyl)- (1R,3S,7S,10R,11S,12S,16R) [CAS]	219989-84-1		Anticancer, other	Cancer, breast
J-104132	5H-Cyclopenta[b]pyridine-6-carboxylic acid, 5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2[(2S)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-, (5S,6R,7R)- [CAS]	198279-45-7	WO 9737665	Antihypertensive, other	Heart failure
J-107088	5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 12- β -D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-(2-hydroxy-1-(hydroxymethyl)ethyl)amino- [CAS]	174402-32-5		Anticancer, other	Cancer, bladder
J-113397	1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazole-2-one				
Janex-1	Phenol, 4-[[6,7-dimethoxy-4-quinazolinyl]amino]- [CAS]	202475-60-3		Analgesic, other	Pain, general
josamycin	Leucomycin V, 3-acetate 4B-(3-methylbutanoate) [CAS]	16846-24-5	JP 41021759	Anticancer, other	Cancer, leukaemia, general
JTV-519	1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]- [CAS]	145903-06-6		Macrolide antibiotic	Infection, general
K-777					
Kainic Acid					
Kalimate	Kalimate- [CAS]	487-79-6		Cardiovascular	Infarction, myocardial
Kallidin		92354-70-6	WO 9212148	Protozoacide	Infection, trypanosomiasis, American
KB-130015	Acetic acid (2,6-diodo-4-(2-methyl-3-benzofuranyl)methyl)phenoxy)- [CAS]	342-10-9	US 6287840		
		147030-48-6		Urological	
				Antiarhythmic	Arrhythmia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
KCB-328	Methanesulfonamide, N-[3-amino-4-[2-[(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl-, monohydrochloride [CAS]	177596-55-3	WO 9604231	Antiarrhythmic	Arrhythmia, general
Kebuzone		853-34-9			
ketamine	2-(2-Chlorophenyl)-2-(methylamino)-cyclohexanone hydrochloride	6740-88-1		Formulation, transmucosal, nasal	Pain, post-operative
ketanserin	2,4-(1H,3H)-Quinazolinodione, 3-[2-[4-(4-fluorobenzoyl)-1-piperidinylethyl]-[CAS]	74050-98-9 83846-83-7	EP 13612	Antihypertensive, other	Hypertension, general
ketazolam	4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- [CAS]	27223-35-4 27762-78-3 469-79-4	GB 1222294	Anxiolytic	
Kethoxal					
Ketobemidone					
ketokonazole	Piperazine, 1-acetyl-4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis- [CAS]	65277-42-1	US 4335125	Antifungal	Infection, fungal, general
ketoprofen	mono(3-benzoyl-Alpha-methylbenzeneacetate) [CAS]	173011-11-5	EP 502502	Formulation, transdermal, systemic	Pain, general
ketorolac	1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, (+/-) [CAS]	74103-06-3 74103-07-4	EP 53021	Analgesic, NSAID	
Ketorolac Tromethamine					
ketotifen	10-H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (E)-2-butenedioate (1:1) [CAS]	34580-13-7 34580-14-8	GB 1355539	Antiasthma	Asthma
Khellin		82-02-0			
kinetin		9001-29-0		Dermatological	Photodamage

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
KNI-272	4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[2-hydroxy-3-[[2-[[5-isoquinolinyloxy]acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl-, [4R-[3(2S*,3S*(R*),4R*)]-[CAS]	147318-81-8	US 5644028	Antiviral, anti-HIV	Infection, HIV/AIDS
KP-103	(R,R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)-2-butanol			Antifungal	Infection, general
KP-157			US 6110961	Antidepressant	Depression, general
KP-544			WO 9919305	Cognition enhancer	Unspecified
KRN-5500	L-glycero-β-L-manno-Heptopyranosylamine, 4-deoxy-4-[[[(2E,4E)-1-oxo-2,4-tetradecadienyl]amino]acetyl]amino]-N-1H-purin-6-yl- [CAS]	151276-95-8	WO 9015811	Anticancer, antibiotic	Cancer, colorectal
KT-136	Alpha-D-Glucopyranoside, β-D-fructofuranosyl, mixt. with 1-ethenyl-2-pyrrolidinone homopolymer compd. with iodine [CAS]	121602-88-8		Formulation, dermal, topical	Ulcer, decubitus
KUL-7211	(-)-2-[(2S)-1,2,3,4-tetrahydro-2-[[2(R)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]naphthalen-7-yloxy]-N,N-dimethylacetamide hydrochloride monohydrate			Urological	Urinary calculus
KW-2170	6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[2-(hydroxyethyl)amino]methyl]-, dihydrochloride [CAS]	207862-44-0		Anticancer, alkylating	Cancer, lung, non-small cell
KW-6002	1H-Purine-2,6-dione, 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl- (E)- [CAS]	155270-99-8		Antiparkinsonian	Parkinson's disease
KW-7158	3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(10-oxo-4,10-dihydrothienol[3,2-C[1]benzothiepin-9-yl)propanamide 5,5 dioxide			Urological	Incontinence

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
L-365260	Urea, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)-, (R)- [CAS]	118101-09-0	EP 284256	Anticancer, other	Cancer, general
L-5-hydroxytryptophan	L-Tryptophan, 5-hydroxy- [CAS]	4350-09-8		Metabolic and enzyme disorders	Unspecified
L-745337	Methanesulfonamide, N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]- [CAS]	158205-05-1	WO 9413635	Analgesic, NSAID	Pain, general
L-758298	Phosphonic acid, [3-[[[(2R,3S)-2-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- [CAS]	172673-20-0	WO 9523798	Antiemetic	Chemotherapy-induced nausea and vomiting
L-826141			WO 9722585	Antiasthma	Unspecified
labetalol	5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]salicylamide HCl	32780-64-6 36894-69-6	US 4012444	Antihypertensive, adrenergic	
lacidipine	3,5-Pyridinedicarboxylic acid, 4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-, diethyl ester, (E) [CAS]	103890-78-4	GB 2164336	Antihypertensive, other	Hypertension, general
<i>Lactic Acid</i>					
lactitol	D-Glucitol, 4-O-β-D-galactopyranosyl- [CAS]	585-86-4		Hepatoprotective	Infection, neurological
Lactulose		4618-18-2			
latitidine	Acetamide, 2-[[2-furanylmethyl]sulfinyl]-N-[4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxyl]-2-butenyl]-, (Z)- [CAS]	118288-08-7 169899-19-8	EP 282077	Antilulcer	Ulcer, gastric
Lamifiban		144412-49-7			
lamivudine	2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, (2R-cis)- [CAS]	134678-17-4	EP 513917	Antiviral, anti-HIV	Infection, HIV/AIDS
lamotrigine	1,2,4-Triazine-3,5-diamine, 6-[2,3-dichlorophenyl]- [CAS]	84057-84-1	EP 21121	Antiepileptic	Epilepsy, partial (focal, local)

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
landiolol	Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester, [S-(R*,R*)]- HCL	133242-30-5	EP 397031	Antiarrhythmic	Tachycardia, general
lanicemine	(S)-Alpha-phenyl-2-pyridine ethanamine dihydrochloride	153322-05-5		Neurological	Unspecified
laniquidar	Methyl 6,11-dihydro-1-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate	197509-46-9	WO 9734897	Radio/chemosensitizer	Cancer, general
lanoconazole	1H-imidazole-1-acetonitrile, Alpha-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-, (E)-(+)- [CAS]	101530-10-3	US 4738976	Antifungal	Infection, fungal, general
Lanoteplase		171870-23-8			
Lanreotide		108736-35-2			
lansoprazole	1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-[CAS]	103577-45-3	EP 174726	Antilucer	Ulcer, duodenal
lanthanum carbonate	Carbonic acid, lanthanum(3+) salt (3:2)[CAS]	587-26-8	US 5968976	Urological	Hyperphosphataemia
lapatinib	4-Quinazolinamine, N-[3-chloro-4-[(3-fluorobenzyl)methoxy phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]]	388082-78-8		Anticancer, other	Cancer, breast
laquinimod		248281-84-7		Multiple sclerosis treatment	Multiple sclerosis, general
lasofoxiene	2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-(5R-cis)-, (S-(R*, R*)))-2,3-dihydroxybutanedioate [CAS]	190791-29-8	WO 9716434	Menopausal disorders	Hormone replacement therapy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
latamoxef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo- [CAS]	64952-97-2 64953-12-4	GB 1547351	Beta-lactam antibiotic	Infection, general
latanoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1Alpha(Z),2S(R*),3Alpha,5Alpha))- [CAS]	130209-82-4	WO 9002553	Prostaglandin	Glaucoma
Lauroguadine		135-43-3			
Laurolinium Acetate		146-37-2			
Lawson		83-72-7			
LAX-111	1-(Z,Z,Z,Z,Z-eltosa-5,8,11,14,17-pentaenoxy)-3-(Z,Z,Z,Z,Z-eltosa-5,8,11,14,17-pentaenoxy)-propane			Neuroleptic	Schizophrenia
Lazabemide	Benzenecarboximidic acid, 4-[(2S)-3-(cyclopentylmethylamino)-2-[[2-naphthalenylsulfonyl]amino]-3-oxopropyl]-hydrazide [CAS]	103878-84-8			
LB-30057			WO 9749673	Antithrombotic	Thrombosis, venous
L-Cystine					
Lefetamine		7262-75-1			
leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	75706-12-6	EP 13376	Antiartifric, immunological	Arthritis, rheumatoid
leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	104881-93-3 75706-12-6	US 5610173	Anticancer, other	Cancer, ovarian
Leiopyrrole		5633-16-9			
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, [2S-[2Alpha,5Alpha,6S(S*)]]- [CAS]	80734-02-7 86273-18-9	EP 61206	Penicillin, oral	Infection, general
lenampicillin					
lentinan	Lentinan [CAS]	37339-90-5		Anticancer, immunological	Cancer, stomach

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<i>Lepirudin</i>					
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester, hydrochloride [CAS]	100427-26-7 132866-11-6	US 4705797	Antihypertensive, other	Hypertension, general
lercanidipine	1H-Benzimidazole, 1-(phenylmethyl)-2-(1-piperazinyl)- [CAS]	143257-98-1	US 5256665	Antiemetic	Nausea and vomiting, general
Lesopitron		132449-46-8			
	Benzoic acid, 4-((3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)-, monopotassium salt [CAS]	138117-50-7	US 6338963	Antiparkinsonian	Parkinson's disease
leteprinin	4-Thiazolidinecarboxylic acid, 2-[2-(2-ethoxy-2-oxoethyl)thio]ethyl- [CAS]	53943-88-7	US 4032534	COPD treatment	Bronchitis, chronic
letosteine	Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis- [CAS]	112809-51-5	EP 236940	Anticancer, hormonal	Cancer, breast
letrozole		480-17-1			
Leucocyanidin					
Leuprolide		53714-56-0			
	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-, monoacetate (salt) [CAS]	53714-56-0 74381-53-6		Formulation, implant	Cancer, prostate
leuprolide acetate					
	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	53714-56-0		Formulation, implant	Cancer, prostate
leuprorelin					
Levallorphan		152-02-3			
	Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]	14769-73-4 16595-80-5	US 4584305	Anthelmintic	Infection, helminth, general
levamisole					
Levcromakalim		94535-50-9			
	1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (S)- [CAS]	102767-28-2	EP 162036	Antiepileptic	Epilepsy, general
levetiracetam					
	2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-(methylethyl)amino) hydrochloride [CAS]	116209-55-3		Formulation, mucosal, topical	Glaucoma
levobetaxolol					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
levobunolol	1(2H)-Naphthalenone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, (S)- [CAS]	27912-14-7 47141-42-4	US 3641152	Formulation, mucosal, topical	Glaucoma
levobupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]	27262-47-1	WO 9510276	Anaesthetic, injectable	Anaesthesia
levocabastine	4-Piperidinecarboxylic acid, 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-, [3S-[1(cis),3Alpha,4β]]- [CAS]	79449-98-2 79516-68-0 79547-78-7	US 4369184	Antiallergic, non-asthma	Rhinitis, allergic, general
levocetirizine	Acetic acid, (2-(4-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy-, (R)- [CAS]	130018-77-8	WO 9406429	Antiallergic, non-asthma	Allergy, general
Levodopa		59-92-7			
levodropropizine	1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]	99291-25-5	EP 147847	Antitussive	Cough
levofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]	100986-85-4 138199-71-0	EP 206283	Quinolone antibacterial	Infection, respiratory tract, lower
Levomethadyl Acetate		1477-40-3			
levomoprolol	2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]	27058-84-0 5741-22-0 77164-20-6	EP 15418	Antihypertensive, adrenergic	
levonorgestrel	18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha)- [CAS]	797-63-7		Formulation, implant	Contraceptive, female
Levophacetoperane		24558-01-8			
Levopropoxyphene		2338-37-6			
Levorphanol		77-07-6			
levosimendan	Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)- [CAS]	131741-08-7 141505-33-1	EP 383449	Cardio stimulant	Heart failure
levosulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-, (S)- [CAS]	23672-07-3	GB 2014990	Antiemetic	Dyspepsia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Levothyroxine					
levovirin	1-β-L-ribofuranosyl-1,2,4-triazole-3-carboxamide			Antiviral, other	Infection, hepatitis-C virus
lexipafant	L-Leucine, N-methyl-N-[[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-, ethyl ester-[CAS]	139133-26-9	WO 9203423	Neurological	Dementia, AIDS-related
LF-15-0195			WO 9624579	Immunosuppressant	Lupus erythematosus, general
LF-16-0687	2-Pyrrolidinecarboxamide, N-[3-[[4-(aminoininomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[[[2,4-dimethyl-8-quinolinyl]oxy]methyl]phenyl]sulfonyl]-, (2S)- [CAS]	209733-45-9	FR 2756562	Neuroprotective	Head trauma
LGD-1550	2,4,6-Octatrienoic acid, 7-(3,5-bis(1,1-dimethylethyl)phenyl)-3-methyl-(2E,4E,6E)- [CAS]	178600-20-9		Anticancer, other	Cancer, cervical
LH		9002-67-9			
LH-RH		9034-40-6			
liarazole	1H-Benzimidazole, 5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- [CAS]	115575-11-6		Formulation, other	Psoriasis
licofelone	1H-Pyrrolizine-5-acetic acid, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl- [CAS]	156897-06-2		Antiarthritic, other	Arthritis, osteo
Licostinel		153504-81-5			
lidadronate	Phosphonic acid, [1-amino-3-(dimethylamino)propylidene]bis- [CAS]	63132-38-7	WO 9702827	Urological	Unspecified
Lidamide		66871-56-5			
lidocaine	Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- [CAS]	137-58-6		Formulation, transdermal, patch	Pain, post-herpetic
Lidofenin		59160-29-1			
Lidoflazine		3416-26-0			
limaprost	Prosta-2,13-dien-1-olic acid, 11,15-dihydroxy-17,20-dimethyl-9-oxo-(2E,11Alpha,13E,15S,17S)-, [CAS]	74397-12-9	GB 2041368	Prostaglandin	Buerger's syndrome

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Lincomycin		154-21-2			
Lindane		58-89-9			
linezolid	Acetamide, N-[(3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl]-, (S)- [CAS]	165800-03-3	WO 9507271	Antibiotic, other	Infection, dermatological
Linoleic Acid		60-33-3			
Linolenic Acid		463-40-1			
Liothyronine		6893023			
Lipase		9001-62-1			
Lipo-dexamethasone palmitate	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-[(1-oxohexadecyloxy)-, (11 β , 16 α)]- [CAS]	14899-36-6		Formulation, optimized, microemulsion	Arthritis, rheumatoid
lipo-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro- α -methyl-, 1-(acetyloxy)ethyl ester [CAS]	91503-79-6	JP 60208910	Formulation, optimized, microemulsion	Pain, cancer
Lipogel HA			EP 525655	Formulation, optimized, liposomes	Unspecified
LiquiVent	perfluorooctylbromide	423-55-2	US 5437272	Lung Surfactant	Respiratory distress syndrome, adult
liranasate	Carbamothioic acid, (6-methoxy-2-pyridinyl)methyl-, O-(5,6,7,8-tetrahydro-2-naphthalenyl) ester [CAS]	88678-31-3	GB 2124617	Antifungal	Infection, dermatological
lisinopril	L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, (S)- [CAS]	76547-98-3 83915-83-7	EP 12401	Antihypertensive, renin system	Hypertension, general
Lisofylline		100324-81-0			
lisuride	Urea, N'-[(8 α)-9,10-dihydro-6-methylergolin-8-yl]-N,N-diethyl-, [CAS]	19875-60-6 305-13-5 18016-80-3		Antiprolactin	Acromegaly
Lithium Citrate		919-16-4			
lithium	Carbonic acid, dilithium salt [CAS]	554-13-2		Formulation, modified-release, <=24hr	Depression, bipolar
lixivaptan	Benzamide, N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl- [CAS]	168079-32-1	US 5736540	Cardiovascular	Heart failure
LJP-1082			US 6207160	Immunosuppressant	Thrombosis, venous

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
LLUAlpha	S-2,7,8-Trimethyl-6-(β -carboxyethyl)-6-hydroxychroman			Antihypertensive, other	Hypertension, general
LMP-160			US 5643893	Antiasthma	Asthma
LMP-420			US 5643893	Antiarthritic, other	Arthritis, rheumatoid
lobaplatin	Platinum, (1,2-cyclobutanedimethanamine-N,N')[2-hydroxypropanoato(2-)-O1,O2]-, [SP-4-3-(S), (trans)]- [CAS]	135558-11-1	DE 4115559	Anticancer, alkylating	Cancer, lung, small cell
Lobeline		90-69-7			
Lobenzarlit		63329-53-3			
lodoxamide	2,2'-((2-chloro-5-cyano-1,3-phenylene)diimino)bis(2-oxoacetate); 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:2)	63610-09-3 53882-12-5	US 4439445	Antiasthma	Asthma
Lofentanil		61380-40-3			
lofepramine	Ethanone, 1-(4-chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]methylamino]- [CAS]	23047-25-8 26786-32-3	GB 1177525	Antidepressant	
lofexidine	1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- [CAS]	31036-80-3	GB 1181356	Antihypertensive, adrenergic	Hypertension, general
Loflucarban		790-69-2			
lomefloxacin	3-Quinolincarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- [CAS]	98079-51-7 98079-52-8	EP 140116	Quinolone antibacterial	Infection, respiratory tract, lower
lomerizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[[2,3,4-trimethoxyphenyl)methyl]-, [CAS]	101477-54-7 101477-55-8	EP 159566	Antimigraine	Migraine
lomifylline	7-(5-oxohexyl)theophylline	10226-54-7	DE 2207860	Neurological	
lomustine	Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso- [CAS]	13010-47-4	JP 48075526	Anticancer, alkylating	
lonafarnib	1-Piperidinecarboxamide, 4-[2-[4-[(1R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzof[5,6]cyclohepta[1,2-b]pyridin-1-yl]-1-piperidinyl]-2-oxoethyl]- [CAS]	193275-84-2	US 5874442	Anticancer, other	Cancer, lung, non-small cell

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Lonapalene		91431-42-4			
Lonazolac		53808-88-1			
lonidamine	1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]- [CAS]	50264-69-2	DE 2310031	Radio/chemosensitizer	Cancer, breast
loperamide	4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-1-piperidine butyramide HCl	34552-83-5 53179-11-6	US 3714159	Antidiarrhoeal	Diarrhoea, general
	1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-, 1-oxide, trans- [CAS]				
loperamide oxide		106900-12-3	EP 219898	Antidiarrhoeal	Diarrhoea, general
	1H-Imidazo[1,2-a][1,4]benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-[(4-methyl-1-piperazinyl)methylene]-8-nitro- [CAS]	61197-73-7 61197-93-1 70111-54-5	GB 1496426	Hypnotic/Sedative	
lornoxolam		106730-54-5			
Lopinone					
loracarbef	1-Azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, [6R-[6Alpha,7S(R*)]]- [CAS]	76470-66-1 121961-22-6	EP 14475	Cephalosporin, oral	Infection, respiratory tract, lower
Lorajmine		47562-08-3			
	1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-1H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester- [CAS]	79794-75-5	EP 42544	Antiallergic, non-asthma	Rhinitis, allergic, general
loratadine					
lorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-	846-49-1		Formulation, oral, orally-disintegrating	Epilepsy, general
	Benzeneacetamide, N-(4-chlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]-[CAS]	58934-46-6 59729-31-6	DE 2642856	Antiarrhythmic	
lorcainide					
	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl- [CAS]	848-75-9	US 3296249	Hypnotic/Sedative	Insomnia
lormetazepam					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
lornoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide- [CAS]	70374-39-9	EP 313935	Analgesic, NSAID	Pain, post-operative
losartan	1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[2-(1H-tetrazol-5-yl)](1,1'-biphenyl)-4-yl[methyl]-, [CAS]	124750-99-8 114798-26-4	EP 253310	Antihypertensive, renin system	Hypertension, general
loteprednol	Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyloxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11β, 17Alpha)- [CAS]	82034-46-6	GB 2079755	Anti-inflammatory, topical	Uveitis
Lotrafiban		171049-14-2			
Lovastatin		75330-75-5			
Loxapine		10/02/1977			
loxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (±)- [CAS]	107097-80-3	WO 8703869	GI inflammatory/bowel disorders	Pancreatitis
loxoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-oxocyclopentyl)methyl]- [CAS]	68767-14-6 80382-23-6 87828-36-2	EP 55588	Antiarthritic, other	Arthritis, rheumatoid
LU-35-138	1-[3-[2-[5-chloro-1-(4-fluorophenyl)-3-1H-indolyl]ethyl]methylamino]propyl]-2-imidazolidinone hydrochloride		WO 9516684	Neuroleptic	Psychosis, general
Lubeluzole		144665-07-6			
lubiprostone	(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid	136790-76-6		Laxative	Constipation
lucanthone	Thioxanthene-9-one, 1-[(2-(diethylamino)ethyl)amino-4-methyl- [CAS]	479-50-5		Radio/chemosensitizer	Cancer, brain
Lucanthone		548-57-2			
Lumefantrine		82186-77-4			
lumiracoxib	Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- [CAS]	220991-20-8		Analgesic, NSAID	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
lutetecan	11H-1,4-Dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[[4-methyl-1-piperazinyl]methyl]-, [CAS]	155773-58-3		Formulation, optimized, liposomes	Cancer, ovarian
lutetium texaphyrin	Lutetium, bis(acetato-O)[9,10-diethyl-20,21-bis-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6,16,13-dinitrilo-1,18-benzodiazacycloicosine-5,14-dipropanolato-N1,N18,N23,N24,N25]-, (PB 7-11-233'2'4)- [CAS]	156436-90-7	WO 9906411	Radio/chemosensitizer	Atherosclerosis
LV-216	Zinc[2-(2,6-dichloroanilino)phenyl]acetate			Anti-inflammatory	Arthritis, rheumatoid
LX-104	Hexadecanamide, N-[4-[2-[2-[2-[O-(N-acetyl- α -neuraminosyl)-(2-3)-O- β -D-galactopyranosyl-(1-4)-O-[β -deoxy- α -L-galactopyranosyl-(1-3)]- β -D-glucopyranosyl]oxy]ethoxy]ethoxy]ethoxy]methyl]phenyl]-2-tetradecyl- [CAS]	158792-45-1		Cognition enhancer	Dementia, senile, general
LY-156735	β -methyl-6-chloromelatonin		EP 655243	Hypnotic/Sedative	Sleep disorder, general
LY-293111	Benzoic acid, 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]- [CAS]	161172-51-6		Anticancer, other	Cancer, melanoma
LY-293558	3-Isoquinolinecarboxylic acid, decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-, [3S-(3 α ,4 α ,6 α ,8 α ,13 α)]-, [CAS]	154652-83-2		Analgesic, other	Pain, neuropathic
LY-355703	1,4-Dioxo-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrate, 10-[[3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2S,3R)-3-phenyloxiranylmethyl]-, (3S,10R,13E,16S)-[CAS]	18256-67-7	WO 9707798	Anticancer, other	Cancer, lung, non-small cell
Lyapolate		25053-27-4			
Lymecycline		992-21-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Lynestrenol		52-76-6			
Lypressin		50-57-7			
Lysine Acetylsalicylate		62952-06-1			
lysine salicylate	L-Lysine, 2-hydroxybenzoate [CAS]	59535-08-9	WO 9624331	Analgesic, NSAID	
lysophospholipids			WO 9843093	Diagnostic	Diagnosis, cancer
M-40403	Dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-1,7-nitrilo-7H-dibenzo[b,h] [1,4,7,10]tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22]manganese				
			US 6180620	Anticancer, other	Unspecified
mabuprofen	Benzeneacetamide, N-(2-hydroxyethyl)-Alpha-methyl-4-(2-methylpropyl)-, (+/-)-[CAS]	82821-47-4	DE 3121595	Anti-inflammatory	
Mabuterol		56341-08-3			
Macrophage Colony-Stimulating Factor		81627-83-0			
MADU		840-50-6			
mafenide	Benzenesulfonamide, 4-(aminomethyl)-monoacetate [CAS]	13009-99-9 138-39-6		Vulnerary	Burns
mafosfamide	Ethanesulfonic acid, 2-[[2-bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl]thio]-, P-oxide, cis-(+)- [CAS]	88859-04-5 98845-64-8	EP 393575	Anticancer, alkylating	Cancer, renal
magaldrate	Aluminum magnesium hydroxide sulfate (Al5Mg10(OH)31(SO4)2), hydrate [CAS]	74978-16-8	US 2923660	Antacid/Antiflatulent	
Magenta I		632-99-5			
Magnesium Acetylsalicylate		132-49-0			
Magnesium Carbonate Hydroxide		39409-82-0			
magnesium chloride	Magnesium chloride (MgCl2) [CAS]	7786-30-3		Formulation, oral, enteric-coated	Nutrition

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Magnesium Citrate		3344-18-1			
magnesium gluconate	D-Gluconic acid, magnesium salt (2:1) [CAS]	3632-91-5		Formulation, other	Hypertension, general
Magnesium Lactate		18917-93-6			
Magnesium Salicylate		18917-89-0			
Malathion		121-75-5			
Malotilate		59937-28-9			
Mandelic Acid		90-64-2			
Mandelic Acid Isoamyl Ester		5421045			
Mangafodipir		118248-94-5 (free acid); 155319-91-8 (hexahydrogen)			
manidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]	89226-50-6 89226-75-5	EP 94159	Antihypertensive, other	Hypertension, general
Mannomustine		551-74-6			
mannose-6-phosphate	mannose-6-phosphate			Vulnerary	Wound healing
Maprotiline		10262-69-8			
maribavir	1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-β-L-ribofuranosyl- [CAS]	176161-24-3		Antiviral, other	Infection, cytomegalovirus
marimastat	N-[2,2-Dimethyl-1(S)-(N-methylcarbamoyl)propyl]-N,3(S)-dihydroxy-2(R)-isobutylsuccinamide	154039-60-8	WO 9402447	Anticancer, other	Cancer, pancreatic
maxacalcitol	1,3-Cyclohexanediol, 4-methylene-5-(2-(octahydro-1-(1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyl-4H-inden-4-ylidene)ethylidene)-, (1S-(1Alpha(R*),3aβ,4E(1S*,3R*,5Z),7aAlpha)-) [CAS]	103909-75-7	US 4891364	Hormone	Hyperparathyroidism

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mazindol	3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro- [CAS]	22232-71-9	US 3763178	Anorectic/Antiobesity	Obesity
Mazipredone		13085-08-0			
MC-5723			US 6043259	Cardiovascular	Unspecified
MCC-478	(2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)			Antiviral, other	Infection, hepatitis-B virus
MCI-154	3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(4-pyridinylamino)phenyl]-, monohydrochloride [CAS]	98326-32-0 98326-33-1	EP 145019	Cardio stimulant	Heart failure
m-Cresyl Acetate		122-46-3			
MDAM	Gamma-Methylene-10-deazaaminopterin			Anticancer, antimetabolite	Cancer, general
MDI-101			US 4886311	Antiacne	Acne
MDI-403		403849-94-5	US 4677120	Antiacne	Acne
MDL-100907	4-Piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)- [CAS]	139290-65-6		Hypnotic/Sedative	Sleep disorder, general
mebendazole	methyl-5-benzoylbenzimidazole-2-carbamate	31431-39-7	GB 1307306	Anthelmintic	
mebeverine	Benzoic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methyl[ethyl]amino]butyl ester [CAS]	3625-06-7		Antispasmodic	Irritable bowel syndrome
Mebhydroline		524-81-2			
Mebrofenin		78266-06-5			
Mebutamate		64-55-1			
mecamylamine	Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2		Neurological	Unspecified
Mechlorethamine		51-75-2			
Mechlorethamine Oxide		302-70-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
meclillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6Beta)]- [CAS]	32887-01-7 32887-03-9	GB 1293590	Penicillin, injectable	Infection, general
Mecizine		569-65-3			
Meclocycline		2013-58-3			
meclofenamate	Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-, monosodium salt [CAS]	6385-02-0 644-62-2		Antiarthritic, other	Arthritis, osteo
Meclofenamic Acid		644-62-2			
Meclofenoxate		51-68-3			
Mecloqualone		340-57-8			
Mecysteine		18598-63-5			
Medazepam		12/06/2898			
medifoxamine	Ethanamine, N,N-dimethyl-2,2-diphenoxy- [CAS]	32359-34-5	FR M5498	Antidepressant	
Medrogestone		977-79-7			
Medronic Acid		1984-15-2			
medroxyprogesterone	Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6Alpha)	71-58-9 520-85-4		Formulation, fixed-dose combinations	Contraceptive, female
Medrysone		2668-66-8			
Mefenamic Acid		61-68-7			
Mefenorex		17243-57-1			
Mefexamide		1227-61-8			
mefloquine	4-Quinolinemethanol, Alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(±)-[CAS]	51773-92-3 53230-10-7 69191-18-0	GB 1594282	Antimalarial	
Mefruside		7195-27-9			
Megestrol		595-33-5			
Meglumine		22154-43-4 131-49-7			
meglutol	2-hydroxy-2-methyl-1,3-propanedicarboxylic acid	503-49-1	US 3629449	Hypolipaeamic/Antiatherosclerosis	Hyperlipidaemia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
melagatran	Glycine, N-[(1R)-2-[(2S)-2-[[[4-(aminiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]- [CAS]	159776-70-2	WO 9616671	Antithrombotic	Thrombosis, general
melanocortin-4 agonist	N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine(1)			Anorectic/Antiobesity	Obesity
Melarsoprol		494-79-1			
Melengestrol		5633-18-1			
melevodopa	Alanine, 3-(3,4-dihydroxyphenyl)-methyl ester [CAS]	7101-51-1	EP 252290	Antiparkinsonian	Parkinson's disease
Melinamide		14417-88-0			
Melitracen		5118-29-6			
meloxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide- [CAS]	71125-38-7	US 4233299	Antiarthritic, other	Arthritis, rheumatoid
melperone	1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)- [CAS]	1622-79-3 3575-80-2	BE 651144	Neuroleptic	
Melphalan		148-82-3			
meluadrine	Benzenemethanol, 2-chloro-Alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (R)-, (R*, R*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	134865-37-5	EP 420120	Labour inhibitor	Labour, preterm
mementine	Tricyclo[3.3.1.1 ^{3,7}]decan-1-amine, 3,5-dimethyl [CAS]	41100-52-1 19982-08-2	EP 392059	Cognition enhancer	Dementia, AIDS-related
MEN-10700	Acetamide, 2-[[[(5R,6S)-6-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl]methyl]methylamino]- [CAS]	195874-55-6	WO 9406803	Beta-lactam antibiotic	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
MEN-10755	5,12-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy-Alpha-L-lyxohexopyranosyl)-2,6-dideoxy-Alpha-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, hydrochloride, (7S,9S)- [CAS]	169317-77-5	WO 9509173	Anticancer, antibiotic	Cancer, breast
Menadiol		481-85-6			
Menadione		58-27-5			
Menadoxime		573-01-3			
Menbutone		3562-99-0			
Menogaril		71628-96-1			
MENT	7Alpha-Methyl-19-nortestosterone			Formulation, transdermal, systemic	Contraceptive, male
menthol	Cyclohexanol, 5-methyl-2-(1-methylethyl)- [CAS]	1490-04-6 89-78-1		Formulation, dermal, topical	Pruritus
Menthyl Valerate		89-47-4			
Meobentine		46464-11-3			
Meparfynol		77-75-8			
mepartricin	Particin, methyl ester [CAS]	1121-32-7	US 3780173	Antifungal	Infection, Candida, general
Mepazine		60-89-9			
Mepenzolate Bromide		76-90-4			
Meperidine		57-42-1			
Mephenesin		59-47-2			
Mephenoxalone		70-07-5			
Mephentermine		100-92-5			
Mephénytoin		50-12-4			
Mephobarbital		115-38-8			
Mepindolol		23694-81-7			
Mepitiostane		21362-69-6			
mepivacaine	N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide	96-88-8		Formulation, modified-release, >24hr	Pain, post-operative
Mepixanox		17854-59-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Meprednisone		1247-42-3			
Meprobamate		57-53-4			
meprosiclarin	Bufa-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl-Alpha-L-mannopyranosyl)oxy]-14-hydroxy-, (3S)- [CAS]				
mepitazolin	Phenol, 3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)- [CAS]	33396-37-1	DE 1910207	Cardio stimulant	Heart failure
mequitazine	10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	54340-58-8 59263-76-2	GB 1285025	Analgesic, other	Pain, general
Meralein		29216-28-2	GB 1250534	Antiallergic, non-asthma	
Meralluride		4386-35-0			
Merbromin		8069-64-5			
Mercaptopmerin		129-16-8			
Mercumallylic Acid		21259-76-7			
Mercuric Chloride, Ammoniated		86-36-2			
Mercuric Oleate		10124-48-8			
Mercuric Oxycyanide		1191-80-6			
		1335-31-5			
merimepodib	Carbamic acid, ((3-(((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl)- (3S)-tetrahydro-3-furanyl ester [CAS]	198821-22-6	US 5807876	Antiviral, other	Infection, hepatitis-C virus
meropenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4Alpha,5i,6i(R*)]]- [CAS]	96036-03-2	EP 126587	Beta-lactam antibiotic	Infection, respiratory tract, lower
Mersalyl		492-18-2			
Mesalamine		89-57-6			
mesalazine	Benzoic acid, 5-amino-2-hydroxy- [CAS]	89-57-6	WO 5541170	Formulation, oral, other	Colitis, ulcerative
Mesna		19767-45-4			
Mesoridazine		5588-33-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mestanolone		521-11-9			
Mesterolone		1424-00-6			
Mestranol		72-33-3			
Mesulfen		135-58-0			
Metaclozepam		84031-17-4			
Metampicillin		6489-97-0			
Metapramine		21730-16-5			
Metaproterenol		586-06-1			
Metaraminol		54-49-9			
Metazocine		3734-52-9			
		17692-51-2			
metergoline	Carbamic acid, [[(8S)-1,6-dimethylergolin-8-yl]methyl]-, phenylmethyl ester [CAS]	21631-37-8			
		2706-42-5	GB	Antiprolactin	Amenorrhoea
metformin	Imidodicarbonimidic diamide, N,N-dimethyl- [CAS]	657-24-9		Formulation, modified-release, <=24hr	Diabetes, Type II
Methacholine		62-51-1			
Methacycline		914-00-1			
Methadone		76-99-3			
Methafurylene		531-06-6			
Methamphetamine		537-46-2			
Methandriol		521-10-8			
Methandrosthenolone		72-63-9			
Methantheline		53-46-3			
Methapyrilene		91-80-5			
Methaqualone		72-44-6			
Metharbital		50-11-3			
Methazolamide		554-57-4			
Methdilazine		1982-37-2			
Methenamine		100-97-0			
Methenolone		153-00-4			
Methestrol		130-73-4			
Methetoin		5696-06-0			
Methicillin		132-92-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methimazole		60-56-0			
Methiodal		126-31-8			
Methionnic Acid		503-40-2			
Methionine		63-68-3			
Methisazone		1910-68-5			
Methitural		467-43-6			
Methixene		02/02/4969			
Methocarbamol		532-03-6			
Methohexital		22151-68-4			
methotrexate	L-Glutamic acid, N-[4-[[[2,4-diamino-6-pteridiny]methyl]methylamino]benzoyl]-[CAS]	59-05-2	US 2512572	Anticancer, antimetabolite	Cancer, general
Methotrimeprazine		60-99-1			
Methoxamine		390-28-3			
Methoxsalen		298-81-7			
Methoxyflurane		76-38-0			
Methoxyphenamine		93-30-1			
Methoxypromazine		61-01-8			
Methscopolamine		155-41-9			
Methsuximide		77-41-8			
Methyclothiazide		135-07-9			
Methyl Blue		28983-56-4			
Methyl Nicotinate		93-60-7			
Methyl Propyl Ether		557-17-5			
Methyl Salicylate		119-36-8			
Methyl tert-Butyl Ether		1634-04-4			
Methylbenzethonium Chloride		25155-18-4			
Methylcobalamin		13422-55-4			
methyldopa	L-Tyrosine, 3-hydroxy-Alpha-methyl-[CAS]	555-30-6		Formulation, modified-release, <=24hr	Hypertension, general
Methylene Blue		61-73-4			
Methylethergonovine		113-42-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methylhexaneamine		105-41-9			
methylphenidate	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester [CAS]	113-43-1 298-59-9		Formulation, modified-release, multi	Attention deficit disorder
Methylprednisolone		83-43-2			
methylprednisolone aceponate	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6Alpha,11β)- [CAS]	86401-95-8	EP 72547	Antipruritic/inflam, allergic	Pruritus
methylprednisolone suleptanate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxocetyl]oxy]-, monosodium salt, (6Alpha,11β)- [CAS]	90350-40-6	JP 59137500	Antiasthma	Asthma
Methylthiouracil		56-04-2			
Methyltrienolone		965-93-5			
Methypyrrolon		125-64-4			
Methysergide		361-37-5			
Metiazinic Acid		13993-65-2			
metipranolol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate [CAS]	22664-55-7	GB 1206148	Antihypertensive, adrenergic	
metoclopramide	Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- [CAS]	364-62-5		Formulation, modified-release, <=24hr	Gastro-oesophageal reflux
Metocurine iodide		7601-55-0			
Metofenazate		388-51-2			
metolazone	6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- [CAS]	17560-51-9	US 4517179	Antihypertensive, diuretic	
Metopimazine		14008-44-7			
Metopon		143-52-2			
metoprolol	2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (+/-)- [CAS]	51384-51-1 56392-17-7 37350-58-6		Formulation, modified-release, other	Hypertension, general
Metralindole		54188-38-4			
Metrizamide		31112-62-6			
Metrizoic Acid		1949-45-7			
Metron S		13946-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Metyrapone		54-36-4			
Metyrosine		672-87-7			
Mexazolam		31868-18-5			
Mexenone		1641-17-4			
Mexiletine		31828-71-4			
mezlocillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl [amino]-7-oxo-, [2S-[2Alpha,5Alpha,6(S*)]]- [CAS]	42057-22-7 51481-65-3 72539-76-5	GB 1301961	Penicillin, injectable	Infection, general
MFH-244	Benzenecarboximidic acid, 3,4,5-trihydroxy-, ethyl ester, hydrochloride	95933-76-9	US 4623659	Cardiovascular	Reperfusion injury
mianserin	Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- [CAS]	21535-47-7 24219-97-4	GB 1173783	Antidepressant	Depression, general
Mibefradil		116644-53-2			
Miboplatin		103775-75-3			
Micafungin		235114-32-6			
miconazole	1H-Imidazole,1-(2,4-dichlorophenyl)-2[2,4-dichlorophenyl]methoxy[ethyl]	22916-47-8		Formulation, modified-release, other	Infection, Candida, general
Micronomicin		52093-21-7			
midaxifylline	1H-Purine-2,6-dione, 8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl- [CAS]	151159-23-8	US 5378844	Cardiovascular	Unspecified
midazolam	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-[CAS]	59467-70-8 59467-94-6	US 4280957	Anaesthetic, injectable	
midecamycin	Leucomycin V, 3,4B-dipropanoate [CAS]	35457-80-8	US 3761588	Macrolide antibiotic	Infection, general
midecamycin acetate	Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate [CAS]	55881-07-7	JP 49124087	Macrolide antibiotic	Infection, general
midesteine	2-Thiophenecarbothioic acid, S-[1-methyl-2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl] ester [CAS]	94149-41-4	EP 120534	COPD treatment	Emphysema, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]- [CAS]	42318-56-0 42794-76-3	EP 164571	Urological	Incontinence
midostaurin	Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-dindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, (9Alpha,10B,11B,13Alpha)- [CAS]	120685-11-2	EP 296110	Anticancer, other	Cancer, leukaemia, acute myelogenous
mifepristone	Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11B,17B)- [CAS]	84371-65-3	EP 57115	Abortifacient	Abortion
miglitol	3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, [2R-(2Alpha,3B,4Alpha,5B)]- [CAS]	72432-03-2	EP 55431	Antidiabetic	Diabetes, Type I
miglustat	3,4,5-Piperidinetriol, 1-buty-2-(hydroxymethyl)-(2R-(2Alpha,3B,4Alpha,5B)) [CAS]	72599-27-0	DE 2758025	Metabolic and enzyme disorders	Gaucher's disease
mildronate	Hydrazinium, 2-(2-carboxyethyl)-1,1,1-trimethyl-, inner salt- [CAS]	76144-81-5	WO 8001068	Cardiostimulant	Heart failure
milnacipran	Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(±)-[CAS]	101152-94-7 92623-85-3	US 4478836	Antidepressant	Depression, general
Miloxacin		37065-29-5			
milrinone	[3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo- [CAS]	78415-72-2	US 4313951	Cardiostimulant	Heart failure
miltefosine	Ethanaminium, 2-[[[hexadecyloxy]hydroxyphosphinyloxy]-N,N,N-trimethyl-, hydroxide, inner salt [CAS]	53949-20-5 58066-85-6	EP 225608	Anticancer, other	Cancer, skin, general
minaprine	4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)- [CAS]	25905-77-5 25953-17-7	GB 1345880	Antidepressant	Depression, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
minocycline	2-Naphthacene-carboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4 α ,4a α ,5 α ,12 α)]-[CAS]	10118-90-8		Formulation, optimized, microparticles	Infection, oral
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-, [CAS]	180064-38-4	EP 354806	Anticancer, other	Cancer, myeloma
minoxidil	2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	US 4139619	Vasodilator, peripheral	Hypertension, general
Miokamycin		55881-07-7			
mirtazapine	Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	85650-52-8 61337-67-5	GB 1543171	Antidepressant	Depression, general
misoprostol	Prost-13-en-1-ol acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11 α ,13 ϵ)-(±)- [CAS]	59122-46-2 59122-48-4	US 4301146	Prostaglandin	Ulcer, gastric
mitomycin	Erythromycin, 8,9-didehydro-N-demethyl-9-deoxy-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxo-, (2E)-2-butenedioate (2:1) [CAS]	154802-96-7	WO 9324509	Gastroprokinetic	Gastro-oesophageal reflux
mitiglinide	Calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolylcarbonyl)propionate, dihydrate-[CAS]	145525-41-3	EP 507534	Antidiabetic	Diabetes, Type II
Mitobronitol		488-41-5			
Mitoguazone		459-86-9			
mitolactol	Galactitol, 1,6-dibromo-1,6-dideoxy- [CAS]	10318-26-0	US 3993781	Anticancer, alkylating	Cancer, cervical

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mitomycin	Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[[(aminocarbonyloxy)methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aAlpha,8S,8aAlpha,8bAlpha)]]- [CAS]	50-07-7		Formulation, parenteral, other	Cancer, stomach
Mitotane		53-19-0			
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-[CAS]	65271-80-9 70476-82-3	US 4197249	Anticancer, other	Cancer, breast
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-[CAS]	65271-80-9 70476-82-9		Formulation, optimized, liposomes	Cancer, general
MIV-210	[3'-Fluoro-2'-3'-dideoxy guanosine)			Antiviral, other	Infection, hepatitis-B virus
mivacurium	Isoquinolinium, 2,2'-[[1,8-dioxo-4-octene-1,8-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, [R*,R*(E)]- [CAS]	106861-44-3	EP 181055	Muscle relaxant	Anaesthesia, adjunct
Mivazerol		125472-02-8			
mizolastine	4-(1H)-Pyrimidinone, 2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]- [CAS]	108612-45-9	EP 217700	Antiallergic, non-asthma	Rhinitis, allergic, general
Mizoribine		50924-49-7			
MKC-733	(R)-N-(3-quinuclidinyl)-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide hydrochloride	194093-42-0	JP 09216888	Gastroprokinetic	Gastro-oesophageal reflux
MLN-519	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S)- [CAS]	211866-70-5	WO 9915183	Neuroprotective	Ischaemia, cerebral
MLN-576	4-Methoxy-benzol[a]phenazine-11-carboxylic acid (2-(dimethylamino)-1-(R)-methyl)ethyl)-amide			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moclobemide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	EP 326023	Antidepressant	Depression, general
modafinil	Acetamide, 2-[(diphenylmethyl)sulfinyl]- [CAS]	68693-11-8	DE 2809625	Psychostimulant	Narcolepsy
moexipril	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (3S-(2(R'(R'),3R*))- [CAS]	103775-10-6 103775-14-0	US 4344949	Antihypertensive, renin system	Hypertension, general
Mofarotene		125533-88-2			
Mofebutazone		2210-63-1			
Mofegiline		119386-96-8			
mofezolac	5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)- [CAS]	78967-07-4	EP 26928	Analgesic, NSAID	Pain, post-operative
MOL-6131	N-[4-(aminomethyl)benzyl]-8(S)-[1-[4-[2-(4-aminophenyl)-acetamido]butyl]piperidin-4-yl]-2-(naphthalen-1-yl)methyl]-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazine-5(R)-carboxamide			Antiasthma	Asthma
Molindone		7416-34-4			
molsidomine	Sydrone Imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)- [CAS]	25717-80-0	US 3769283	Vasodilator, coronary	
mometasone	Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11 β ,16 α)- [CAS]	105102-22-5 83919-23-7	EP 57401	Antipruritic/inflamm, allergic	Psoriasis
Monatepil		103377-41-9			
Monobenzone		103-16-2			
monolaurin	Dodecanoic acid, monoester with 1,2,3-propanetriol [CAS]	27215-38-9	US 4885282	Dermatological	Ichthyosis
montelukast	Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, [CAS]	151767-02-1 158966-92-8		Antiasthma	Asthma
Monteplase		122007-85-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Moperone		1050-79-9			
Mopidamol		13665-88-8			
Moprolol		5741-22-0			
moracizine	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]-, ethyl ester [CAS]	29560-58-5 31883-05-3	US 3864487	Antiarrhythmic	Tachycardia, ventricular
Morazone		6536-18-1			
Moricizine		31883-05-3			
Moroxydine		3731-59-7			
Morphazinamide		952-54-5			
morphine	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5 α), 6 α), [CAS]	57-27-2 6055-06-7 64-31-3		Formulation, parenteral, other	Pain, cancer
morphine-6-glucuronide	morphine-6-glucuronide			Formulation, inhalable, systemic	Pain, general
mosapramine	Spiro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one, 1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydro-, (+)- [CAS]	89419-40-9 98043-60-8	US 4337260	Neuroleptic	
mosapride	Benzamide, 4-amino-5-chloro-2-ethoxy-N-(((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)- [CAS]	112885-41-3 112885-42-4	EP 243959	GI inflammatory/bowel disorders	Gastritis
motexafin gadolinium	Gadolinium, bis(acetato-kappaO)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16:16,13-dinitrilo-1,18-benzodiazacycloicosine-5,14-dipropanolato-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-233'2'4) [CAS]	246252-06-2		Radio/chemosensitizer	Cancer, brain
Motretinide		56281-36-8			
Moveltpiril		85856-54-8			
Moxalactam		64952-97-2			
Moxastine		3572-74-5			
Moxaverine		10539-19-2			
Moxestrol		34816-55-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moxifloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, hydrochloride (4aS-cis)- [CAS]	186826-86-8 151096-09-2	DE 19546249	Quinolone antibacterial	Infection, respiratory tract, general
moxisylyte	Phenol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylethyl)-, acetate (ester), [CAS]	964-52-3 54-32-0		Male sexual dysfunction	Impotence
moxonidine	5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- [CAS]	75438-57-2	DE 2849537	Antihypertensive, other	Hypertension, general
M-PGA	(-)-(S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isindol-2-yl)pentanedioic acid		US 5712291	Anticancer, other	Cancer, general
MPI-5010	Platinum diamminedichloro-, (SP-4-2) + (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol				
MPI-5020	2,4-(1H,3H)-Pyrimidinedione, 5-fluoro- [CAS]	51-21-8	US 6224883	Formulation, parenteral, other	Cancer, head and neck
MPL		198076-81-2	US 5750146	Formulation, parenteral, other	Cancer, breast
MRS-1754			US 6060481	Immunostimulant, other	Vaccine adjunct
	1-Piperazineethanol, 4-(diphenylacetyl)-Alpha-[(5-quinolinyl)oxy)methyl]-, (2E)-2-butenedioate(2:3) (salt) [CAS]			Antiasthma	Asthma
MS-209		158681-49-3		Radio/chemosensitizer	Cancer, breast
MS-275	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide			Anticancer, antimetabolite	Cancer, lung, general
MS-325		201688-00-8			
MS-377			EP 839805	Neuroleptic	Schizophrenia
Mupirocin		12650-69-0			
Muscarine		300-54-9			
Muzolimine		55294-15-0			
MX-1013			US 6153591	Hepatoprotective	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mycophenolate mofetil	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)- [CAS]	116680-01-4 128794-94-5	WO 9119498	Immunosuppressant	Transplant rejection, general
mycophenolic acid	4-hexanoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-,	37415-62-6 24280-93-1		Formulation, oral, enteric-coated	Transplant rejection, general
Myrophine		467-18-5			
N-(Hydroxymethyl)nicotinamide		3569-99-1			
N,N,N',N'-Tetraethylphthalamide		83-81-8			
N2-Formylsulfisomidine		795-13-1			
N4-β-D-Glucosylsulfanilamide		53274-53-6			
N4-Sulfanilylsulfanilamide		547-52-4			
Nabilone		51022-71-0			
nabumetone	2-Butanone, 4-(6-methoxy-2-naphthalenyl) [CAS]	42924-53-8	GB 1476721	Anti-inflammatory	Arthritis, osteo
N-acetylcysteine	L-Cysteine, N-acetyl- [CAS]	616-91-1		Anticancer, other	Cancer, general
N-Acetyl methionine		65-82-7			
nadifloxacin	1H,5H-Benzo[<i>h</i>]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+/-)- [CAS]	124858-35-1	US 4399134	Quinolone antibacterial	Acne
nadolol	2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- [CAS]	42200-33-9	US 4346106	Antihypertensive, adrenergic	
Nadoxolol		54063-51-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nafamostat	Benzoic acid, 4-[(aminoinominomethyl)amino]-, 6-[(aminoinominomethyl)-2-naphthalenyl ester]-[CAS]	80251-32-7 81525-10-2 82956-11-4	EP 450232	GI inflammatory/bowel disorders	Pancreatitis
nafarelin	Luteinizing hormone-releasing factor (pig), 6-[3-(2-naphthalenyl)-D-alanine]-[CAS]	76932-56-4 86220-42-0	EP 21234	Releasing hormones	Endometriosis
Nafcillin		147-52-4			
Naftrotyl		31329-57-4			
naftidrofuryl	2-Furanpropanoic acid, tetrahydro- α -(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester	31329-57-4		Formulation, modified-release, other	Unspecified
naftifine	1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)- [CAS]	65472-88-0 65473-14-5	US 4282251	Antifungal	Infection, dermatological
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)- α -(1-naphthalenyl)methyl- [CAS]	57149-07-2	US 3997666	Antihypertensive, adrenergic	Hypertension, general
nalbuphine	Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5 α), 6 α [CAS]	20594-83-6 23277-43-2	US 3393197	Analgesic, other	Pain, general
Nalidixic Acid		389-08-2			
nalmeferene	Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5 α), 6 α [CAS]	55096-26-9	JP 56167687	Dependence treatment	Poisoning, drug
Nalorphine		62-67-9			
naloxone	Morphinan-6-one, 17-allyl-4,5 α -epoxy-3,14-dihydroxy-, hydrochloride [CAS]	357-08-4 465-65-6		Septic shock treatment	
naltrexone	Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 α), 6 α [CAS]	16590-41-3 16676-29-2	US 3332950	Dependence treatment	Addiction, narcotic/opiate
NAMI	Imidazolium trans(imidazole)(dimethylsulfoxide)tetrahydroproruthenate (III)			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
namindil	Guanidine, N-cyano-N'-(4-cyanophenyl)-N''-[(1R)-1,2,2-trimethylpropyl]-[CAS]	220641-11-2		Dermatological	Alopecia, general
Nandrolone		434-22-0			
Naphazoline		835-31-4			
Naphthalene		91-20-3			
naproxen betainate	Methanaminium, 1-carboxy-N, N, N-trimethyl- salt with (R)-6-methoxy- α -methyl-2-naphthaleneacetic acid (1:1), sodium salt [CAS]	104124-26-7	US 4672077	Antiarthritic, other	Arthritis, rheumatoid
naproxen	2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, [CAS]	26159-34-2 22204-53-1	GB 1211134	Analgesic, NSAID	Pain, general
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	121679-13-8	EP 303507	Antimigraine	Migraine
Narceine		131-28-2			
Narcobarbital		125-55-3			
Natamycin		7681-93-8			
nateglinide	D-phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-[CAS]	105816-04-4	EP 196222	Antidiabetic	Diabetes, Type II
N-Butyldoxynojirimycin		72599-27-0			
N-Butylscopolammonium Bromide		149-64-4			
NC-503			US 5643562	Anti-inflammatory	Amlyoidosis
NC-531			US 5643562	Cognition enhancer	Alzheimer's disease
NCX-1000			WO 0061604	Hepatoprotective	Cirrhosis, hepatic
NCX-4016	Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester [CAS]	175033-36-0	WO 9716405	Symptomatic antidiabetic	Insulin-related metabolic syndrome
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitrooxy)butyl ester [CAS]	256499-26-0		GI inflammatory/bowel disorders	Inflammatory bowel disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NCX-950	Alpha'-[[[1,1-dimethylethyl)amino]methyl]-4-hydroxy]-1,3-benzenedimethanol nitrate			Antiasifma	Asifma
n-Docosanol		661-19-8			
	Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]				
NE-100		149409-57-4	WO 9307113	Neuroleptic	Schizophrenia
Nealbarbital		561-83-1			
	2H-1-Benzopyran-2-methanol, Alpha,Alpha'-[[iminobis(methylene)]bis[6-fluoro-3,4-dihydro]-, (2R*(R*(R*(S*)))-(1+)-[CAS]	118457-14-0 99200-09-6			
nebivolol			EP 145067	Antihypertensive, adrenergic	Hypertension, general
nebostinel	N1-(4,4-Dimethylcyclohexyl)-L-isoglutamine	163000-63-3	EP 0688312	Cognition enhancer	Unspecified
Nebracetam		97205-34-0			
nedaplatin	Platinum, diammine[hydroxyacetato(2-)-O1,O2]-, (SP-4-3)- [CAS]	95734-82-0	EP 216362	Anticancer, alkylating	
	4H-Pyran[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7			Rhinitis, allergic, general, Ocular disorder, general
nedocromil			EP 555718	Antiasthma, Ophthalmological	
nefazodone	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-, [CAS]	82752-99-6 83366-66-9	US 4338317	Antidepressant	Depression, general
nefiracetam	1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo- [CAS]	77191-36-7	US 4341790	Cognition enhancer	Dementia, senile, general
nefopam	1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- [CAS]	13669-70-0 23327-57-3	US 3487153	Analgesic, NSAID	
Negamycin		33404-78-3			
	3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2S*,3S*),3Alpha,4aß,8aß)-, [CAS]	159989-65-8 159989-64-7		Antiviral, anti-HIV	Infection, HIV/AIDS
Nemonapride		75272-39-8			
Neostigmine		59-99-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nepadutant	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-L-asparagyl-L-Alpha-aspartyl-L-tryptophyl-L-phenylalanyl], (4-1)-lactam [CAS]	183747-35-5	WO 9628467	Antiasthma	Asthma
neramexane	1,3,3,5,5-pentamethylcyclohexylamine	202807-80-5 219810-59-0		Dependence treatment	Addiction, alcohol
neridronic acid	Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- [CAS]	79778-41-9		Musculoskeletal	Osteogenesis imperfecta
Nerifolin		466-07-9			
N-Ethylamphetamine		457-87-4			
neticonazole	1H-Imidazole, 1-[2-(methylthio)-1-[2-(pentyloxy)phenyl]ethenyl]-, monohydrochloride, (E)- [CAS]	130773-02-3 130726-68-0	EP 445540	Antifungal	Infection, Candida, general
netilmicin	D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-glycero-hex-4-enopyranosyl-(1-4)]-2-deoxy-N1-ethyl- [CAS]	56391-56-1 56391-57-2	GB 1473733	Aminoglycoside antibiotic	Infection, general
nevirapine	6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- [CAS]	129618-40-2	EP 429987	Antiviral, anti-HIV	Infection, HIV/AIDS
NGD-98-2			WO 9635689	Anxiolytic	Anxiety, general
Nialamide		51-12-7			
Niaprazine		27367-90-4			
Nicametate		3099-52-3			
nicaraven	3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediyl)bis- [CAS]	79455-30-4	EP 29602	Neuroprotective	Haemorrhage, subarachnoid
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5	US 3985758	Neuroprotective	Hypertension, general
nicergoline	Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8b)-, 5-bromo-3-pyridinecarboxylate(ester)	27848-84-6		Formulation, modified-release, other	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Niceritrol		5868053			
Niclosamide		50-65-7			
Nicoclonate		10571-59-2			
Nicofuranose		15351-13-0			
Nicomol		27959-26-8			
Nicomorphine		639-48-5			
nicorandil	3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl]- [CAS]	65141-46-0	US 4792564	Vasodilator, coronary	Hypertension, general
Nicotinamide		98-92-0			
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5		Formulation, inhalable, other	Addiction, nicotine
Nicotinic Acid		59-67-6			
Nicotinic Acid Benzyl Ester		94-44-0			
Nicotinyl Alcohol		100-55-0			
nifedipine	4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine	21829-25-4	GB 1173862	Vasodilator, coronary	Hypertension, general
nifekalant	2,4-(1H,3H)-Pyrimidinedione, 6-[[2-[(2-hydroxyethyl)]3-(4-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-, [CAS]	130636-43-0 130656-51-8	EP 369627	Antiarrhythmic	Arrhythmia, general
Nifenalol		7413-36-7			
Niflumic Acid		4394-00-7			
Nifuratel		4936-47-4			
Nifurfoline		3363-58-4			
Nifuroxazide		965-52-6			
Nifuroxime		6236051			
Nifurpirinol		13411-16-0			
Nifurprazine		1614-20-6			
Nifurtimox		23256-30-6			
Nifurtoinol		1088-92-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nifurzide	2-Thiophenecarboxylic acid, 5-nitro-, [3-(5-nitro-2-furanyl)-2-propenylidene]hydrazide [CAS]	39978-42-2	US 3847911	Antidiarrhoeal	Infection, GI tract
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0		Formulation, other	Infection, general
Nikethamide		59-26-7			
nilutamide	2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-[CAS]	63612-50-0	US 4472382	Anticancer, hormonal	Cancer, prostate
nilvadipine	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	75530-68-6	US 4338322	Antihypertensive, other	Hypertension, general
nimesulide	Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- [CAS]	51803-78-2	US 3940597	Anti-inflammatory	Pain, general
Nimetazepam		2011-67-8			
nimodipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	66085-59-4	EP 533014	Neuroprotective	
Nimorazole		6506-37-2			
	Urea, N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitroso-[CAS]	103745-00-2			
nimustine		42471-28-3			
		55661-38-6	GB 1374344	Anticancer, alkylating	Cancer, brain
Ninopterin		2179-16-0			
	N-[4(S)-(Cyclopropylamino)-3-(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-benzopyran-6-yl]-4-methoxybenzeneacetamide				
NIP-142			WO 9804542	Antiarrhythmic	Fibrillation, atrial
	N'-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-[N-[1-(4-fluorobenzyl)benzimidazol-2-yl]-amino]propyl-N-methylurea hydrochloride			Antipruritic/inflam, allergic	Eczema, atopic
NIP-531					
	N-[2-[[5-[(dimethylamino)methyl]furfuryl]thioethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine				
niperotidine		84845-75-0	GB 2104071	Antilulcer	Ulcer, GI, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nipratriol	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 3-nitrate [CAS]	81486-22-8 86247-86-1	EP 42299	Formulation, mucosal, topical	Glaucoma
Niridazole		61-57-4			
nisoldipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	63675-72-9	GB 1516793	Antihypertensive, other	Hypertension, general
nitazoxanide	Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)- [CAS]	55981-09-4	US 5387598	Protozoacide	Infection, GI tract
nitisinone	1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- [CAS]	104206-65-7	EP 186118	Metabolic and enzyme disorders	Cirrhosis, hepatic
nitracrine	1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)- [CAS]	4533-39-5 6514-85-8	FR 1458183	Anticancer, other	Cancer, ovarian
Nitrazepam		146-22-5			
nitrendipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester- [CAS]	39562-70-4	GB 1358951	Antihypertensive, other	Hypertension, general
nitrofuribiprofen	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitrooxy)butyl ester [CAS]	158836-71-6	EP 670825	Urological	Incontinence
Nitrofurantoin		67-20-9			
Nitrofurazone		59-87-0			
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	55-63-0		Formulation, transdermal, patch	Angina, general
Nitromersol		133-58-4			
nitronaproxen	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl 4-(nitrooxy)butyl ester (AlphaS)- [CAS]	163133-43-5	WO 9509831	Analgesic, NSAID	Pain, post-operative
nitroxazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-[3-(dimethylamino)propyl]-2-nitro-, monohydrochloride [CAS]	16398-39-3	NL 6608671	Antidepressant	
Nitroxoline		4008-48-4			
nizatidine	1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-[[thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]	76963-41-2	EP 49618	Antilulcer	Ulcer, duodenal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nizofenone	3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin	54533-85-6			
NM-3			JP 08176138	Anticancer, other	Cancer, general
NM-702	4-Bromo-5-(3-pyridylmethylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone hydrochloride			Antithrombotic	Peripheral vascular disease
N-Methylephedrine		552-79-4			
N-Methylepinephrine		554-99-4			
N-Methylglucamine		6284-40-8			
NN-414	6-chloro-3-(1-methylcyclopropylamino)-4H-thieno[3,2-e]-[1,2,4]thiadiazine-1,1-dioxide			Antidiabetic	Diabetes, Type II
NNC-05-1869	(R)-1-(3-(10,11-dihydro-5H-dibenzof[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidine carboxylic acid			Symptomatic antidiabetic	Neuropathy, diabetic
Nogalamycin		1404-15-5			
notatrexed	4(1H)-Quinazolinone, 2-amino-6-methyl-5-(4-pyridinylthio)-, [CAS]	152946-68-4 147149-76-6	WO 9320055	Anticancer, antimetabolite	Cancer, liver
nolomitrole	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+/-)-[CAS]				
nolpitanium	1-Azoniabicyclo[2.2.2]octane, 1-[2-[3-(4-dichlorophenyl)-1-[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-, chloride, (S)-[CAS]	138531-51-8 153050-21-6	WO 9529147 EP 591040	Cardio stimulant GI inflammatory/bowel disorders	Heart failure Inflammatory bowel disease
nomegestrol	19-Norpregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-, [CAS]	58652-20-3	DE 2522533	Menstruation disorders	Menstrual disorder, general
Nomifensine		24526-64-5			
Noprylsulfamide		576-97-6			
Norbolethone		1235-15-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nordazepam		1088-11-5			
Nordefrin		6539-57-7 (unspecified); 74812-63-8 (R*,S*)-(±)- form			
Nordihydroguaiaretic Acid		27686-84-6 (meso-form); 500-38-9 (unspecified)			
Norelgestromin, Ethinyl Estradiol					
Norepinephrine		51-41-2			
Norethandrolone		52-78-8			
Norethindrone		68-22-4			
Norethynodrel		68-23-5			
Norfenefrine		536-21-0			
norfloxacin	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro 1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	68077-27-0 70458-96-7	US 4146719	Quinolone antibacterial	Infection, general
Norgesterone		13563-60-5			
Norgestimate		35189-28-7			
Norgestrel		6533-00-2			
Norgestrienone		848-21-5			
Norlevorphanol		1531-12-0			
Normethadone		467-85-6			
Normethandrone		514-61-4			
Normorphine		466-97-7			
Norphenazone		89-25-8			
Norpipanone		561-48-8			
Norpseudoephedrine		492-39-7			
Nortriptyline		72-69-5			
Norvinisterone		6795-60-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Noscapine		128-62-1			
Novembichin		1936-40-9			
Novobiocin		303-81-1			
Noxiptilin		3362-45-6			
Noxythiolin		15599-39-0			
NS-1209	Butanoic acid, 2-[[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-3-hydroxy-, [CAS]	254751-28-5	WO 9426747	Antiepileptic	Epilepsy, general
NS-1231	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-(3,2-h)naphthalene-2,3-dione-3-oxime			Neuroprotective	
NS-126			US 5063222	Antiallergic, non-asthma	Ischaemia, cerebral Rhinitis, allergic, general
NS-220	2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazoly]butyl]-1,3-dioxane-r-2-carboxylic acid				
NS-2330	NS 2330 [CAS]	402856-42-2		Hypolipaeic/Antiatherosclerosis	Atherosclerosis
NSA inhibitors			US 6030785	Cognition enhancer Antiviral, other	Alzheimer's disease Infection, hepatitis-C virus
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[5-(1-piperidinyl)pentyl]oxy]-, monohydrochloride [CAS]				
NS-8	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile	178429-67-9	WO 9607641	Neuroprotective	Ischaemia, cerebral
NSC-330507	17-Allylaminogeldanamycin			Urological	Incontinence
NSC-619534	2-chloroethyl phenyl selenone 2,5-diazinidinyl-3-[hydroxymethyl][6-methyl-1,4-benzoquinone			Anticancer, antibiotic Anticancer, alkylating	Cancer, general Cancer, general
NSC-697726				Anticancer, antibiotic	Cancer, general
N-Sulfanilyl-3,4-xylamide		120-34-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NU-6027	2,4-Pyrimidinediamine, 6-(cyclohexylmethoxy)-5-nitroso- [CAS]	220036-08-8		Anticancer, other	Cancer, general
NV-07	2,4,6-(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]	53745-16-7	US 6455032	Antipruritic/inflamm, non-allergic	Keratosis
NVP-SRA880	[(3R,4aR,10aR)-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g]quinoline-3-carboxylic acid-4-(4-nitrophenyl)piperazine amide, hydrogen maleate			Neurological	Unspecified
NW-1029	(S)-(+)-2-[4-(2-fluorobenzoyloxy)benzylamino]propanamide methanesulfonate			Analgesic, other	Pain, general
NXY-059	CPI 22 [CAS]	168021-79-2	US 5780510	Neuroprotective	Ischaemia, cerebral
Nylidrin		447-41-6			
NZ-314	1-Imidazolidineacetic acid, 3-[(3-nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	128043-99-2	EP 353198	Symptomatic antidiabetic	Neuropathy, diabetic
NZ-419	5-hydroxy-1-methylimidazolidine-2,4-dione		EP 412940	Urological	Renal failure
Obidoxime Chloride		114-90-9			
OC-108	OC 108 [CAS]	162602-62-2		Vasoprotective, topical	Venous insufficiency
ocinaplon	Methanone, 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]- [CAS]	96604-21-6	EP 129847	Anxiolytic	Generalized anxiety disorder
Octabenzone		1843-05-6			
Octacaine		13912-77-1			
Octamoxin		4684-87-1			
Octaverine		549-68-8			
octenidine	1-Octanamine, N,N'-(1,10-decanediyl)di-1(4H)-pyridinyl-4-ylidene)bis- [CAS]	70775-75-6 71251-02-0 86767-75-1	WO 8705501	Stomatological	Periodontitis
Octodrine		543-82-8			
Octopamine		104-14-3			
Octoflamine		137-86-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
octreotide	L-Cysteineamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2-7)-disulfide, [R-(R*,R*)]- [CAS]	83150-76-9		Formulation, fixed-dose combinations	Cancer, general
Octyl		5466-77-3			
Methoxycinnamate					
ofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+/-)- [CAS]	82419-36-1	EP 47005	Quinolone antibacterial	
o-Iodohippurate		133-17-5			
olanzapine	10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- [CAS]	132539-06-1	EP 454436	Neuroleptic	Schizophrenia
Oleandrin		465-16-7			
Oleic Acid		112-80-1			
olmesartan medoxomil	1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144689-63-4	EP 503785	Antihypertensive, renin system	Hypertension, general
olopatadine	11-[(Z)-3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, monohydrochloride	113806-05-6 140462-76-6	EP 235796	Ophthalmological	Conjunctivitis
olpadronic acid	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	63132-39-8	WO 9619998	Osteoporosis treatment	Osteoporosis
olsalazine	Benzoic acid, 3,3'-azobis[6-hydroxy- [CAS]	15722-48-2 53200-51-4	US 4559330	GI inflammatory/bowel disorders	Colitis, ulcerative
olipiraz	3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl- [CAS]	64224-21-1	DE 2705641	Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OM-294DP	2-[3(R)-(Dodecanoyloxy)tetradecanamido]-N-[4-[3(R)-hydroxytetradecanamido]-5-(phosphonooxy)pentyl]-4-(phosphonooxy)butyramide			Anticancer, immunological	Unspecified
Omacor	ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate + ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate	81926-94-5 86227-47-6		Hypolipaeamic/Antiatherosclerosis	Hypertiglyceridaemia
omapatrilat	7H-Pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo, (4S-(4Alpha(R*),7Alpha,10as))- [CAS]	167305-00-2	US 5508272	Antihypertensive, renin system	Hypertension, general
omeprazole	1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]- [CAS]	73590-58-6	US 4255431	Antilulcer	Ulcer, GI, general
omiloxetine	Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel. [CAS]	176894-09-0		Antidepressant	Depression, general
omoconazole	1H-Imidazole, 1-[2-[2-(4-chlorophenoxy)ethoxy]-2-(2,4-dichlorophenyl)-1-methylethenyl]-, (Z)- [CAS]	74512-12-2	EP 8804	Antifungal	Infection, dermatological
Onapristone	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[[2-methyl-1H-imidazol-1-yl)methyl]- [CAS]	96346-61-1			
ondansetron	Benzoic acid, 4-[[1(E)-3-[[2-ethoxy-2-oxoethyl]-2-propenylamino]-2-methyl-3-oxo-1-propenyl]-, 4-(aminoiminomethyl)phenyl ester, monomethanesulfonate [CAS]	99614-01-4 99614-02-5	US 4847281	Antiemetic	Chemotherapy-induced nausea and vomiting
ONO-3403		181586-07-2		GI inflammatory/bowel disorders	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ONO-4128	1,4,9-Triazaspiro(5.5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)- [CAS]	342394-93-8		Antiviral, anti-HIV	Infection, HIV/AIDS
ONO-8815 Ly	L-lysine (Z)-7-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E)-4-(1-ethylcyclobutyl)-4-hydroxy-1-butenyl]cyclopentyl]-5-heptenoate			Labour inhibitor	Labour, preterm
ONT-093			US 5756527	Radio/chemosensitizer	Cancer, general
OPC-14523	2(1H)-Quinolinone, 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy- [CAS]	145969-30-8	EP 512525	Antidepressant	Depression, general
OPC-31260	Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-	137975-06-5	WO 9105549	Urological	Unspecified
OPC-51803	(5R)-2-[1-(2-chloro-4-(1-pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide			Antidiabetic	Diabetes, insipidus
OPC-6535	2-Pyridinecarboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- [CAS]	145739-56-6	WO 9209586	GI inflammatory/bowel disorders	Inflammatory bowel disease
Opiniazide		2779-55-7			
opioid analgesics	2-(4-trifluoromethylphenyl)-N-methyl-[1-phenyl-2-(1-pyrolidinyl)ethyl]acetamide			Analgesic, other	Pain, general
Opipramol		315-72-0			
Orazamide		2574-78-9			
orazipone	2,4-Pentanedione, 3-((4-methylsulfonyl)phenyl)methylene)- [CAS]	137109-78-5	EP 440324	Antiasthma	Unspecified
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]	210821-63-9		Antidepressant	Depression, general
Org-24448			US 6166008	Neuroleptic	Schizophrenia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
oritavancin	Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-Alpha-L-arabino-hexopyranosyl)-N3"-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-, (4"R)- [CAS]	171099-57-3	US 5840684	Peptide antibiotic	Infection, dermatological
orlistat	L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2Alpha(R*),3S]]- [CAS]	96829-58-2	EP 129748	Anorectic/Antiobesity	Obesity
ormeloxifene	Pyrrolidine, 1-[2-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl]-, trans- [CAS]	31477-60-8	DE 2329201	Female contraceptive	Contraceptive, female
Ornidazole		16773-42-5			
Ornipressin		3397-23-7			
Ornithine		70-26-8			
ornoprostil	Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70667-26-4	US 4278688	Prostaglandin	Ulcer, gastric
Orotic Acid		65-86-1			
Orphenadrine		83-98-7			
Orthocaine		536-25-4			
Osalmid		526-18-1			
osanelant	Acetamide, N-[1-[3-(3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl-N-methyl- [CAS]	160492-56-8	EP 673928	Neuroleptic	Schizophrenia
osaterone	2-Oxapregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- [CAS]	105149-00-6	EP 193871	Prostate disorders	Benign prostatic hyperplasia
oseltamivir	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)5-amino-3-(1-ethylpropoxy)-ethyl ester, (3R-(3Alpha,4S,5Alpha))-[CAS]				
OSI-7836	4'-Thio-beta-D-arabinofuranosylcytosine	196618-13-0	WO 9626933	Antiviral, other	Infection, influenza virus
				Anticancer, antimetabolite	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OSI-7904	Pentanedioic acid, 2-[5-[[[1,2-dihydro-3-methyl-1-oxobenzof[quinoxalin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isindol-2-yl]-, (S)- [CAS]	139987-54-5	WO 9119700	Formulation, optimized, liposomes	Cancer, general
ospemifene	Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- [CAS]	128607-22-7	WO 9607402	Menopausal disorders	Osteoporosis
otilonium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[4-[[2-(octyloxy)benzoyl]amino]benzoyl]oxy]-, bromide [CAS]	26095-59-0	GB 1181406	Antispasmodic	Irritable bowel syndrome
Ouabain		630-60-4			
Oxaceprol		33996-33-7			
Oxacillin		66-79-5			
Oxaflozane		26629-87-8			
oxaliplatin	Platinum, (1,2-cyclohexanediamine-N,N'')[[ethanedioato(2-)-O,O']-, [SP-4-2-(1R-trans)]-, [CAS]	61825-94-3	EP 393575	Anticancer, alkylating	Cancer, colorectal
Oxalyt-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-67-5	DE 2249274	Urological	
Oxamarin		15301-80-1			
Oxametacine		27035-30-9			
Oxamniquine		21738-42-1			
oxandrolone	2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5Alpha, 17beta)- [CAS]	53-39-4	US 3128283	Reproductive/gonadal, general	Sex-chromosome abnormality, Turner's syndrome
Oxantel		36531-26-7			
Oxapropanium		541-66-2			
oxaprozin	2-Oxazolepropanoic acid, 4,5-diphenyl- [CAS]	21256-18-8	GB 1206403	Antiarthritic, other	Arthritis, osteo
oxatamide	2H-Benzimidazol-2-one, 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro- [CAS]	60607-34-3	GB 1579365	Antiallergic, non-asthma	Rhinitis, allergic, general
oxazepam	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	604-75-1		Formulation, oral, orally-disintegrating	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
oxazolam	Oxazolol[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl- [CAS]	27167-30-2	US 3772371	Anxiolytic	
oxcarbazepine	5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- [CAS]	28721-07-5 29331-92-8	DE 2011087	Antiepileptic	Epilepsy, general
Oxeladin		468-61-1			
Oxendolone		33765-68-3			
Oxethazaine		126-27-2			
Oxetorone		26020-55-3			
oxiconazole	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (Z)- [CAS]	64211-45-6	GB 1514870	Antifungal	Infection, fungal, general
Oxidronic Acid		15468-10-7			
Oxiniacic Acid		2398-81-4			
Oxiracetam		62613-82-5			
oxitropium	3-Oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-(1 α ,2 β ,4 β ,5 α)-[CAS]	30286-75-0	GB 1178305	Antiasthma	
Oxolamine		959-14-8			
Oxolinic Acid		14698-29-4			
Oxophenarsine		538-03-4			
Oxprenolol		6452-71-7			
Oxybenzone		131-57-7			
oxybutynin	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester- [CAS]	5633-20-5		Formulation, modified-release, other	Incontinence
Oxycinchophen		485-89-2			
oxycodone	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5 α)-[CAS]	76-42-6		Formulation, transmucosal, nasal	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Oxyfedrine		15687-41-9			
Oxygent	Octane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro- [CAS]	423-55-2		Haematological	Surgery adjunct
Oxymesterone		145-12-0			
Oxymetazoline		1491-59-4			
oxymetholone	Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α), 17 β - [CAS]	434-07-1		Hormone	Anaemia, general
Oxymethurea	(5 α)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	140-95-4			
oxymorphone		76-41-5		Formulation, modified-release, immediate	Pain, general
Oxypendyl		5585-93-3			
Oxypertine		153-87-7			
Oxyphenbutazone		129-20-4			
Oxyphencyclimine		125-53-1			
Oxyphenisatin		115-33-3			
Oxyphenonium		50-10-2			
Oxypinocamphone		10136-65-9			
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione [CAS]	2465-59-0		Antigout	Hyperuricaemia
Oxytetracycline		79-57-2			
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (E)- [CAS]	78712-43-3 82571-53-7	GB 2025946	Antithrombotic	Vasospasm, cerebral
p-(Benzylsulfonamido)benzoic Acid		536-95-8			
P-100			US 6313177	Antiviral, anti-HIV	Infection, HIV/AIDS
P-1202	Pentanoic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]	79416-27-6	US 6034267	Dermatological	Keratosis
P32/98	Di-(3N-[(2S,3S)-2-amino-3-methylpentanoyl]-1,3-thiazolidine)fumarate			Antidiabetic	Diabetes, Type II
PA-824			WO 9701562	Antimycobacterial	Infection, tuberculosis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PACAP 38	Pituitary adenylate cyclase-activating peptide-38 [CAS]	128606-20-2	US 5128242	Neuroprotective	Nerve injury, general
pacitaxel	5 β ,20-Epoxy-1,2Alpha,4,7 β ,10 β ,13Alpha-hexahydroxytax-11-en-9-one-4,10-diacetate-2-benzoate-13-(Alpha-phenyl)hippurate)	33069-62-4			
PADRE	1H-Isindol-1-one, 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)- (R)- [CAS]		US 6413935	Formulation, optimized, nanoparticles	Cancer, breast
pagodone		133737-32-3	US 4960779	Anxiolytic	Panic disorder
PAI inhbs			WO 9404512	Antithrombotic	Thrombosis, venous
palindore	8H-1,4-dioxino[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenyl)methylamino]methyl]-, 2(S)-, (2E)-2-butendioate (1:1)	189681-71-8		Neuroleptic	Schizophrenia
Palivizumab		188039-54-5			
palonosetron	3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride	135729-62-3	US 5202333	Antiemetic	Chemotherapy-induced nausea and vomiting
Pamabrom		606-04-2			
Pamaquine		491-92-9			
pamicrogel	1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-, ethyl ester [CAS]	101001-34-7	EP 159677	Antithrombotic	Thrombosis, cerebral
pamidronate	(3-Amino-1-hydroxypropylidene)diphosphonic acid- [CAS]	40391-99-9		Formulation, implant	Hypercalcaemia of malignancy
p-Aminobenzoic Acid		150-13-0			
p-Aminohippuric Acid		61-78-9			
p-Aminopropiophenone		70-69-9			
p-Aminosalicylic Acid		65-49-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Panavir	4,4'-isopropylidenedithiobis-2,6-di- <i>t</i> -butylphenol			Neuroprotective	Vasospasm, cerebral
Pancuronium		15500-66-0			
Panipenem		87726-17-8			
Pantethine		16816-67-4			
pantoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- [CAS]	102625-70-7	EP 166287	Antiulcer	Ulcer, duodenal
Pantothenic Acid <i>Papain</i>		79-83-4			
Papaverine		58-74-2			
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2		Formulation, oral, other, modified-release	Pain, general
Paraf lutizide		1580-83-2			
Paraldehyde		123-63-7			
Paramethadione		115-67-3			
Paramethasone		53-33-8			
Paranyline		1729-61-9			
Parathyroid Hormone		9002-64-6			
parecoxib	Propanamide, N-[(4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl]-, sodium salt [CAS]	198470-85-8	WO 9738986	Analgesic, NSAID	Pain, post-operative
Parethoxycaine		94-23-5			
Pargyline		555-57-7			
paricalcitol	19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1 α ,3 β ,7 α ,22 α)- [CAS]	131918-61-1	EP 387077	Hormone	Hyperparathyroidism
paromomycin	O-2-Amino-2-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[O-2,6-diamino-2,6-dideoxy- β -L-idopyranosyl-(1-3)- β -D-ribofuranosyl-(1-5)]-2-deoxy-D-streptamine	7542-37-2		Protozoacide	Infection, leishmaniasis
paroxetine	Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)- [CAS]	61869-08-7	EP 223403	Antidepressant, formulation, oral, orally-disintegrating	Depression, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Paroxypropione		70-70-2			
Parsalimide		30653-83-9			
PaTrim-2	4-Bromothénylguanine			Radio/chemosensitizer	Cancer, melanoma
Pazinacione		103255-66-9			
	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-[CAS]	127045-41-4 127046-45-1 136905-87-8	DE 3913245	Quinolone antibacterial	Infection, general
p-Bromoacetanilide		103-88-8			
PC-NSAIDs			US 4918063	Formulation, other	Arthritis, general
	6-(2,6-Dichlorophenyl)-2-[4-(diethylaminoethoxy)-phenylamino]-8-pyrido[2,3-D]pyrimidine-7-one			Anticancer, other	Cancer, general
PD-0166285					
Pecilocin		19504-77-9			
	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	70458-92-3	GB 1598915	Quinolone antibacterial	Infection, urinary tract
	Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine (human), pegylated [CAS]	218620-50-9		Somatostatin	Acromegaly
Pelletierine		4396-1-4			
	L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrido[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt [CAS]	137281-23-3 150399-23-8	US 5248775	Anticancer, antimetabolite	Cancer, mesothelioma
pemetrexed					
pemilolast	4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)- [CAS]	100299-08-9 69372-19-6	US 4457932	Antialsthma	Asthma
Pemoline		2152-34-3			
Pempidine		79-55-0			
PEN-203			US 5955446	Antiviral, other	Infection, human papilloma virus
Penamecillin		983-85-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
penbutolol	2-Propanol, 1-(2-cyclopentylphenoxy)-3-[[1,1-dimethylethyl)amino]-, (S)-, sulfate (2:1) (salt) [CAS]	38363-32-5 38363-40-5	GB 1215751	Antihypertensive, adrenergic	
peniclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1	JP 60058982	Antiviral, other	Infection, herpes simplex virus
Penethamate		808-71-9			
penfluridol	4-Piperidinol, 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]- [CAS]	26864-56-2	DE 2040231	Neuroleptic	
Penicillamine		52-67-5			
Penicillin G		61-33-6			
Penicillin G Benzathine		1538-09-6			
Penicillin G Procaine		6130-64-9			
Penicillin N		525-94-0			
Penicillin O		87-09-2			
Penicillin V		87-08-1			
Penimepicycline		4599-60-4			
Penntuss			US 4221778	Formulation, modified-release, other	Rhinitis, allergic, general
Pentaerythritol Chloral		78-12-6			
Pentaerythritol		2209-86-1			
Dichlorohydrin					
Pentaerythritol		597-71-7			
Pentagastrin		5534-95-2			
Pentagestrone		7001-56-1			
Pentalyte	Starch, 2-hydroxyethyl ether [CAS]	9005-27-0	US 5407428	Plasma substitute	Surgery adjunct
Pentamethonium		541-20-8			
pentamidine	Benzenecarboximidamide, 4,4'-[1,5-pentanediylbis(oxy)]bis- [CAS]	100-33-4		Formulation, inhalable, systemic	Infection, Pneumocystis jiroveci prophylaxis
Pentazocine		359-83-1			
Pentetate		12111-24-9			
Pentetic Acid		67-43-6			
Pentetreotide		138661-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Penthienate		60-44-6			
Pentifylline		1028-33-7			
Pentigetide		62087-72-3			
Pentisomide		78833-03-1			
Pentobarbital		76-74-4			
Pentolinium		52-62-0			
Pentorex		434-43-5			
pentosan	Xylan, [CAS]	37319-17-8	US 5180715	Urological	Inflammation, urinary tract
pentostatin	Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-25-1	US 3923785	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
pentoxifylline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- [CAS]			Neuroprotective	Amyotrophic lateral sclerosis
Pentoxyl		147-61-5			
Pentritinol		1607-17-6			
Pentylene tetrazole		54-95-5			
peplomycin	Bleomycinamide, N1-[3-[(1-phenylethyl)amino]propyl]-, (S)- [CAS]	68247-85-8	US 4195018	Anticancer, antibiotic	
Perazine		84-97-9			
Perflubron		423-55-2			
Perfosamide		62435-42-1; 39800-16-3 (unspecified)			
pergolide	Ergoline, 8-[(methylthio)methyl]-6-propyl-, (8S)-, monomethanesulfonate- [CAS]	66104-22-1 66104-23-2	US 4797405	Antiparkinsonian	Parkinson's disease
Perhexiline		6621-47-2			
Pericyazine		2622-26-6			
perifosine	Piperidinium, 4-[[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	EP 594999	Anticancer, other	Cancer, prostate
perillyl alcohol	1-Cyclohexene-1-methanol, 4-(1-methylethenyl)- [CAS]	536-59-4	US 5110832	Anticancer, other	Cancer, breast
Perimethazine		13093-88-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aδ,7aδ]]-, compd. with 2-methyl-2-propanamine (1:1) [CAS]	107133-36-8 82834-16-0 95153-31-4	EP 49658	Antihypertensive, renin system	Hypertension, general
Periodyl		53586-99-5			
perisoxal	1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	2139-25-5 2055-44-9	JP 04217925	Anti-inflammatory	
Perlapipe		1977-11-3			
Permethrin		52645-53-1			
persiprone	1H-Isindole-1,3(2H)-dione, 2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-, cis- [CAS]	129273-38-7 150915-41-6	CA 2167004	Neuroleptic	Schizophrenia
Perphenazine		58-39-9			
Petroleum Benzin		8030-30-6			
PH-10		84-12-8	US 6331286	Antipsoriasis	Psoriasis
Phanquinone					
Pharmaprojects No. 4994			WO 9638482	Immunological	Unspecified
Pharmaprojects No. 5325			WO 9703986	Neuroleptic	Schizophrenia
Pharmaprojects No. 5972			WO 0204426	Antiasthma	Asthma
Pharmaprojects No. 6362			US 6057346	Antiviral, anti-HIV	Infection, HIV/AIDS
Pharmaprojects No. 6446	(R)-N-[4-[2-[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide			Anorectic/Antiobesity	Obesity
Pharmaprojects No. 6590			WO 0206223	Psychostimulant	Attention deficit disorder
Pharmaprojects No. 6656			US 6455026	Genomics-based drug discovery	Cancer, brain
Pharmaprojects No. 6691			US 6299900	Formulation, other	Pain, general
Pharmaprojects No. 6743	3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]acrylamide			Antibacterial, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pharmaprojects No. 6748	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methylidibenzo[c,f]pyrazino[1,2-a]azepin				
Phenacaine		620-99-5		Antidepressant	Depression, general
Phenacetamide		63-98-9			
Phenacetin		62-44-2			
Phenadoxone		467-84-5			
Phenallymal		115-43-5			
Phenamet		3819-34-9			
Phenazocine		127-35-5			
Phenazopyridine		136-40-3			
Phenbutamide		3149-00-6			
Phencyclidine		77-10-1			
Phendimetrazine		634-03-7			
Phenelzine		51-71-8			
Phenesterine		3546-10-9			
Phenetharbital		357-67-5			
Phenethicillin		132-93-4			
Pheneturide		90-49-3			
Phenformin		114-86-3			
Phenglutarimide		1156-05-4			
Phenindamine		82-88-2			
Phenindione		83-12-5			
Pheniprazine		55-52-7			
Pheniramine		86-21-5			
Phenmetrazine		134-49-6			
Phenobarbital		50-06-6			
Phenobutiodil		554-24-5			
Phenocoll		103-97-9			
Phenotide		78-05-7			
Phenolphthalein		77-09-8			
Phenolphthalol		81-92-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenolsulfonphthalein		143-74-8			
Phenoltetrachlorophthal- ein		639-44-1			
Phenoperidine		562-26-5			
Phenosulfazole		515-54-8			
Phenoxybenzamine		59-96-1			
Phenoxypropazine		3818-37-9			
Phenprobamate		673-31-4			
Phenprocoumon		435-97-2			
phenserine	Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), (3aS-cis)- [CAS]	101246-66-6		Cognition enhancer	Alzheimer's disease
Phensuximide		86-34-0			
Phentermine		122-09-8			
Phentetiothalein		18265-54-8			
phenylamine	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1 50-60-2		Formulation, oral, other	Impotence
Phenyl Acetylsalicylate		134-55-4			
Phenyl Aminosalicylate		133-11-9			
Phenyl Salicylate		118-55-8			
Phenylbutazone		50-33-9			
Phenylephrine		61-76-7			
Phenylethanamine		7568-93-6			
Phenylmercury		102-98-7			
Phenylmethylbarbituric Acid		76-94-8			
phenylpropanolamine	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Anorectic/Antiobesity, formulation, optimized, microparticles	
Phenylpropylmethylaniline		93-88-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenyltoloxamine		92-12-6			
Phenylramidol		553-69-5			
phenytoin	2,4-Imidazolidinedione, 5,5-diphenyl- [CAS]	57-41-0		Formulation, oral, other	Epilepsy, general
Phethenylate		510-34-9			
Phloroglucinol		108-73-6			
Pholcodine		509-67-1			
Pholedrine		370-14-9			
Phosphocreatine		67-07-2			
Phosphocysteamine		5746-40-7			
Phosphorylcholine		107-73-3			
Phthalylsulfacetamide		131-69-1			
Phthalylsulfathiazole		85-73-4			
p-Hydroxyephedrine		365-26-4			
Phylloquinone		84-80-0			
Physostigmine		57-47-6			
Phytic Acid		83-86-3			
PI-88	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)-hydrogen sulphate [CAS]	185077-23-0		Anticancer, other	Cancer, melanoma
Piberaline		39640-15-8			
piboserod	2H-(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	152811-62-6	WO 9318036	Antiarrhythmic	Fibrillation, atrial
Picilorex		62510-56-9			
Picloxydine		5636-92-0			
Picoperine		21755-66-8			
Picosulfate		10040-45-6			
Picotamide		32828-81-2			
Picumast		39577-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pidotimod	4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2-pyrididinyl)carbonyl]- [CAS]	121808-62-6	EP 276752	Immunomodulator, anti-infective	Infection, respiratory tract, lower
Pifarnine		56208-01-6			
piketoprofen	Benzeneacetamide, 3-benzoyl-Alpha-methyl-N-(4-methyl-2-pyridinyl)- [CAS]	60576-13-8	GB 1436502	Anti-inflammatory, topical	
Pildralazine		64000-73-3			
pilocarpine	2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7		Formulation, implant, Stomatological	
	2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenoic acid, compd. with (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone [CAS]	62783-28-2	DE 2636559	Formulation, mucosal, topical	Glaucoma
Piloplex	1H-Pyrolizine-7a(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, monohydrochloride [CAS]	88069-49-2 88069-67-4	US 4564624	Antiarrhythmic	Arrhythmia, general
plisicainide		534-84-9			
Pimeclone					
	15,19-Epoxy-3H-pyrrodo(2,1-c)(1,4)oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S-(3R*E(1S*,3S*,4R*)), 4S*,5R*,8S*,9E*,12R*,14R*,14R*,5S*,16R*,18S,8,19S*,26aR*)) [CAS]	137071-32-0	EP 626385	Antipruritic/inflamm, allergic	Eczema, atopic
Pimefylline		10001-43-1			
	Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha(1E,3S*,5S*),5B,6aAlpha]]- [CAS]	139403-31-9		Dermatological	Ulcer, general
pimilprost		13495-09-5			
Piminodine		74150-27-9			
Pimobendan					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pimozide	2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro- [CAS]	2062-78-4	FR M3695	Neuroleptic	
Pinacidil		85371-64-8			
	Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, [CAS]	53251-94-8 59995-65-2			
pinaverium			EP 406743	Antispasmodic	Irritable bowel syndrome
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-[CAS]	52463-83-9	DE 2339790	Anxiolytic	
Pindolol		13523-86-9			
	2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, monohydrochloride (+/-)- [CAS]	111025-46-8 112529-15-4	EP 193256	Antidiabetic	Diabetes, Type II
Pipacycline		1110-80-1			
Pipamazine		84-04-8			
Pipamperone		1893-33-0			
Pipazethate		2167-85-3			
Pipebuzone		27315-91-9			
Pipecurium		52212-02-9			
	Piperazinium, 4,4'-[[2ß,3Alpha,5Alpha,16ß,17ß]-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1,1'-dimethyl-, [CAS]	52212-02-9 68399-57-5	GB 1398050	Muscle relaxant	Anaesthesia, adjunct
pipecuronium					
	Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)-[CAS]	51940-44-4	GB 1451911	Antibacterial, other	Infection, urinary tract
Pipemidic acid		125-51-9			
Pipenzolate Bromide		3819-00-9			
Piperacetazine					
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2Alpha,5Alpha,6ß(S*)]]-, [CAS]	59703-84-3 61477-96-1	GB 1508062	Penicillin, injectable	Infection, general
piperacillin					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Piperazine Adipate		142-88-1			
Piperidione		77-03-2			
Piperidolate		82-98-4			
Piperilate		4546-39-8			
piperine analogues			WO 002544	Dermatological	Vitiligo
Piperocaine		136-82-3			
Piperonal		120-57-0			
Piperoxan		59-39-2			
Piperylone		25 31-4-6			
Pipobroman		54-91-1			
Piposulfan		2608-24-4			
	Hexadecanoic acid, 2-[1-[3-[2-[(dimethylamino)sulfonyl]-10H-phenothiazin-10-yl]propyl]-4-piperidinyl]ethyl ester [CAS]	37517-26-3 39860-99-6	US 4782077	Neuroleptic	
pipotiazine		18174-58-8			
Pipoxolan		467-60-7			
Pipradrol					
	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene]-, ethyl ester [CAS]	17243-64-0	US 3971794	GI inflammatory/bowel disorders	Motility dysfunction, GI, general
Piracetam		7491-74-9			
	5,12-Naphthacenedione, 10-[[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy]-, [8S-[8Alpha,10Alpha(S*)]]- [CAS]	72496-41-4	US 4303785	Anticancer, antibiotic	Cancer, breast
pirarubicin		71002-09-0			
Pirazolac		38029-10-6 38677-81-5 65652-44-0			
	2,6-Pyridinedimethanol, Alpha6-[[[(1,1-dimethylethyl)amino]methyl]-3-hydroxy-, monoacetate (salt) [CAS]		US 3786160	Antiasthma	Asthma
Pirenoxine		1043-21-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pirenzepine	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1	FR 1505795	Antitumor	
piretanide	Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)- [CAS]	55837-27-9	US 4010273	Antihypertensive, diuretic	Hypertension, general
pirfenidone	2(1H)-Pyridinone, 5-methyl-1-phenyl- [CAS]	53179-13-8		Respiratory	Fibrosis, pulmonary
piribedil	Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- [CAS]	3605-01-4	US 3299067	Vasodilator, peripheral	Parkinson's disease
Piridocaine		87-21-8			
Pirifibrate		55285-45-5			
Piritramide		302-41-0			
Piritrexim		72732-56-0			
pitindole	1H-Pyrazino[3,2,1-k]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU 276060	Antidepressant	Depression, general
pimrenol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-.Alpha.phenyl-, cis-(+)- [CAS]	61477-94-9 68252-19-7	US 4112103	Antiarrhythmic	Tachycardia, supraventricular
Piroctone		50650-76-5			
Piroheptine		16378-21-5			
Piromidic Acid		19562-30-2			
piroxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4	US 3862319	Anti-inflammatory	
piroxicam betadex	β-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide- [CAS]	121696-62-6 96684-39-8	EP 153998	Formulation, other	Pain, musculoskeletal
piroxicam cinnamate	2-Propenoic acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	EP 79639	Antiarthritic, other	Inflammation, general
Pirozadil		54110-25-7			
Pirprofen		31793-07-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pitavastatin	6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), [S-[R*,S*-(E)]]- [CAS]	147526-32-7	EP 304063	Hypolipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
pivagabine	N-trimethylacetate-4-aminobutyric acid	63542-93-4		Neurological	Anxiety, general
pivaloyloxymethyl	Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester [CAS]	122110-53-6	EP 302349	Anticancer, other	Cancer, lung, non-small cell
Pivalylbenzhydrazine		306-19-4			
Pivampicillin		33817-20-8			
pivampicillin/pivmecillinam		98445-47-7		Penicillin, oral	Infection, general
Pivcefalexin		63836-75-9			
pivmecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha,5Alpha,6S)]- [CAS]	32886-97-8	GB 1293590	Penicillin, oral	Infection, general
pixantone	Benz[<i>g</i>]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2 <i>Z</i>)-2-butenedioate(1:2) [CAS]	144675-97-8	EP 503537	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
pizotifen	4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2- <i>b</i>]thien-4-ylidene)-1-methylpiperidine	15574-96-6	DE 2346747	Antimigraine	
Pizotyline		15574-96-6			
PKI-166	Phenol, 4-(4-(((1 <i>R</i>)-1-phenylethyl)amino)-1 <i>H</i> -pyrrolo[2,3- <i>d</i>]pyrimidin-6-yl)- [CAS]	187724-61-4		Anticancer, other	Cancer, general
p-Lactophenetide		539-08-2			
Plafibride		63394-05-8			
plasminogen activator	Plasminogen activator [CAS]	105913-11-9	EP 151996	Fibrinolytic	Infarction, myocardial
Plasmocid		551-01-9			
Platonin		3571-88-8			
Plaunotol		64218-02-6			
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1 <i>R</i> ,2 <i>S</i>)- [CAS]	198022-65-0	EP 805145	Antifungal	Infection, Candida, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PLD-147	(OC-6-43)-Bis(acetato)(1-adamantylamine)amine-dichloro-platinum (IV)			Anticancer, alkylating	Cancer, general
pleconaril	1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- [CAS]	153168-05-9	US 5464848	Antiviral, other	Infection, respiratory tract, general
Plicamycin		18378-89-7			
p-Methyldiphenhydramine		19804-27-4			
PMS-601			WO 0001677	Antiviral, anti-HIV	Infection, HIV/AIDS
<i>Pneumococcal Vaccine, Diphtheria Conjugate</i>					
<i>Pneumococcal Vaccine, Polyvalent</i>					
PNU-288034	N-[[[(5s)-3[4[(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide]			Antibiotic, other	Infection, general
Podophyllotoxin		518-28-5			
polaprezinc	Zinc, bis(N-β-alanyl-L-histidinato-N3,OAlpha)-, (T-4)- [CAS]	107667-60-7	EP 303380	Antitumor	Ulcer, duodenal
Poldine Methylsulfate		545-80-2			
Policresulen		9011-2-3			
Polidexide		9064-92-0			
polidocanol	Polyethylene glycol monododecyl ether	3055-99-0			
		9002-92-0		Vasoprotective, systemic	Venous insufficiency
<i>Poliovirus Vaccine Inactivated</i>					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
poly-ADPRT inhibitors			WO 9845253	Anticancer, other	Cancer, general
Polyestradiol Phosphate		28014-46-2			
Polyphenon E	Polyphenon E [CAS]	188265-33-0			Infection, human papilloma virus
Polythiazide		346-18-9		Antiviral, other	
porfimer	Photofrin [CAS]	87806-31-3			
Porfiromycin		801-52-5	US 4882234	Anticancer, other	Cancer, lung, non-small cell
posaconazole	D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(1S,2S)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)- [CAS]	171228-49-2	US 5714490	Antifungal	Infection, fungal, general
Posatairelin		78664-73-0			
potassium chloride	Potassium chloride (KCl) [CAS]	7447-40-7		Formulation, oral, enteric-coated	
Potassium Gluconate		299-27-4			
Potassium		1321-14-8			
Guaiacolsulfonate		138-84-1			
Potassium p-Aminobenzoate		7722-64-7			
Potassium Permanganate		9003-39-8			
Povidone		25655-41-8			
Povidone-Iodine		62756-44-9			
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]		DE 2633028	Formulation, oral, other	Unspecified
PR-2699	(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetone nitrile			Antifungal	Infection, fungal, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PR-608	(S)-(-)-1-[4,4-bis(4-fluorophenyl)butyl]-4-(2-hydroxy-3-phenylaminopropyl)piperazine trihydrochloride			Antiparkinsonian	Parkinson's disease
Practolol		6673-35-4			
Praimaline		35080-11-6			
Pralidoxime		51-15-0			
pralnacasan	6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxamide, N-((2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl)octahydro-9-((1-isoquinolinylcarbonyl)amino)-6,10-dioxo-, (1S,9S)- [CAS]	192755-52-5		Antiarthritic, immunological	Arthritis, rheumatoid
pramipexole	2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)- [CAS]	104632-26-0	EP	Antiparkinsonian	Parkinson's disease
pramiracetam	1-Pyrrolidineacetamide, N-[2-bis(1-methylethyl)aminoethyl]-2-oxo-, monohydrochloride [CAS]	68497-62-1 72869-16-0 75733-50-5	US	Cognition enhancer	Amnesia
Pramiverin		14334-40-8			
pramlintide	1,2-Dithia-5,8,11,14,17-pentaazacycloicosane, cyclic peptide deriv. [CAS]	151126-32-8	US	Antidiabetic	Diabetes, Type I
Pramoxine		140-65-8			
pranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-phenyl-2-propenyl ester, (E)- [CAS]	99522-79-9	EP	Antihypertensive, other	Hypertension, general
Pranlukast		103177-37-3			
pranoprofen	5H-[1]Benzopyrano[2,3-b]pyridine-7-acetic acid, Alpha-methyl- [CAS]	52549-17-4		Formulation, mucosal, topical	Ocular disorder, general
prasterone	Androst-5-en-17-one, 3-hydroxy-, (3S)- [CAS]	53-43-0		Labour inducer	
prazosin	4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2'-(1H-tetrazol-5-yl)](1,1'-biphenyl)-4-yl]methyl]- [CAS]	153804-05-8	US	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pravastatin	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- β , delta, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S- [1 α pha(β S*, deltaS*), 2 α pha, 6 α pha, 8 β (R*), 8a α pha]]- [CAS]	81093-37-0 81131-70-6	US 4346227	Hypolipemic/Antiatherosclerosis	Atherosclerosis
Prazepam		2955-38-6			
praziquantel	4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- [CAS]	55268-74-1	US 4001411	Schistosomicide	
prazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-[CAS]	19216-56-9 19237-84-4	US 4092315	Antihypertensive, adrenergic	Hypertension, general
Prednicarbate		73771-04-7			
prednimustine	Pregna-1,4-diene-3,20-dione, 21-[4-[4-bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-11,17-dihydroxy-, (11 β S)- [CAS]	29069-24-7	GB 1272841	Anticancer, alkylating	
Prednisolone		50-24-8			
Prednisolone 21-Diethylaminoacetate		5626-34-6			
prednisolone farnesil	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]-, [11 β S, 21(2E,6E)]- [CAS]	118244-44-3	EP 332143	Antiartritic, other	Arthritis, rheumatoid
Prednisolone Sodium Phosphate		125-02-0			
Prednisone		53-03-2			
Prednival		15180-00-4			
Prednylidene		599-33-7			
pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]	148553-50-8		Antiepileptic	Epilepsy, general
Pregnan-3α-ol-20-one		128-20-1			
Premarin + trimegestone	Estro-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17 β (S)]- [CAS]	74513-62-5		Menopausal disorders	Hormone replacement therapy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
prenalterol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, hydrochloride, (S)-[CAS]	57526-81-5 61260-05-7	GB 1470039	Cardio stimulant	
Prenoxdiazine		982-43-4			
Prenylamine		390-64-7			
prezatide	Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L-lysinate)(N2-(N-glycyl-L-histidyl)-L-lysinate(2-))-, hydrogen, [CAS]	130120-57-9		Vulnery	Wound healing
Pridinol		511-45-5			
Prifinium		4630-95-9			
Prilocaine		721-50-6			
Primaquine		90-34-6			
Primidone		125-33-7			
Prinomastat		192329-42-3			
PRO-2000			US 5614599	Antiviral, anti-HIV	Infection, HIV prophylaxis
Probenecid		57-66-9			
Probutol		23288-49-5			
procalnamide	Benzamide, 4-amino-N-[2-(diethylamino)ethyl]- [CAS]	51-06-9 614-39-1		Formulation, other	Arrhythmia, general
Procaine		59-46-1			
Procarbazine		671-16-9			
procaterol	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1-methylethyl)amino]butyl]-, monohydrochloride [CAS]	59828-07-8 60443-17-6 72332-33-3	GB 1496766	Antiasthma	
prochlorperazine	10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-, (Z)-2-butenedioate	58-38-8 84-02-6		Formulation, oral, other	Nausea and vomiting, general
procodazol	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0	ES 407882	Anticancer, immunological	Cancer, general
Procyclidine		77-37-2			
Procymate		13931-64-1			
Prodipine		31314-38-2			
Proflavine		92-62-6			
Progabide		62666-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
progesterone	Pregn-4-ene-3,20-dione [CAS]	57-83-0		Formulation, transmucoasal, systemic	Amenorrhoea
proglumetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethyl ester, (+/-) [CAS]	57132-53-3 59209-40-4	GB	Anti-inflammatory	Inflammation, general
proglumide	Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+/-) [CAS]	6620-60-6	DE	Antilulcer	Ulcer, gastric
Proheptazine		77-14-5			
Prolactin		9002-62-4			
Prolintane		493-92-5			
Prolonium		123-47-7			
Promazine		58-40-2			
Promedol		64-39-1			
Promegestone		34184-77-5			
promestriene	Estra-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17 β) [CAS]	39219-28-8	GB	Reproductive/gonadal, general	Acne
Promethazine		60-87-7			
Pronethalol		54-80-8			
propacetamol	Glycine, N,N-diethyl-, 4-(acetylamino)phenyl ester [CAS]	66532-85-2 66532-86-3	US	Formulation, parenteral, other	
propafenone	1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl- [CAS]	54063-53-5	GB	Antiarrhythmic	Fibrillation, ventricular
Propagermanium		12758-40-6			
Propallylonal		545-93-7			
Propamidine		104-32-5			
propane-1,2-diol	1,2-propanediol	57-55-6		Formulation, dermal, topical	Infection, fungal, general
Propanidid		1421-14-3			
Propantheline		50-34-0			
Proparacaine		499-67-2			
Propatyl		2921-92-8			
propenidazole	ethyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76448-31-2		Antifungal	Infection, trichomoniasis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
propentofylline	1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl- [CAS]	55242-55-2	GB 1470220	Neuroprotective	Ischaemia, cerebral
Propicillin		551-27-9			
Propiomazine		362-29-8			
Propionic Acid		79-09-4			
propionyl L-carnitine	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)- [CAS]	119793-66-7 20084-19-1	GB 2008578	Vasodilator, peripheral	Peripheral vascular disease
Propipocaine		3670-68-6			
Propiram		15686-91-6			
propiverine	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-8 60569-19-9		Urological	Incontinence
Propizepine		10321-12-7			
propofol	Phenol, 2,6-bis-(1-methylethyl)- [CAS]	2078-54-8	US 4056635	Anaesthetic, injectable	Anaesthesia
Propoxycaine		550-83-4			
Propoxyphene		469-62-5			
propranolol	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	318-98-9 525-66-6		Formulation, modified-release, <=24hr	Hypertension, general
Propylhexedrine		101-40-6			
Propylidone		587-61-1			
Propylthiouracil		51-52-5			
Propyphenazone		479-92-5			
Proquazone		22760-18-5			
Proscillaridin		466-06-8			
Prostacyclin		35121-78-9			
Prostaglandin E₁		745-65-3			
Prostaglandin E₂		363-24-6			
Prostaglandin F_{2α}		551-11-1			
Prosultiamine		59-58-5			
Protein C		60202-16-6			
Protheobromine		50-39-5			
Prothipendyl		303-69-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Protiofate		58416-00-5			
Protionamide		14222-60-7			
protizinic acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha, 10-dimethyl-, (+/-) [CAS]	13799-03-6	US 3450698	Anti-inflammatory	
Protoanemonin		108-28-1			
Protokylol		136-70-9			
Protoporphyrin IX		553-12-8			
Protriptyline		438-60-8			
Pro-Urokinase		82657-92-9			
Proxazole		5696-9-3			
Proxibarbal		2537-29-3			
proxigermanium	Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis- [CAS]	12758-40-6	FR 2005110	Antiviral, other	Infection, hepatitis-B virus
Proxiphylline		603-00-9			
Prozapine		3426-8-2			
Prucalopride		179474-81-8			
prulifloxacin	1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo- [CAS]	123447-62-1	EP 315828	Quinolone antibacterial	Infection, respiratory tract, general
Pseudococaine		478-73-9			
pseudoephedrine + triprolidine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*, R*)]-, mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]				
pseudoephedrine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	90-82-4, 8054-27-1, 345-78-8		Formulation, modified-release, other	Rhinitis, allergic, general
Psilocybin		520-52-5		Formulation, oral, other	Infection, respiratory tract, general
PSK-3841	Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	154992-24-2		Dermatological	Alopecia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
p-Sulfamylbenzylamine		4393-19-5			
PT-141			US 6051555	Male sexual dysfunction	Impotence
Pteropterin		89-38-3			
Puromycin		53-79-2			
PX-12	1-Methylpropyl 2-mercaptoimidazolyl disulfide			Anticancer, other	Cancer, general
Pyrantel		15686-83-6			
Pyrazinamide		98-96-4			
Pyridinol Carbamate		1882-26-4			
Pyridostigmine Bromide		101-26-8			
Pyridoxal 5-Phosphate		54-47-7			
Pyridoxine		58-56-0			
Pyrilamine		91-84-9			
Pyrimethamine		58-14-0			
Pyrinoline		1740-22-3			
Pyrisuccideanol		33605-94-6			
Pyrithione		1121-30-8			
Pyrrithyldione		77-04-3			
Pyritinol		1098-97-1			
Pyrocatechol		120-80-9			
Pyrogallol		87-66-1			
Pyronaridine		74847-35-1			
Pyrovalerone		3563-49-3			
Pyroxilin		9004-70-0			
Pyrrobutamine		91-82-7			
Pyrrocaine		2210-77-7			
Pyrrolnitrin		1018-71-9			
Pyvinium Pamoate		3546-41-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
quazepam	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)- [CAS]	36735-22-5	US 3845039	Hypnotic/Sedative	Insomnia
Quercetin		117-39-5			
quetiapine	Ethanol, 2-[2-(4-dibenzolb, f[1,4]thiazepin-11-yl)-1-piperazinyl]ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2	EP 240228	Neuroleptic	Schizophrenia
Quinacillin		1596-63-0			
quinacrine	N-(6-Chloro-2-methoxy-9-acridinyl)-N,N-diethyl-1,4-pentanediamine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl	83-89-6		Neurological	Creutzfeldt-Jakob disease
quinagolide	Sulfamide, N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl)-, (3Alpha,4aAlpha,10aß)- (+/-) [CAS]	87056-78-8 94424-50-7 97805-49-7	EP 77754	Antiprolactin	Hyperprolactinaemia
quinapril	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*)],3R*]]- [CAS]	82586-55-8 85441-61-8 90243-99-5	EP 49605	Antihypertensive, renin system	Hypertension, general
quinaprilat	3-Isoquinolinecarboxylic acid, 2-[2-[[1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*)],3R*]]- [CAS]	82769-85-2	EP 46953	Antihypertensive, renin system	Hypertension, general
Quinapyramine		20493-41-8			
Quinbolone		2487-63-0			
Quinestradiol		1169-79-5			
Quinestrol		152-43-2			
Quinethazone		73-49-4			
quinfamide	2-Furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester [CAS]	62265-68-3	US 3997542	Amoebicide	
quinidine	Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	747-45-5 56-54-2		Formulation, modified-release, other	Arrhythmia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Quinine		130-95-0			
Quinocidine		525-61-1			
Quinupramine		31721-17-2			
Quinupristin		120138-50-3			
R-107500	cis-2,3,3a,8-tetrahydro-N,N-dimethylidibenz[c,f]isoxazolo[2,3-a]jzepine-2-methanamine				
R-667			WO 9614320	Anxiolytic	Anxiety, general
			WO 0204439	COPD treatment	Emphysema, general
rabeprazole	1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt- [CAS]	117976-89-3 117976-90-6			
	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (+/-)- [CAS]	112573-72-5 81110-73-8	EP 268956	Antiulcer	Ulcer, gastric
racemethorphan		510-53-2	EP 38758	Antidiarrhoeal	Diarrhoea, general
	Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinylethoxy)phenyl]-, hydrochloride [CAS]	82640-04-8 84449-90-1		Osteoporosis treatment	Osteoporosis
raloxifene	L-glutamic acid, N-[[5-[[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]- [CAS]	112887-68-0	EP 239362	Anticancer, antimetabolite	Cancer, colorectal
ralitrexed	9H-Carbazole-9-propanoic acid, 3-[[[4-fluorophenyl]sulfonyl]amino]-1,2,3,4-tetrahydro-, (R)- [CAS]	116649-85-5	EP 242518	Antiallergic, non-asthma	Rhinitis, allergic, perennial
ramatroban		3615-24-5			
Ramifenazone	Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aIs,6aIs]]- [CAS]	87269-97-4 87333-19-5	EP 79022	Antihypertensive, renin system	Heart failure
ramipril	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3 132036-88-5	EP 381422	Antiemetic	Nausea and vomiting, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ramot project No. 1097			US 5730992	Dermatological	Unspecified
Ranimustine		58994-96-0			
ranitidine	1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]	66357-35-5	US 4128658	Antiulcer	Ulcer, duodenal
ranitidine bismuth citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy-bismuth(3+) salt (1:1), compd. with N-(2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl)-N'-methyl-2-nitro-ethenediamine (1:1)- [CAS]	128345-62-0	EP 533281	Antiulcer	Ulcer, duodenal
ranolazine	1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)- [CAS]	95635-55-5 95635-56-6	EP 126449	Antianginal	Angina, general
Ranpirnase		133737-96-9			
Rapacuronium		156137-99-4			
rasagiline	1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (R)-, [CAS]	161735-79-1	US 5457133	Antiparkinsonian	Parkinson's disease
Raubasine		483-04-5			
ravuconazole	Benzonitrile, 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]- [CAS]	182760-06-1		Antifungal	Infection, meningitis, general
raxofelast	2-Benzofuranacetic acid, 5-(acetoxy)-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	US 4999350	Symptomatic antidiabetic	Nephropathy, diabetic
razoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediy)bis- [CAS]	21416-67-1, 21416-87-5	GB 1234935	Anticancer, other	Cancer, general
RC-529	Tetradecanoic acid (1R)-1-(2-((2-(2-deoxy-3-O-((3R)-1-oxo-3-(1-oxotetradecyl)oxy)tetradecyl)amino-4-O-phosphono-β-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester, compd. with N,N-diethylethanamine (1:1) [CAS]	216014-46-9		Immunostimulant, other	Vaccine adjunct
rebamipide	4-Quinolonepropanoic acid, Alpha-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- [CAS]	90098-04-7	DE 3324034	Antiulcer	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rebimastat	L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl- [CAS]	259188-38-0		Anticancer, other	Cancer, lung, non-small cell
reboxetine	Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,S*)- [CAS]	71620-89-8, 98769-81-4	US 4229449	Antidepressant	Depression, general
Remacemide		128298-28-2			
remifentanyl	1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-methyl ester- [CAS]	132539-07-2, 132875-61-7	EP 383579	Analgesic, other	Pain, general
reminertant	Tricyclo[3.3.1.1 ^{3,7}]decane-2-carboxylic acid, 2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]- [CAS]	146362-70-1	EP 699438	Neuroleptic	Schizophrenia
Remoxipride		80125-14-0			
renzapride	Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy- [CAS]	109872-41-5, 88721-77-1	JP 58188885	Gastroprokinetic	Irritable bowel syndrome
repaglinide	Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]	135062-02-1	WO 9300337	Antidiabetic	Diabetes, Type II
repertaxin L-lysine salt	2(R)-4-Isobutylphenylpropionyl methanesulfonamide L-lysine salt		WO 0024710	Cardiovascular	Reperfusion injury
repinotan	1,2-Benzisothiazol-3(2H)-one, 2-(4-(((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)amino)butyl)-, 1,1-dioxide, monohydrochloride [CAS]	144980-29-0, 144980-77-8	US 5137901	Neuroprotective	Ischaemia, cerebral
repinast	4H-Pyranol[3,2-c]quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, 3-methylbutyl ester [CAS]	73080-51-0	US 4298610	Antiasthma	
Reposal		3625-25-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
reproterol	1H-Purine-2,6-dione, 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3-dimethyl- [CAS]	13055-82-8 54063-54-6	FR M5969	Antiasthma	Asthma
Rescimetol		73573-42-9			
Rescinnamine		24815-24-5			
Reserpiline		131-02-2			
Reserpine		50-55-5			
Resibufogenin		465-39-4			
resiquimod	1H-Imidazo(4,5-c)quinoline-1-ethanol(ethoxymethyl)-Alpha, Alpha-dimethyl- [CAS]	144875-48-9	US 5389640	Antiviral, other	Infection, hepatitis-C virus
Resorcinol		108-46-3			
Reteplase		133652-38-7			
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester [CAS]	150812-12-7	DE 4200259	Antiepileptic	Epilepsy, general
retinoic acid	Retinoic acid [CAS]	302-79-4		Formulation, parenteral, other	Cancer, leukaemia, acute myelogenous
Revimid			US 6281230	Anticancer, other	Cancer, myeloma
R-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl	5104-49-4		Anticancer, other	Cancer, prostate
Rho (D) Immune Globulin (Human)					
Rho-kinase inhibitors			WO 0156988	Antiasthma	Unspecified
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- [CAS]	36791-04-5	US 4211771	Antiviral, other	Infection, haemorrhagic fever
Riboflavin		146-17-8			
ribostamycin	D-Streptamine, O-2,6-diamino-2,6-dideoxy-Alpha-D-glucopyranosyl-(1-4)-O-[β-D-ribofuranosyl-(1-5)]-2-deoxy- [CAS]	25546-65-0	GB 1254883	Aminoglycoside antibiotic	Infection, general
Ricinoleic Acid		141-22-0			
Ridogrel		110140-89-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rifabutin	Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo-[CAS]	72559-06-9	US 4219478	Antimycobacterial	Infection, Mycobacterium avium complex
rifalazil	Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo- [CAS]	129791-92-0 129791-94-2 133633-12-2	EP 366914	Antimycobacterial	Infection, tuberculosis
rifametan	Rifamycin, 3-[[[1-(diethylamino)ethylidene]hydrazono]methyl]- [CAS]	94168-98-6	EP 119571	Antimycobacterial	Infection, general
Rifamide		2750-76-7			
rifampicin + trimethoprim	Rifamycin, 3-[[[4-methyl-1-piperazinyl]imino]methyl]-, mixt. with 5-[[[3,4,5-trimethoxyphenyl]methyl]-2,4-pyrimidinediamine [CAS]	61498-94-0		Formulation, fixed-dose combinations	Infection, general
Rifampin		13292-46-1			
Rifamycin SV		6998-60-3			
rifapentine	Rifamycin, 3-[[[4-cyclopentyl-1-piperazinyl]imino]methyl]- [CAS]	61379-65-5	DE 2608218	Antibiotic, other	Infection, tuberculosis
rifaximin	Epoxy pentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, [2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]	80621-81-4	GB 2079270	Antibiotic, other	Infection, GI tract
rifaximine cream	4-deoxy-4'-methylpyrido[1',2'-1,2]imidazo[5,4-c]rifamycin SV	80621-81-4	BE 888895	Formulation, dermal, topical	Infection, dermatological
Rilmazafone		99593-25-6			
rilmidenine	2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro- [CAS]	54187-04-1			
riluzole	2-Benzothiazolamine, 6-(trifluoromethoxy)-[CAS]	54249-57-9	DE 2362754	Antihypertensive, adrenergic	Hypertension, general
Rimantadine		1744-22-5	EP 50551	Neuroprotective	Amyotrophic lateral sclerosis
		13392-28-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rimazolium	4H-Pyrido[1,2-a]pyrimidin-3-(ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-, [CAS]	28610-84-6 35615-72-6	DE 2461349	Analgesic, NSAID	
rimexolone	Androsta-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11 β ,16 α), [CAS]	49697-38-3	DE 2301317	Ophthalmological	Inflammation, ocular
Rimiterol		32953-89-2			
	1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride [CAS]	158681-13-1	US 5624941	Anorectic/Antiobesity	Obesity
	1,3-Benzenediol, 2,4,6-triiodo- [CAS]	19403-92-0	US 3755251	Antiviral, other	
Rioprostil		77287-05-9			
	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt	115438-72-1	EP 304961	Osteoporosis treatment	Paget's disease
Risedronic Acid		105462-24-6			
	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-, [CAS]	106266-06-2	EP 196132	Neuroleptic, formulation, optimized, microencapsulate	Schizophrenia
Ritanserlin		87051-43-2			
Ritipenem		84845-57-8			
	Benzenemethanol, 4-hydroxy-Alpha-[1-[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, (R*, S*)-, [CAS]	23239-51-2 26652-09-5	US 3410944	Labour inhibitor	Labour, preterm
	2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*, 8R*, 10R*, 11R*))-, [CAS]	155213-67-5	WO 9414436	Antiviral, anti-HIV	Infection, HIV/AIDS
Rituximab		174722-31-7			
	Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester, (S)-[CAS]	123441-03-2 129101-54-8	DE 3805744	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rizatriptan	1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, [CAS]	145202-66-0 159776-67-7 144034-80-0	EP 497512	Antimigraine	Migraine
RJR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-, (3E)-, (2E)-2-butenedioate (1:1) [CAS]	183288-99-5		Cognition enhancer	Alzheimer's disease
RNA Stealth Nucleosides	5-Formyluridine			Antiviral, other	Infection, hepatitis-C virus
Ro-0094889	2',3'-Di-O-acetyl-5'-vinylcytidine			Anticancer, antimetabolite	Cancer, general
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl-, [CAS]	180384-56-9	WO 9619459	Cardiovascular	Haemorrhage, subarachnoid
Rociverine	Pyrrrolidinium, 1-[[2β,3α,5α,16β,17β]-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstane-16-yl]-1-(2-propenyl)-, bromide-, [CAS]	53716-44-2			
rocuronium		104855-17-6 104884-91-5 119302-91-9 143558-00-3	EP 287150	Muscle relaxant	Muscle spasm, general
rofecoxib	2(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-, [CAS]	162011-90-7	US 5474995	Analgesic, NSAID	Arthritis, osteo
roflumilast	Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-, [CAS]	162401-32-3	WO 9501338	COPD treatment	Chronic obstructive pulmonary disease
rokitamycin	Leucomycin V, 4B-butanolate 3B-propanoate [CAS]	74014-51-0	US 4242504	Macrolide antibiotic	Infection, general
Rolipram		61413-54-5			
Rolitetracycline		751-97-3			
Romurtide		78113-36-7			
Ronifibrate		42597-57-9			
ropinirole	2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, monohydrochloride-, [CAS]	91374-20-8 91374-21-9	EP 266033	Antiparkinsonian	Parkinson's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ropivacaine	2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]	84057-95-4 98717-15-8	EP 239710	Anaesthetic, local	Anaesthesia
Roquinimex		84088-42-6			
rosaprostol	Cyclopentanepentanoic acid, 2-hexyl-5-hydroxy- [CAS]	56695-65-9	GB 1523355	Prostaglandin	
Rosaramicin		35834-26-5			
Rose Bengal		632-68-8			
rosiglitazone	2,4-Thiazolidinedione, 5-((4-(2-methyl-2-pyridinylamino)ethoxy)phenyl)methyl-, (Z)-2-butenedioate (1:1) [CAS]	122320-73-4 155141-29-0	US 5002953	Antidiabetic	Diabetes, Type II
rosoxacin	3-Quinolonecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- [CAS]	40034-42-2	US 3753993	Quinolone antibacterial	Infection, gonorrhoea
rostaporphin	Tin, dichloro[ethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kappaN23,kappaN24,kappaN25,kappaN26], (OC-6-13)- [CAS]	114494-17-6		Ophthalmological	Macular degeneration
rosuvastatin	6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy- (S-(R*, S*-(E))) [CAS]	147098-20-2	JP 2648897	Hypolipaeic/Antiatherosclerosis	Hyperlipidaemia, general
rotigotine	1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (S)- [CAS]	99755-59-6	US 4564628	Antiparkinsonian	Parkinson's disease
Rotraxate		92071-51-7			
Roxarsone		121-19-7			
roxatidine	Acetamide, 2-(acetyloxy)-N-[3-[3-(1-piperidinyl)methyl]phenoxy]propyl-, [CAS]	78628-28-1 93793-83-0	EP 24510	Antilucer	Ulcer, gastric
roxifiban	L-Alanine, 3-(((3-(4-(aminoliminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-, [CAS]	176022-59-6	US 5849736	Antithrombotic	Thrombosis, general
Roxindole		112192-04-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
roxithromycin	Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime] [CAS]	80214-83-1 80214-86-4	EP 33255	Macrolide antibiotic	Infection, general
RPR-109881A	Benzenepropanoic acid, β -(((1,1-dimethylethoxy)carbonyl)amino)- α -hydroxy-(1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acetyloxy)-1-(benzyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca(3,4)cyclopropa (4,5) benz (1,2-b) oxet-4-yl ester, dihydrate α R, betaS [CAS]	192573-38-9		Anticancer, other	Cancer, lung, general
RPR-130401	4,9-Ethano-3aH-benz[<i>f</i>]isoindole-3a-carboxylic acid, 1,2,3,4,9,9a-hexahydro-2-[2-(2-methoxyphenyl)-1-oxo-2-propenyl]-9-(4-methylphenyl)-, (3aR,4S,9S,9aR)-rel- [CAS]	210282-69-2	WO 9829390	Anticancer, other	Cancer, general
R-roscovitine	N,N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine		US 6316456	Anticancer, other	Cancer, lung, non-small cell
RS-0406				Neuroprotective	Alzheimer's disease
RSR-13		131179-95-8			
Rubijervine		79-58-3			
rubitecan	1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]	91421-42-0	US 6485514	Anticancer, other	Cancer, pancreatic
ruboxistaurin	9H,18H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione, 9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (S)- [CAS]	169939-94-0		Symptomatic antidiabetic	Retinopathy, diabetic
Rufinamide		106308-44-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rifloxacin	7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 102052-47-1 106017-08-7	EP 165375	Quinolone antibacterial	Infection, general
rupatadine	5H-Benzof[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, trihydrochloride- [CAS]	156611-76-6	EP 0577957	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Rutin		153-18-4			
RWJ-54428	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxymino)acetyl]amino]-3-[(3-[(2-aminoethyl)thio]methyl)-4-pyridinyl]thio]-8-oxo-, (6R,7R)- [CAS]	189448-35-9	WO 9713772	Cephalosporin, injectable	Infection, beta-lactamase resistant
S-0139	Olean-12-en-28-oic acid, 27-[[3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-butenyl)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS]	193969-54-9	WO 9727314	Cardiovascular	Ischaemia, cerebral
S-15535	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS]	146998-34-7		Cognition enhancer	Cognitive disorder, general
S-18886	1-Naphthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl [CAS]	165537-73-5		Antithrombotic	Thrombosis, general
S-34730	7-chloro-6-sulfamoyl-2-(1H)-quinoleinone-3-phosphonic acid			Neuroprotective	Unspecified
S-3578	7[5-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-(1-(N-methylaminopropyl)-1H-imidazo[4,5-b]pyridinium-4-methyl-3-cephem-4-carboxylate monosulfate			Cephalosporin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
S-36496	2-[N-[4-(4-Chlorophenylsulfonylamino)butyl]-N-{3-[(4-isopropylthiazol-2-yl)methoxy]benzyl}sulfamoyl]benzoic acid			Antiasthma	Asthma
S-36527	2-[N-[4-(4-Chlorophenylsulfonylamino)butyl]-N-{3-[2-(4-cyclobutylthiazol-2-yl)ethyl]benzyl}sulfamoyl]benzoic acid			Antiasthma	Asthma
S-5751	(1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiophen-3-ylcarboxamido)-6,6-dimethylbicyclo[3.1.1]hept-3yl]-5(Z)-heptenoic acid			Antiallergic, non-asthma	Allergy, general
S-8510	Imidazo[4,5-d]pyranol[4,3-b]pyridine, 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-, phosphate (1:1) [CAS]	151466-23-8	EP 556008	Cognition enhancer	Alzheimer's disease
S-8921	2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS]	151165-96-7	WO 9308155	Hypolipaeamic/Antiatherosclerosis	Hypercholesterolaemia
Sabcomeline		159912-53-5			
Sabeluzole		104383-17-7			
S-Adenosylmethionine		29908-03-0			
safinamide	(S)-(+)-2-[4-(3-fluorobenzoyloxy)benzylamino]propanamide methansulfonate	133865-89-1	AU 711309	Antiepileptic	Epilepsy, general
Salacetamide		487-48-9			
Salazosulfadimidine		2315-8-4			
salbutamol	1,3-Benzenedimethanol, Alpha 1-[[[1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9	EP 451745	Formulation, inhalable, topical, dry powder	Asthma
Salicin		138-52-3			
Salicyl Alcohol		90-01-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Salicylamide		65-45-2			
Salicylamide O-Acetic Acid		25395-22-6			
Salicylanilide		87-17-2			
Salicylic Acid		69-72-7			
Salicylsulfuric Acid		89-45-2			
Salinazid		495-84-1			
salmeterol	1,3-Benzenedimethanol, 4-hydroxy-Alpha1, [[16-(4-phenylbutoxy)hexyl]amino]methyl]-, (±)- 1-hydroxy-2-naphthalenecarboxylate [CAS]	89365-50-4 94749-08-3	WO 9006775	Antiasthma	Asthma
Salsalate		552-94-3			
Salverine		6376-26-7			
Samarium ¹⁵³ Sm Lexidronam		154427-83-5			
sampatriat	L-Tyrosine, N2-(methylsulfonyl)-L-lysyl-1-[(2S)-3-amino-2-carboxypropyl]cyclopentanecarbonyl- [CAS]	129981-36-8	EP 358398	Antihypertensive, renin system	Hypertension, general
Sancycline		808-26-4			
Saperconazole		110588-57-3			
sapropterin	4(1H)-Pteridinone, 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-, dihydrochloride, [6R-[6R*(1R*,2S*)]]- [CAS]	69056-38-8 62989-33-7	EP 191335	Antidepressant	Hyperphenylalaninaemia
saquinavir	Butanediamide, N1-[3-[3-[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S-[2[1R*(R*),2S*),3Alpha,4a8,8a8]]- [CAS]	127779-20-8	EP 432695	Antiviral, anti-HIV	Infection, HIV/AIDS
Saralasin		34273-10-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
saregutant	Benzamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, (S)- [CAS]	142001-63-6	EP 474561	Antiasthma	Asthma
sarizotan	3-Pyridinemethanamine, N-((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)- [CAS]	177975-08-5		Antiparkinsonian	Parkinson's disease
sarpogrelate	Butanedioic acid, mono[2-(dimethylamino)-1-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl ester [CAS]	125926-17-2	EP 398326	Antithrombotic	
Satigrel	Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)- [CAS]	111753-73-2			
satraplatin		129580-63-8	EP 328274	Anticancer, alkylating	Cancer, prostate
Satumomab		144058-40-2			
SB-237376	N-[3-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl-4-nitrobenzamide, HCl			Antiarrhythmic	Fibrillation, atrial
SB-238039	(5-(2-phenylamino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole			Anticancer, other	Cancer, general
SB-277011	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide			Neuroleptic	Schizophrenia
Scarlet Red		85-83-6			
SCH-00013	Benzonitrile, 4-[2-[3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1-(2H)-pyridinyl]-1-hydroxyethyl]- [CAS]	217963-18-3	EP 618204	Cardio stimulant	Heart failure
Sch-23863	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo[a,d] cyclohepten-S-yl]-N, N-dimethylethanamine			Immunosuppressant	Inflammation, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sch-57790	1-Piperazineacetoneitrile, 4-cyclohexyl-alpha-[4-[(S)-(4-methoxyphenyl)sulfinyl]phenyl]- [CAS]	221660-80-6		Cognition enhancer	Alzheimer's disease
Sch-63390	7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]	174648-45-4		Antiparkinsonian	Parkinson's disease
Scillarenein		465-22-5			
Scopolamine		51-34-3			
Scopolamine N-Oxide		97-75-6			
scopolamine	Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.0 ^{2,4}]non-7-yl ester, [7(S)-(1Alpha,2ß,4ß,5Alpha,7ß)]- [CAS]	51-34-3	US 4262003	Formulation, transdermal, other	Nausea and vomiting, general
SCS technology			US 6046188	Antiasthma	Unspecified
secalciferol	9,10-Seccholesta-5,7,10(19)-triene-3,24,25-triol, (3ß,5Z,7E,24R)- [CAS]	55721-11-4	EP 301167	Osteoporosis treatment	Osteodystrophy
secnidazole	1H-Imidazole-1-ethanol, Alpha,2-dimethyl-5-nitro- [CAS]	3366-95-8	FR M3270	Protozoicide	Infection, trichomoniasis
Secobarbital		309-43-3			
selegiline	Benzeneethanamine, N,Alpha-dimethyl-N-2-propynyl-, (R)- [CAS]	14611-51-9	GB 1153578	Antiparkinsonian	
Selenomethionine		1464-42-2			
Sematilide		101526-83-4			
Semotiadil		116476-13-2			
seocalcitol	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, (1R-(1Alpha(1R*,2E,4E),3aß,4E(1R*,3S*,5Z),7aAlpha))- [CAS]	134404-52-7	WO 9100855	Anticancer, other	Cancer, liver
Sepimostat		103926-64-3			
seratrodast	Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+/-)- [CAS]	103187-07-1 112665-43-7	EP 232089	Antiasthma	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sertaconazole	1H-Imidazole, 1-[2-[(7-chlorobenzo[b]thien-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]- [CAS]	99592-32-2	EP 151477	Antifungal	Infection, dermatological
sertindole	2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]- [CAS]	106516-24-9	EP 392959	Neuroleptic	Schizophrenia
sertaline	1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)- [CAS]	79559-97-0 79617-96-2 79617-97-3	EP 30081	Antidepressant	Depression, general
Setastine		64294-95-7			
sevelamer	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	152751-57-0 52757-95-6	US 5496545	Urological	Renal failure
sevoflurane	Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)- [CAS]	28523-86-6	DE 1954268	Anaesthetic, inhalation	Anaesthesia
SG-210	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]- [CAS]	143162-65-6		Symptomatic antidiabetic	Neuropathy, diabetic
sibutramine	Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl- α -[2-methylpropyl]- [CAS]	106650-56-0 84485-00-7	GB 2098602	Anorectic/Antiobesity	Obesity
siccanin	(4aS-(4a α ,6a α ,11b α ,13a α ,13b α)-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzo[a]furo[2,3,4-mn]xanthen-11-ol	22733-60-4	JP 37003548	Antifungal	
sildenafil	Piperazine, 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl, 2-hydroxy-1,2,3-propanetricarboxylate- (1:1) [CAS]	171599-83-0 139755-83-2	WO 9428902	Male sexual dysfunction	Impotence
sildenafil	1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]- [CAS]	160970-54-7	EP 600675	Urological	Dysuria
Silver Lactate		128-00-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Silver Picrate		146-84-9			
silver sulfadiazine	N'-2-pyrimidinylsulfanilamide monosilver salt	22199-08-2 68-35-9		Anti-infective, other	Infection, general
Simetride		154-82-5			
Simfibrate		14929-11-4			
	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1Alpha,3Alpha,7B,8B(2S*,4S*),8aB]]-[CAS]	79902-63-9	US 4444784	Hypolipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
Sincalide		25126-32-3			
Sintropium Bromide		79467-19-9			
Sisomicin		32385-11-8			
	3-Quinolincarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, [1R-[1Alpha(S*),2Alpha]]-, hydrate	127254-12-0	EP 341493	Quinolone antibacterial	Infection, general
sitafloxacin	1,6-Hexanediamine, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolyl)- [CAS]	5330-29-0 57695-04-2		Protozoacide	Infection, leishmaniasis
sitamaquine	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[[4,5-(methylenedioxy)-o-tolylacetyl]-3-thiophenesulfonamide	184036-34-8	US 5464853	Antihypertensive, other	Hypertension, pulmonary
sitaxsentan	Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]- [CAS]	127373-66-4	EP 347168	Respiratory	Systemic inflammatory response syndrome
sivelestat	Butanamide, 2-[[[4-(fluorophenyl)sulfonyl]amino]-N-[(1S)-1-formyl-3-methylbutyl]-, (2S)-formyl-3-methylbutyl]-, (2S)- [CAS]	190274-53-4	EP 771565	Ophthalmological	Cataract
SJA-6017	6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1-ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indole-1-one				
SL-65-1498			EP 607076	Anxiolytic	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SLV-306	(3S,2'R)-3-[1-[2'-(Ethoxycarbonyl)-4'-phenyl-butyl]-cyclopentan-1-carbonylamino]-2,3,4,5-tetrahydro-2-oxo-1H-benzapin-1-acetic acid			Antihypertensive, diuretic	Hypertension, general
SLV-308	2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride	269718-83-4		Antiparkinsonian	Parkinson's disease
Sm153 leixidronam	Samarate(5-)-153Sm, (((1,2-ethanediybis(nitriobis(methylene)))tetrakis(phosphonato))(8-)-N,N',OP,OP',OP'',OP'''), pentasodium, (OC-6-21)- [CAS]	160369-78-8		Analgesic, other	Pain, cancer
S-Methylmethionine		4727-40-6			
SMP-300	N-(Aminoiminomethyl)-11-chloro-5,6,7,8-tetrahydro-8-oxo-4H-pyrrolo[3,2,1-kl][1]benzazocine-2-carboxamide monomethanesulfonate monohydrate			Antianginal	Angina, general
SN-38	(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyranol[3',4':6,7]indolizino[1,2-b]quindolin-9-yl	100286-90-6		Formulation, optimized, liposomes	Cancer, colorectal
SNAP-7941	((+)-methyl (4S)-3-[(3-{4-[3-(acetylamino)phenyl]-1-piperidinyl}propyl)amino] carbonyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate hydrochloride)			Anxiolytic	Anxiety, general
SOA-132	2-Naphthalenecarboxamide, N-[2-[4-(diphenylmethoxy)-1-piperidinylethyl]-3-hydroxy-5-(3-pyridinylmethoxy)- [CAS]	143964-80-1		Formulation, inhalable, topical	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
soblidotin	L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*,2R*(1S*,2S*)]]]- [CAS]	149606-27-9	WO 9303054	Anticancer, other	Cancer, lung, non-small cell
Sobrerol		498-71-5			
sobuzoxane	Carbonic acid, 1,2-ethanediylbis[(2,6-dioxo-4,1-piperazinediyl)methyl]ene[bis(2-methylpropyl) ester [CAS]	98631-95-9	EP 140327	Anticancer, other	Cancer, lymphoma, T-cell
Sodium Arsanilate		127-85-5			
Sodium Arsphenamine		1936-28-3			
<i>Sodium Chloride</i>					
Sodium Dibunat		14992-59-7			
Sodium Folate		6484-89-5			
Sodium Formaldehydesulfoxylate		149-44-0			
Sodium Glycerophosphate		1334-74-3			
<i>Sodium Hyaluronate</i>					
Sodium Iodomethamate		519-26-6			
Sodium Nitrite		7632-00-0			
Sodium Nitroprusside		14402-89-2			
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2		Psychostimulant	Narcolepsy
Sodium Phenolsulfonate		1300-51-2			
sodium phenylbutyrate	Butyric acid, 4-phenyl-, sodium salt- [CAS]	1716-12-7		Formulation, other	Hyperammonaemia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sodium phosphate	Sodium phosphate monobasic anhydrous		US 6162464	Formulation, oral, other	Surgery adjunct
sodium prasterone sulfate	3 β -hydroxy-5-androsten-17-one(sodium sulfate dihydrate)		EP 380036	Formulation, mucosal, topical	Labour, induction
Sodium Propionate		137-40-6			
sodium salicylate	Benzoic acid, 2-hydroxy-, monosodium salt [CAS]	54-21-7		Formulation, oral, solubility-enhanced	Pain, general
Sodium Tetradecyl Sulfate		139-88-8			
sofalcone	Acetic acid, [5-[(3-methyl-2-butenyloxy]-2-[3-[4-[(3-methyl-2-butenyloxy)phenyl]-1-oxo-2-propenyl]phenoxy]- [CAS]	64506-49-6	GB 1523241	Antitumor	
Solasulfone		133-65-3			
	Butanedioic acid compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1) [CAS]	242478-38-2		Urological	Overactive bladder
Sorbitate	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	6184-06-1	BE 883352	Hypolipemic/Antiatherosclerosis	
Sorbitol		50-70-4			
Sorivudine		77181-69-2			
sotalol	Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- [CAS]	3930-20-9 959-24-0		Antiarrhythmic	
Soterinol		13642-52-9			
Sozoiodolic Acid		554-71-2			
spaglumic acid	L-Glutamic acid, N-(N-acetyl-L-Alpha-aspartyl)- [CAS]	3106-85-2 80619-64-3		Formulation, mucosal, topical	Conjunctivitis
sparfloxacin	3-Quinolonecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis- [CAS]	110871-86-8	EP 221463	Quinolone antibacterial	Infection, respiratory tract, general
Sparteine		90-39-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SPA-S-843	Candicin D, 18-decarboxy-40-demethyl-3,7-dideoxo-N ³ -(dimethylamino)acetyl)-18-(((2-(dimethylamino)ethyl)amino)carbonyl)-3,7-dihydroxy-N ⁴ -methyl-5-oxo cyclic 15,19-hemiacetal, comp with L-ascorbic acid (1:2) [CAS]	202748-83-2	US 5298495	Antifungal	Infection, fungal, general
Spasmolytol		25333-96-4			
SPD-754	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl- (2R-cis)-	160707-69-7	US 6228860	Antiviral, anti-HIV	Infection, HIV/AIDS
Spectinomycin		1695-77-8			
SPI-339	4-[3-(4-Oxo-4,5,6,7-tetrahydroindol-yl)propionylamino]benzoic acid ethyl ester			Cognition enhancer	Alzheimer's disease
Spiperone		749-02-0			
spirapril	1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-, [8S-[7R*(R*),8R*]]- [CAS]	83647-97-6	EP 50800	Antihypertensive, renin system	Hypertension, general
Spirogermanium		41992-23-8			
spironolactone	Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, Gamma-lactone, (7Alpha, 17Alpha)- [CAS]	52-01-7	EP 124147	Formulation, dermal, topical	Acne
SR-121463	Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy- [CAS]	185913-78-4	WO 9715556	Cardiostimulant	Heart failure
SR-144190	Morpholine, 4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl]-1-piperidinyl]ethyl]-, (2R)- [CAS]	201152-86-5	WO 9623787	Anxiolytic	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SR-146131	1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl-[CAS]	221671-61-0	WO 9915525	Anorectic/Antiobesity	Obesity
SR-271425	N-[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide		-	Anticancer, alkylating	Cancer, general
SR-27897	1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]-[CAS]	136381-85-6	EP 432040	Anticancer, other	Cancer, pancreatic
SR-31747	Cyclohexanamine, N-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	EP 376850	Anticancer, other	Cancer, myeloma
SR-58611	Acetic acid, [[(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-ethyl ester, hydrochloride [CAS]	121524-09-2	EP 303546	GI inflammatory/bowel disorders	Irritable bowel syndrome
SS732	(R)-(-)-2-(2,4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol		US 5385900	Formulation, mucosal, topical	Infection, ocular
SS-750	Propanamide, N, N'(dithiodi-2,1-ethanedyl)bis(3-amino)- [CAS]		US 6083968	Antifungal	Infection, fungal, general
β -alethine	(2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide	646-08-2		Anticancer, immunological	Cancer, myeloma
SSR-149415	2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazin-4,5,6-triindol-1-yl)-N,N-dimethylacetamide		WO 0155130	Antidepressant	Depression, general
SSR-180575				Neuroprotective	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SSR-181507	(3-Exo)-8-benzoyl-N-[[[2S]-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine HCl		US 6221879	Neuroleptic	Schizophrenia
SSR-591813	(5aS,8S,10aR)-5a,6,9,10-tetrahydro,7H,11H-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine			Dependence treatment	Addiction, nicotine
SST-101	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, transdermal, other	Angina, general
SSY-726	(-)-(R)-3-Methyl-3-(methylsulfonyl)-1-(1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol		US 5147886	Antifungal	Infection, fungal, general
ST-200	1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, chloride, (R)- [CAS]	5080-50-2	DE 3015635	Cognition enhancer	Dementia, senile, general
Stachylin			WO 9711947	Antiviral, other	Infection, Influenza virus
Stallimycin		636-47-5			
Stampidine			US 6350736	Antiviral, anti-HIV	Infection, HIV/AIDS
Stannous		15578-26-4			
Pyrophosphate					
stannosporfin	(OC-6-13)-Dihydrogen dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-N21,N22,N23,N24]stannate(2-)	106344-20-1		Hepatoprotective	Hyperbilirubinaemia
Stanolone		521-18-6			
Stanozolol		10418-03-8 (2'H form); 302-96-5 (1'H form)			
Staph aureus ther			US 6376662	Genomics-based drug discovery	Infection, MRSA
STAT4 inhibitors			WO 9629341	Immunosuppressant	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
stavudine	Thymidine, 2',3'-didehydro-3'-deoxy- [CAS]	3056-17-5	EP 501511	Antiviral, anti-HIV	Infection, HIV/AIDS
Stenbolone		5197-58-0			
stepronin	Glycine, N-[1-oxo-2-[(2-thienylcarbonyl)thio]propyl]- [CAS]	72324-18-6	US 4242354	Antitussive	Cough
Stibocaptate		27279-76-1			
Stibophen		15489-16-4			
Stilbamidine		122-06-5			
stiripentol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl- [CAS]	49763-96-4		Antiepileptic	Epilepsy, general
Streptodornase		37340-82-2			
Streptomycin		57-92-1			
Streptonicozid		5667-71-0			
Streptonigrin		3930-19-6			
Streptozocin		18883-66-4			
strontium ranelate	3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2)- [CAS]	135459-87-9	EP 415850	Osteoporosis treatment	Osteoporosis
strontium-89 chloride	Strontium chloride (89SrCl ₂) [CAS]	38270-90-5		Analgesic, other	Pain, cancer
Succimer		304-55-2			
Succinimide		123-56-8			
Succinylcholine		55-94-7			
Succinylcholine		71-27-2			
Succinylsulfathiazole		116-43-8			
Succisulfone		5934-14-5			
Suclofenide		30279-49-3			
sucralate	Aluminium, hexadeca-μ-hydroxytetraacosahydroxy(μ8-(1,3,4,6-tetra-O-sulfo-β-D-fructofuranosyl-Alpha-D-glucopyranoside tetrakis(hydrogen sulfato)(8-)))hexadeca- [CAS]	54182-58-0	JP 58208233	Antulcer, Formulation, oral, other	Ulcer, general
sufentanil	Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7	US 3998834	Analgesic, other, formulation implant	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sulbactam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S-cis)- [CAS]	68373-14-8	GB 2000138	Antibiotic, other	Infection, general
sulbactam + ampicillin		117060-71-6	US 4234579	Antibiotic, other	Infection, general
sulbenicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[phenylsulfoacetyl]amino]-, [2S-[2Alpha,5Alpha,6beta(S*)]]- [CAS]	28002-18-8 41744-40-5			
Sulbentine		350-12-9	GB 1289358	Penicillin, injectable	Infection, pseudomonal
	Propanoic acid, 2-methyl-, dithiobis[3-[1-[[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]ethylidene]-3,1-propanediyl] ester [CAS]	3286-46-2 67-16-3			
sulbutiamine				Neurological	Unspecified
	1H-Imidazole, 1-[2-[[[(4-chlorophenyl)methyl]thio]-2-(2,4-dichlorophenyl)ethyl]-, (+/-)- [CAS]	61318-90-9 61318-91-0	US 4056652	Antifungal	Infection, fungal, general
Sulesomab		167747-19-5			
Sulfabenzamide		127-71-9			
Sulfacetamide		144-80-9			
Sulfachlorpyridazine		80-32-0			
Sulfachrysoidine		485-41-6			
Sulfacytine		17784-12-2			
Sulfadiazine		68-35-9			
Sulfadiazole		115-68-4			
Sulfadimethoxine		122-11-2			
Sulfadoxine		2447-57-6			
Sulfaethidole		94-19-9			
Sulfaguanidine		57-67-0			
Sulfaguanole		27031-08-9			
Sulfalene		152-47-6			
Sulfaloxic Acid		14376-16-0			
Sulfamerazine		127-79-7			
Sulfamer		651-06-9			
Sulfamethazine		57-68-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfamethizole		144-82-1			
Sulfamethomidine		3772-76-7			
Sulfamethoxazole		723-46-6			
Sulfamethoxypyridazine		80-35-3			
Sulfametrele		32909-92-5			
Sulfamidochrysoidine		103-12-8			
Sulfamoxole		729-99-7			
Sulfanilamide		63-74-1			
Sulfanilic Acid		121-57-3			
Sulfanilylurea		547-44-4			
Sulfaperine		599-88-2			
Sulfaphenazole		526-08-9			
Sulfaproxyline		116-42-7			
Sulfapyrazine		116-44-9			
Sulfapyridine		144-83-2			
Sulfarside		1134-98-1			
Sulfarsphenamine		618-82-6			
sulfasalazine	Benzoic acid, 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]- [CAS]	599-79-1		Formulation, oral, enteric-coated	Arthritis, rheumatoid
Sulfasomizole		632-00-8			
Sulfasymazine		1984-94-7			
Sulfathiazole		72-14-0			
Sulfathiourea		515-49-1			
Sulfinalol		66264-77-5			
Sulfipyrazone		57-96-5			
Sulfiram		95-05-6			
Sulfisomidine		515-64-0			
Sulfisoxazole		127-69-5			
Sulfobromophthalein		71-67-0			
SulfonethyImethane		76-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfoniazide		3691-81-4			
Sulfonmethane		115-24-2			
Sulfuridazine		14759-06-9			
Sulfoxone		144-75-2			
sulindac	cis-5-fluoro-2-methyl-1-[(p-methylsulfonyl)benzylidene]indene-3-acetic acid	38194-50-2	US 3725548	Anti-inflammatory	Inflammation, general
Sulisatin		54935-03-4			
Sulisobenzone		4065-45-6			
Sulmarin		29334-07-4			
Sulmazole		73384-60-8			
Suloctidil		54063-56-8			
Sulphan Blue		129-17-9			
sulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-[CAS]	15676-16-1		Alimentary/Metabolic, other	
sulprostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-(methylsulfonyl)-, [1R-[1Alpha(Z),2R(1E,3R*),3Alpha]]- [CAS]	60325-46-4	US 4024179	Prostaglandin	Abortion
sultamicillin	4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyl)oxy)methyl ester, S, S-dioxide, (2S-(2.alpha.(2R*,5S*),5.alpha.,6.beta.(S*))-[CAS]	117060-71-6 76497-13-7	GB 2044255	Penicillin, oral	Infection, general
Sulthiame		61-56-3			
sultopride	Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]	53583-79-2	FR M5916	Neuroleptic	Psychosis, general
Sulfosilic Acid		57775-26-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sumanirole	4H-imidazo[4,5,1-j]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) [CAS]	179386-44-8	WO 9514020	Antiparkinsonian	Parkinson's disease
sumatriptan	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-46-2 103628-48-4	EP 147107	Antimigraine	Migraine
SUN-N8075	1-(4-amino-2,3,5-trimethylphenoxy)-3-[4-(4-fluorobenzyl)phenyl]piperazin-1-yl]propan-2(s)-ol dimethanesulfonate			Neuroprotective	Infarction, cerebral
suplatast	Sulfonium, [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, [CAS]	94055-76-2	JP 59167564	Antiasthma	Asthma
Suprofen		40828-46-4			
Suramin		129-46-4			
surfactant TA	Beractant [CAS]	108778-82-1	WO 9117766	Lung Surfactant	Respiratory distress syndrome, general
Suriclone		53813-83-5			
Suxibuzone		27470-51-5			
SYM-1010					
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3	US 5830998	Antiepileptic	Epilepsy, general
	4-(Aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydrophthalazine-2-carboxamide			Analgesic, other	Pain, general
SYM-2207				Neuroprotective	Ischaemia, cerebral
Synclosene		87-90-1			
Syn-1253	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid			Quinolone antibacterial	Infection, peritoneum
Syn-2190	1-Azetidinesulfonic acid, 3-[[[(2E)-[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]-2-thienylacetyl]amino]-2-methyl-4-oxo-, (2S,3S)- [CAS]	214963-75-4	WO 9847895	Antibacterial, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Syn-2869	3H-1,2,4-Triazol-3-one, 4-(4-(4-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazinyl)phenyl)-2,4-dihydro-2((4-(trifluoromethoxy)phenyl)methyl)- [CAS]	210562-98-4	US 6153616	Antifungal	Infection, Aspergillus
Syneprhine		94-07-5			
Syrosingopine		84-36-6			
T-1095	1-Propanone, 3-(5-benzofuran)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-β-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]	209746-59-8	EP 850948	Antidiabetic	Diabetes, general
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutamyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutamyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutamyl-L-alanyl-L-glutamyl-L-isoleucyl-L-glutamyl-L-glutamyl-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparagyl-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutamyl-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]	251562-00-2	WO 9959615	Antiviral, anti-HIV	Infection, HIV/AIDS
T-3912	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid			Quinolone antibacterial	Infection, dermatological
T-588	Benzo(b)thiophene-5-methanol, Alpha-((2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142935-03-3	EP 565965	Cognition enhancer	Alzheimer's disease
T-67	Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)- [CAS]	195533-53-0		Anticancer, other	Cancer, liver
T-82			US 5190951	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TA-2005	2-(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS]	137888-11-0	US 4579854	Antiasthma	Asthma
TA-2005	2-(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS]		WO 189480	Formulation, inhalable, solution	Asthma
TA-993	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel(-), (2Z)-2-butenedioate [CAS]	122024-98-0	JP 01045376	Antithrombotic	Peripheral vascular disease
tabimorelin	(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2-hexenamido]-N-methyl-N-[(R)-Alpha-(methylcarbamoyl)phenethyl]-2-naphthalenepropionamide	170851-70-4 193079-69-5		Releasing hormones	Growth hormone deficiency
tacalcitol	9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3S,5Z,7E,24R)- [CAS]	57333-96-7 93129-94-3	EP 129003	Antipsoriasis	Keratosis
tacedinaline	Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- [CAS]	112522-64-2	DE 3613571	Anticancer, other	Cancer, pancreatic
tacrine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	1684-40-8 321-64-2	EP 332147	Cognition enhancer	Alzheimer's disease
Tacrolimus		104987-11-3			
tadalafil	Pyrazino(1',2':1,6)pyrido(3,4-b)indole 1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]	171596-29-5	US 6143746	Male sexual dysfunction	Impotence
tafenoquine	1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]- [CAS]	106635-80-7 106635-81-8 80065-55-0	US 4617394	Antimalarial	Infection, malaria
tafluposide	(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]propionamide	179067-42-6	WO 9612727	Anticancer, other	Cancer, general
TAK-375				Hypnotic/Sedative	Insomnia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TAK-427	2-[6-[[3-[4-(Diphenylmethoxy)-piperidin-2-yl]-2-benzimidazol-2-yl]propionic acid dihydrate			Antipruritic/inflamm, allergic	Eczema, atopic
TAK-559	(E)-4-[4-[5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzoylimino]-4-phenylbutyric acid			Antidiabetic	Diabetes, general
Taka-Diastase		9001-19-8			
talampanel	7H-1,3-Dioxolo[4,5-h][2,3]benzodiazepine, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (8R)-[CAS]	161832-65-1	US 5639751	Antiepileptic	Epilepsy, general
Talampicillin		47747-56-8			
talaporfin	N-[[[(2S,3S)-18-Carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl porphyrin-20-yl]acetyl]-L-aspartic acid	220201-34-3		Radio/chemosensitizer	Cancer, lung, general
Talastine		16188-61-7			
Talbutal		115-44-6			
Talinolol		57460-41-0			
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- [CAS]	101626-70-4	DE 3503963	Antiparkinsonian	Schizophrenia
talmetant	4-Quinolonecarboxamide, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]- [CAS]	36085-73-1	WO 9532948	GI inflammatory/bowel disorders	Irritable bowel syndrome
talniflumate	3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, 1,3-dihydro-3-oxo-1-isobenzofuran-1-yl ester [CAS]	174636-32-9			
talitirelin	L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]	66898-62-2	BE 858864	Anti-inflammatory	Inflammation, ocular
talitirelin	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	103300-74-9	JP 61033197	Neurological	Dyskinesia, general
tamoxifen		10540-29-1	US 4536516	Anticancer, hormonal	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tamsulosin	Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0	EP 34432	Prostate disorders	Benign prostatic hyperplasia
tandospirone	4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-[4-{4-(2-pyrimidinyl)-1-piperazinyl}butyl]-, (3aAlpha,4R,7R,7aAlpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	112457-95-1 87760-53-0	EP 82402	Anxiolytic	Anxiety, general
Tannoform		9010-29-1			
Taprostene		108945-35-3			
tariquidar	3-Quinolincarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]- [CAS]	206873-63-4	WO 9817648	Radio/chemosensitizer	Cancer, lung, non-small cell
TAS-103	6-[[2-(Dimethyl-amino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride	174634-09-4	WO 9532187	Anticancer, other	Cancer, lung, non-small cell
Tasosartan		145733-36-4			
Taurocholic Acid		81-24-3			
Taurolidine		19388-87-5			
tazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]-, butyl ester [CAS]	82989-25-1	US 4778816	Antiasthma	
tazarotene	3-Pyridinecarboxylic acid, 6-[[3,4-dihydro-4,4-dimethyl-2H-1-benzothiofuran-6-yl]ethynyl]-, ethyl ester [CAS]	118292-40-3	EP 284288	Antipsoriasis	Psoriasis
Tazobactam		89786-04-9			
tazobactam + piperacillin			JP 58225091	Antibiotic, other	Infection, general
TBC-3711	N-Methyl-N-propargyl-10-aminomethyl-dibenzo(b,f)oxepin	374680-51-0		Cardiovascular	Heart failure
TCH-346	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethenyl-1H-imidazole [CAS]			Neuroprotective	Anyotrophic lateral sclerosis
tebipenem		82200-24-6		Beta-lactam antibiotic	Infection, streptococcal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tecadenoson	Adenosine, N-[(3R)-tetrahydro-3-furanyl]- [CAS]	204512-90-3	WO 9808855	Antiarrhythmic	Tachycardia, supraventricular
tecastermizole	1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl- [CAS]	75970-99-9	US 4219559	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Technetium ^{99m}Tc					
Bicisate		121281-41-2			
Technetium ^{99m}Tc					
Mertiatide		125224-05-7; 104348-91-6			
Technetium ^{99m}Tc					
Sestamibi		109581-73-9			
Technetium ^{99m}Tc					
Teboroxime		104716-22-5			
Teclothiazide					
Teclozan		4267-5-4			
		5560-78-1			
tedisamil	Spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane], 3',7'-bis(cyclopropylmethyl)- [CAS]	90961-53-8	EP 102833	Antiarrhythmic	Fibrillation, atrial
Teflurane		124-72-1			
tegafur	2,4-(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)- [CAS]	17902-23-7	GB 1168391	Anticancer, antimetabolite	Cancer, general
tegafur + uracil	2,4-(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, mixt. with 2,4-(1H,3H)-pyrimidinedione- [CAS]	74578-38-4	EP 224885	Anticancer, antimetabolite	Cancer, breast
tegaserod	Hydrazinecarboximidamide, 2-((5-methoxy-1H-indol-3-yl)methylene)-N-pentyl-, (Z)-2-butenedioate [CAS]	189188-57-6 145158-71-0		GI inflammatory/bowel disorders	Irritable bowel syndrome
Teicoplanin		61036-64-4			
telbivudine	β-L-2'-deoxythymidine	3424-98-4		Antiviral, other	Infection, hepatitis-B virus
Telenzepine		80880-90-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
telithromycin	3-De((2,6-dideoxy-3-C-methyl-3-O-methyl-Alpha-L-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))- [CAS]	191114-48-4	EP 680967	Macrolide antibiotic	Infection, respiratory tract, general
telmestaine	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (R)- [CAS]	122946-43-4		COPD treatment	Bronchitis, chronic
telmisartan	(1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)- [CAS]	144701-48-4	EP 502314	Antihypertensive, renin system	Hypertension, general
telomerase inhibits			WO 9941261	Anticancer, other	Cancer, general
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US 3197467	Hypnotic/Sedative	Insomnia
temiverine	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-1,1-dimethyl-2-butynyl ester, [CAS]	129927-33-9	GB 2222828	Urological	Pollakisuria
temocapril	1,4-Thiazepine-4(5H)-acetic acid, 6-[[1-(ethoxycarbonyl)-3-phenylpropylamino]tetrahydro-5-oxo-2-(2-thienyl)-, [2S-[2Alpha,6B(R*)]]- [CAS]	102090-90-4 110221-44-8 111902-57-9	US 4495188	Antihypertensive, renin system	Hypertension, general
Temocillin		66148-78-5			
temoporfin	Phenol, 3,3',3''-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- [CAS]	122341-38-2	EP 337601	Radio/chemosensitizer	Cancer, head and neck
temozolomide	Imidazo[5,1-c]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]	85622-93-1	DE 3231255	Anticancer, alkylating	Cancer, brain, general
tenatoprazole	1H-Imidazo(4,5-b)pyridine, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- [CAS]	113712-98-4	US 4808596	Antilicer	Ulcer, gastric
Tenecteplase		191588-94-0			
Tenidap		120210-48-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
teniposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-β-D-glucopyranosyl]oxy], [5R-[5Alpha,5aβ,8aAlpha,9β(R*)]]- [CAS] 29767-20-2	US 3524844	Anticancer, other		Cancer, lymphoma, non-Hodgkin's
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)- [CAS] 147127-20-6		Antiviral, anti-HIV		Infection, HIV/AIDS
tenofovir disoproxil	2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylethoxymethyl) bis(1-methylethylester, 5-oxide (R)-, (E)-2-butenedioate	202138-50-9	Antiviral, anti-HIV		Infection, HIV/AIDS
Tenonitroazole		3810-35-3			
tenoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS] 59804-37-4	GB 1519811	Antiarthritic, other		
Tenuazonic Acid		610-88-8			
teprenone	5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl- [CAS] 3796-63-2		Antiulcer		
terazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[[tetrahydro-2-furanyl]carbonyl]- [CAS] 63074-08-8	US 4112097	Antihypertensive, adrenergic		Hypertension, general
terbinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)- [CAS] 78628-80-5	EP 24587	Antifungal		Infection, dermatological
terbutaline	1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]- [CAS] 23031-25-6		Formulation, mucosal, topical		Dysmenorrhoea
terconazole	Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis- [CAS] 67915-31-5	US 4358449	Antifungal		Vaginitis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
terfenadine	1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- [CAS]	50679-08-8	US 3878217	Antiallergic, non-asthma	
terguride	Urea, N,N-diethyl-N'-[[6Alpha]-6-methylergolin-8-yl]- [CAS]	37686-84-3	EP 159522	Antiprolactin	Hyperprolactinaemia
Terlipressin		14636-12-5			
Terodiline		15793-40-5			
Terofenamate		29098-15-5			
Terpin		80-53-5			
	2-Propanol, 1-[(3,4-dihydro-2H-1-benzothioipyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-, hydrochloride, (+)- [CAS]	33580-30-2 83688-84-0 34784-64-0	GB 1308191	Antihypertensive, adrenergic	Hypertension, general
tert-butanol		75-85-4			
tert-Pentyl Alcohol					
	(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]propanoic acid			Antidiabetic	Diabetes, Type II
tesaglitazar					
tesmilifene	Ethanamine, N,N-Diethyl-2-(4-phenylmethyl)phenoxy)- [CAS]	92981-78-7		Radio/chemosensitizer	Cancer, breast
Testolactone		968-93-4			
Testosterone	androst-4-en-3-one, 17-hydroxy-, (17 β) - [CAS]	58-22-0 5949-44-0		Formulation, transdermal, systemic	Hormone replacement therapy
tetrabamate		60763-47-5	DE 2748794	Anxiolytic	Addiction, alcohol
Tetrabarbital		76-23-3			
Tetrabenazine		58-46-8			
Tetracaine		136-47-0			
Tetrachloroethylene		127-18-4			
tetracine	Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester [CAS]	94-24-6		Formulation, transdermal, systemic	Pain, general
	2-Naphthacene-carboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5aAlpha,6S,12aAlpha)]- [CAS]				
tetracycline		60-54-8		Formulation, oral, other	Infection, oral

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tetrahydrozoline		84-22-0			
Tetrandrine		518-34-3			
Tetrantoin		52094-70-9			
Tetrazepam		10379-14-3			
Tetrofosmin		127502-06-1			
tetroxoprim	2,4-Pyrimidinediamine, 5-[3,5-dimethoxy-4-(2-methoxyethoxy)phenyl]methyl-, [CAS]	53808-87-0 74515-38-1	US 3992379	Trimethoprim and analogues	Infection, general
Tevenel®		4302-95-8			
tezacitabine	Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)- [CAS]	130306-02-4	US 5616702	Anticancer, antimetabolite	Cancer, colorectal
tezosentan	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)- [CAS]	180384-57-0		Cardio stimulant	Oedema, general
thalidomide	1H-Isindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- [CAS]	50-35-1		Dermatological	Infection, dermatological
Thenaldine		86-12-4			
Theryldiamine		91-79-2			
Theobromine		83-67-0			
Theofibrate		54504-70-0			
theophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, [CAS]	58-55-9 5967-84-0		Formulation, modified-release, other	Asthma
Thiabendazole		148-79-8			
Thiacetazone		104-06-3			
thiacymserine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]	145209-51-4		Cognition enhancer	Alzheimer's disease
Thialbarbital		467-36-7			
Thiamine		59-43-8			
Thiamine		154-87-0			
Thiamine		67-16-3			
Thiamiprine		5581-52-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thiamphenicol		15318-45-3			
Thiamylal		77-27-0			
Thiazesim		5845-26-1			
Thiazinamium		58-34-4			
Thiazolinobutazone		54749-86-9			
Thiazolsulfone		473-30-3			
Thibenzazoline		6028-35-9			
Thiethylperazine		1420-55-9			
Thimerfonate		5964-24-9			
Thimerosal		54-64-8			
Thiobarbital		77-32-7			
Thiobutabarbital		2095-57-0			
Thiocarbamizine		91-71-4			
Thiocarbarsone		120-02-5			
Thiocolchicine		2730-71-4			
Thiocresol		26445-03-4			
Thioctic Acid		62-46-4			
Thioglycerol		96-27-5			
Thioguanine		154-42-7			
Thioimreg	L-Thiotyrosinyl-glycyl-glycine			Anticancer, immunological	Cancer, general
Thiopental		71-73-8			
Thiopropazate		84-06-0			
Thiopropazine		316-81-4			
Thioridazine		50-52-2			
Thiothixene		5591-45-7			
Thiovir	Thiophosphonoformic acid			Antiviral, anti-HIV	Infection, HIV/AIDS
Thiphenamil		82-99-5			
Thiram		137-26-8			
Thonzylamine		63-56-9			
Thozalinone		655-05-0			
Thromboplastin		9035-58-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thurfyl Nicotinate		70-19-9	US 6245750	Anticancer, other	Cancer, colorectal
thymectacin					
Thymol		89-83-8			
Thymopentin		69558-55-0			
Thymyl N-		578-20-1			
Isoamylcarbamate					
Thyropropic Acid		51-26-3			
Thyroxine		51-48-9			
Tiadenol		6964-20-1			
tiagabine	3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-, (R)- [CAS]	115103-54-3	WO 8700171	Antiepileptic	Epilepsy, general
Tiamenidine		31428-61-2			
tianeptine	Heptanoic acid, 7-[(3-chloro-6,11-dihydro-6-methyl-2-thienyl)-1,2-thiazepin-11-yl]amino]-, S,S-dioxide [CAS]	72797-41-2 66981-73-5	GB 1269551	Antidepressant	Depression, general
tiapride	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	GB 1394563	Neuroleptic	
tiaprofenic acid	2-Thiopheneacetic acid, 5-benzoyl- α -methyl- [CAS]	33005-95-7	GB 1331505	Antiarthritic, other	
Tiaramide		32527-55-2			
tiazofurin	4-Thiazolecarboxamide, 2- β -D-ribofuranosyl- [CAS]	60084-10-8	EP 54432	Anticancer, antimetabolite	Cancer, leukaemia, chronic myelogenous
Tibezonium	19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7 α ,17 α)-[CAS]	54663-47-7			
tibolone		5630-53-5	EP 389035	Menopausal disorders	Hormone replacement therapy
Ticarcillin		34787-01-4			
ticlopidine	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- [CAS]	53885-35-1 55142-85-3	GB 1554424	Antithrombotic	
Ticrynafen		40180-04-9			
tiemonium	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium	6252-92-2 144-12-7		Antispasmodic	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tigecycline	2-Naphthacene-carboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- [CAS]	220620-09-7	EP 582829	Tetracycline	Infection, general
Tigemonam		102507-71-1			
Tigloidine		495-83-0			
Tilidine		20380-58-9			
Tilisolol		85136-71-6			
tlimacoxib	Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-68-4	WO 9619463	Alimentary/Metabolic, other	Polyp
tlidronic acid	Phosphonic acid, [[(4-chlorophenyl)thio]methylene]bis- [CAS]	89987-06-4	EP 100718	Osteoporosis treatment	Paget's disease
Timentin		86482-18-0		Antibiotic, other	Infection, general
timepidium	Piperidinium, 3-(di-2-thienylmethylene)-5-methoxy-1,1-dimethyl-, [CAS]	35035-05-3	GB 1358446	Antispasmodic	
Timiperone		57648-21-2			
timolol	(-)-1-(4-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanolmaleate (1:1) salt	26839-75-8 26921-17-5	GB 1253709	Antihypertensive, adrenergic, antiglaucoma	
Timonacic		444-27-9			
Tin Ethyl Etiopurpurin		113471-15-1			
tinazoline	1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)thio]- [CAS]	62882-99-9	US 3376311	Vasodilator, peripheral	
Tinidazole		19387-91-8			
Tinoridine		24237-54-5			
Tiocarlide		910-86-1			
Tioclomarol		22619-35-8			
tioconazole	1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-[CAS]	61675-64-7 65899-73-2	US 4062966	Antifungal	Infection, fungal, general
tiopronin	Glycine, N-(2-mercaptopropanoyl)-[CAS]	1953-02-2	US 3246025	Urological	Homocystinuria

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tiotropium	3-Oxa-9-azoniatricyclo(3.3.1.0 ^{2,4})nonane, 7-((hydroxydi-2-thienylacetyl)oxy)-9-dimethyl-, [CAS]	136310-93-5	EP 418716	COPD treatment	Chronic obstructive pulmonary disease
Tioxolone		4991-65-5			
Tipepidine		5169-78-8			
tipifamib	2(1H)-Quinolone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl [CAS]	192185-68-5 192185-72-1	WO 9716443	Anticancer, other	Cancer, breast
tipranavir	N-[3-[1(R)-[4-Hydroxy-2-oxo-6(R)-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	174484-41-4		Antiviral, anti-HIV	Infection, HIV/AIDS
tiqizium	2H-Quinolizinium, 3-(di-2-thienylmethylene)octahydro-5-methyl-, [CAS]	71731-58-3	US 4205074	Antispasmodic	
tiropazamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxide- [CAS]	20028-80-2 27314-97-2 5424-06-6	DE 2204574	Radio/chemosensitizer	Cancer, lung, non-small cell
Tiratricol		51-24-1			
tiirilazad	Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16Alpha)-, [CAS]	110101-65-0 110101-67-2 110101-66-1	WO 8701706	Neuroprotective	Haemorrhage, subarachnoid
tirofiban	L-Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, [CAS]	142373-60-2 144494-65-5	EP 478363	Antithrombotic	Infarction, myocardial
tiropamide	Benzenepropanamide, Alpha-(benzoylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropyl-, (+)-, [CAS]	55837-29-1	DE 2503992	Antispasmodic	Muscle spasm, general
Titanium Sulfate		13825-74-6			
tiocortol	Pregn-4-ene-3,20-dione, 21-[2,2-dimethyl-1-oxopropyl]thio]-11,17-dihydroxy-, (11S)- [CAS]	55560-96-8 61951-99-3	GB 1475795	Antiallergic, non-asthma, mucosal, topical	Rhinitis, allergic, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tizanidine	2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-[CAS]	51322-75-9	GB 1429926	Muscle relaxant	Spastic paralysis
TLK-199	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteiny-2-phenyl-, diethyl ester, (2R)- [CAS]	168682-53-9	US 5679643	Immunostimulant, other	Myelodysplastic syndrome
TLK-286	Glycine, L-Gamma-glutamyl-3-[[2-([bis[2-chloroethyl]amino]phosphinyl)oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-, (2R)- [CAS]	158382-37-7	US 5545621	Anticancer, other	Cancer, ovarian
TNF- β analogue			RU 2035185	Anticancer, immunological	Cancer, general
TNP-470		129298-91-5			
TO-186	Pregna-1,4-diene-3,20-dione, 9-fluoro-11 β ,17,21-trihydroxy-16 β .beta.-methyl-, 17-butyrate 21-proponate [CAS]	5534-02-1		Antipruritic/inflam, allergic	
tobramycin	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1,6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl)-(1-4)-2-deoxy- [CAS]	32986-56-4		Formulation, inhalable, topical	Infection, respiratory tract, general
tocainide	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	41708-72-9	US 4218477	Antiarrhythmic	Fibrillation, ventricular
Tocamphyl		5634-42-4			
tocladesine	8-Chloroadenosine 3':5'-cyclic phosphate	41941-56-4		Anticancer, other	Cancer, colorectal
Tocoretinate		40516-48-1			
Todalazine		14679-73-3			
Tofenacin		15301-93-6			
tofilmist	5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-b]pyridine,9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)-			Antiasthma	Asthma
tofisopam	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-[CAS]	185954-27-2			
Tolazamide		22345-47-7	GB 1334271	Anxiolytic	Anxiety, general
		1156-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolazoline		59-98-3			
Tolbutamide		64-77-7			
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	EP 237929	Antiparkinsonian	Parkinson's disease
tolciclate	Carbamothioic acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS]	50838-36-3	GB 1364407	Antifungal	Infection, dermatological
Tolcyclamide		664-95-9			
tolevamer	Benzenesulfonic acid, 4-ethenyl-, homopolymer,	28038-50-8		Antibacterial, other	Infection, Clostridium, general
tolfenamic acid	Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- [CAS]	13710-19-5	DE 1543295	Anti-inflammatory	Inflammation, general
Tolindate		27877-51-6			
Toliprolol		2933-94-0			
Tolmetin		26171-23-3			
Tolnaftate		2398-96-1			
Tolonidine		4201-22-3			
Tolonium		92-31-9			
toloxatone	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	29218-27-7	GB 1250538	Antidepressant	
Tolperisone		728-88-1			
Tolpropamine		5632-44-0			
Tolrestat		82964-04-3			
tolserine	Carbamic acid, (2-methylphenyl)-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-30-9		Cognition enhancer	Alzheimer's disease
tolterodine	Phenol, 2-(3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5	EP 325571	Urological	Incontinence
tolvaptan	Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- [CAS]	150683-30-0	EP 450097	Cardiovascular	Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolycaine		3686-58-6			
Topiramate	Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate [CAS]	97240-79-4			
topoisomerase inhibitors			EP 533483	Antiepileptic	Epilepsy, generalized, tonic-clonic
	1H-Pyranol[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[[dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]		US 5733880	Anticancer, other	Cancer, general
topotecan		123948-87-8	EP 321122	Anticancer, other	Cancer, ovarian
torasemide	3-Pyridinesulfonamide, N-[[1-methylethyl]amino]carbonyl]-4-[(3-methylphenyl)amino]- [CAS]	56211-40-6	US 4018929	Antihypertensive, diuretic	Hypertension, general
torcetrapib	ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	262352-17-0		Hypolipaeamic/Antiatherosclerosis	Atherosclerosis
torcitabine	β-L-2'Deoxyctidine			Antiviral, other	Infection, hepatitis-B virus
toremifene	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	89778-26-7 89778-27-8	EP 95875	Anticancer, hormonal	Cancer, breast
Torsemide		56211-40-6			
Tositumomab		208921-02-2			
tosufloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, [CAS]	100490-36-6 115964-29-9	US 4704459	Quinolone antibacterial	Infection, urinary tract
tramadol	Cyclohexanol, 2-[[dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+/-)-[CAS]	27203-92-5 36282-47-0		Analgesic, other	Pain, general
Tramazoline		1082-57-1			
trandolapril	1H-Indole-2-carboxylic acid, 1-[2-[[1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1' [R* (R*)], 2' Alpha, 3' Alpha, 7' alpha]]- [CAS]	87679-71-8 87679-37-6 52-53-9	DE 3151690	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tranexamic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- [CAS]	1197-18-8	US 3950405	Antifibrinolytic	Menstrual disorder, general
tranilast	Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- [CAS]	53902-12-8	US 3940422	Vulnerary	Wound healing
trans-retinoic acid	Retinoic acid [CAS]	302-79-4		Anticancer, other	Cancer, general
Tranlycypromine		155-09-9			
trapidil	[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	15421-84-8	DD 55956	Vasodilator, coronary	
Trastuzumab		180288-69-1			
travoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethylester (1R,(1'Alpha(Z),2S,(1'E,3R'),3'Alpha,5'Alpha) [CAS]	157283-68-6		Formulation, mucosal, topical	Glaucoma
Traxanox		58712-69-9			
traxoprodil	1-Piperidineethanol, 4-hydroxy-Alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-, (AlphaS,betaS)- [CAS]	134234-12-1 188591-67-5		Analgesic, other	Pain, general
trazodone	1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- [CAS]	19794-93-5 25332-39-2	US 4215104	Antidepressant	
Tremacamra		155576-45-7			
Trenbolone		10161-33-8			
Trengestone		5192-84-7			
treosulfan	1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, [S-(R',R'')]- [CAS]	299-75-2	WO 8401506	Anticancer, alkylating	
treprobutone	Benzenebutanoic acid, 2,4,5-trifethoxy-Gamma-oxo- [CAS]	41826-92-0	GB 1387733	Antispasmodic	
treprostinol	Prosta-5,13-dien-1-olic acid, 6,9-epoxy-11,15-dihydroxy-, [5Z,9Alpha,11Alpha,13E,15S]- [CAS]	35121-78-9 61849-14-7	US 6054486	Formulation, parenteral, other	Hypertension, pulmonary
tretrinoiln	Retinoic acid [CAS]	302-79-4		Formulation, dermal, topical	Acne

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
treloquinol	6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[[3,4,5-trimethoxyphenyl)methyl]-, (S)-[CAS]	18559-59-6 30418-38-3 21650-42-0	ZA 6802416	Antiasthma	
TRH		24305-27-9			
TRI-50b	TRI 50b [CAS]	226214-49-9		Antithrombotic	Thrombosis, general
Triacetin		102-76-1			
Triamcinolone Acetonide		76-25-5			
Triamcinolone Benetonide		31002-79-6			
Triamcinolone Hexacetonide		5611-51-8			
triamcinolone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11 β , 16 α) [CAS]	76-25-5 124-94-7		Formulation, inhalable, topical	Asthma
Triamterene		396-01-0			
Triapine	Triapine [CAS]	236392-56-6	US 6458816	Anticancer, antimetabolite	Cancer, leukaemia, general
Triaziquone		68-76-8			
triazolam	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]-triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	US 3980790	Hypnotic/Sedative	Insomnia
Tribenoside		10310-32-4			
Trichlorfon		52-68-6			
Trichlormethiazide		133-67-5			
Trichlormethine		555-77-1			
Trichloroethylene		79-01-6			
Triclobisonium		79-90-3			
Triclocarban		101-20-2			
Triclofenol Piperazine		5714-82-9			
Triclofos		306-52-5			
Triclosan		3380-34-5			
Tricromyl		85-90-5			
Tridihexethyl Iodide		125-99-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
trientine	1,2-Ethanediamine, N,N2-bis(2-aminoethyl)-, [CAS]	38260-01-4 112-24-3		Metabolic and enzyme disorders	Wilson's disease
Triethanolamine		102-71-6			
Triethylenemelamine		51-18-3			
Triethylenephosphoramide		545-55-1			
Triethylenethiophosphoramide		52-24-4			
Trifluoperazine		117-89-5			
Trifluoperidol		749-13-3			
Trifluopromazine		146-54-3			
trifluridine	Thymidine, Alpha, Alpha-trifluoro- [CAS]	70-00-8	US 3201387	Antiviral, other	Infection, herpes virus, general
triflusal	Benzoic acid, 2-(acetyloxy)-4-(trifluoromethyl)- [CAS]	322-79-2	US 4096252	Antithrombotic	Thrombosis, general
Trihexyphenidyl		52-49-3			
trilostane	Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4Alpha,5Alpha,17Beta)- [CAS]	13647-35-3	US 3296255	Anticancer, hormonal	Cancer, breast
Trimazosin		35795-16-5			
trimebutine	Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester, (Z)-2-butenedioate (1:1) [CAS]	34140-59-5 39133-31-8	DE 2151716	Antispasmodic	
Trimecaine		616-68-2			
Trimeprazine		84-96-8			
Trimetazidine		5011-34-7			
Trimethadione		127-48-0			
Trimethaphan		68-91-7			
Trimethobenzamide		138-56-7			
Trimethoprim		738-70-5			
Trimetozine		635-41-6			
trimerexate	2,4-Quinazolinodiamine, 5-methyl-6-[[[3,4,5-trimethoxyphenyl]amino]methyl]- [CAS]	52128-35-5 82952-64-5	US 4391809	Antifungal	Infection, Pneumocystis jiroveci

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tripipramine	5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N, β -trimethyl-, (Z)-2-butenedioate (1:1) [CAS]	521-78-8 739-71-9		Antidepressant	
Trimoprostil		69900-72-7			
Trioxsalen		3902-71-4			
tripamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-(octahydro-4,7-methano-2H-isoindol-2-yl)-, (3 α Alfa,4Alfa,7Alfa,7 α Alfa)- [CAS]	73803-48-2	JP 7305585	Antihypertensive, diuretic	Hypertension, general
Triparanol		78-41-1			
Tripeleennamine		91-81-6			
Triprolidine		486-12-4			
tripitrelin	Luteinizing hormone-releasing factor (pig), 6-D-tryptophan- [CAS]	124508-66-3 57773-63-4	US 4010125	Releasing hormones	Cancer, prostate
trifiozine	Morpholine, 4-[[thioxo(3,4,5-trimethoxyphenyl)methyl]- [CAS]	35619-65-9	US 3862138	Antiulcer	
Tritoqualine		14504-73-5			
TRK-530	Phosphonic acid, [[4-(methylthio)phenyl]thio]methylene]bis-, disodium salt [CAS]	151425-92-2	WO 9410181	Antiarthritic, other	Arthritis, rheumatoid
TRK-820	2-Propenamide, N-[(5Alfa,6 β)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, monohydrochloride, (2E)- [CAS]	152658-17-8	WO 9315081	Antipruritic/inflamm, non-allergic	Pruritus
Troclosene		2244-21-5			
trofosfamide	3,2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide	22089-22-1	GB 1188159	Anticancer, alkylating	
Troglitazone		97322-87-7			
Troleandomycin		2751-9-9			
Trolnitrate		588-42-1			
tromantidine	N-(1-adamantyl)-2-(2-dimethylaminoethoxy)acetamide	53783-83-8	DE 1941218	Antiviral, other	Infection, herpes simplex virus
Tromethamine		77-86-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tropacine		6878-98-4			
Tropesin		65189-78-8			
Tropicamide		1508-75-4			
tropine	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-carboxy-2-phenylethyl ester, (+/-)- [CAS]	65189-78-8		Antiarthritic, other	
tropisetron	1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-[CAS]	89565-68-4	GB 2125398	Antiemetic	Chemotherapy-induced nausea and vomiting
Trospectomycin		88669-04-9			
trosipium	3Alpha-Hydroxy Spiro[1'AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinium] benziolate	10405-02-4		Urological	Pollakisuria
trovafoxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, (1Alpha,5Alpha,6Alpha)-, [CAS]	147059-72-1 147059-75-4	US 5164402	Quinolone antibacterial	Infection, respiratory tract, general
troxacitabine	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2S-cis)-[CAS]	145918-75-8		Anticancer, other	Cancer, leukaemia, acute myelogenous
Troxaerutin		7085-55-4			
troxipide	Benzamide, 3,4,5-trimethoxy-N-3-piperidinyl-, (+/-)- [CAS]	30751-05-4 99777-81-8	US 3647805	Antitumor	Ulcer, gastric
Trypan Red		574-64-1			
Tryparsamide		554-72-3			
Tryptophan		73-22-3			
TSH		9002-71-5			
TSN-09	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-, 5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha,(S)]- [CAS]	52485-79-7		Formulation, transdermal, patch	Pain, cancer
TU-2100	Nonanedioic acid, bis[(2-(ethoxycarbonyl)phenyl)] ester		US 6180669	Antiacne	Acne

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tuaminoheptane		123-82-0			
Tubercidin		69-33-0			
Tubocurarine Chloride		57-94-3			
tuobuterol	Benzenemethanol, 2-chloro-Alpha-[[[(1,1-dimethylethyl)amino]methyl]- [CAS]	41570-61-0	DE 2244737	Antiasthma	Asthma
TV-3326	N-(Propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate			Cognition enhancer	Alzheimer's disease
TY-11223	Acetic acid, [2-[2,3,3a,6,7,7a-hexahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadienyl)-1H-inden-5-yl]ethoxy]-, [1S-[1Alpha(R*),2S,3aAlpha,7aAlpha]]-, [CAS]	140694-43-5	US 4837342	Antithrombotic	Unspecified
TY-12533	6,7,8,9-Tetrahydro-2-methyl-5H-cyclohepta[b]pyridine-3-carbonylguanidine maleate		US 6258829	Antiarrhythmic	Unspecified
TYB-3215	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, modified-release, other	Angina, general
Tybamate		4268-36-4			
tyloxapol	4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	25301-02-4		Formulation, inhalable, topical	Cystic fibrosis
Tymazoline		24243-97-8			
Tyramine		51-67-2			
Tyropanoate		7246-21-1			
Ubenimex		58970-76-6			
ufenamate	Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, butyl ester [CAS]	67330-25-0	BE 861852	Antipruritic/inflamm, non-allergic	
Undecylenic Acid		112-38-9			
Unoprostone		120373-36-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
UR-8880	4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-imidazol-1-yl]benzenesulfonamide- [CAS]			Anti-inflammatory	Inflammation, general
Uracil Mustard		66-75-1			
Uralyt-U	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:6:6), hydrate [CAS]	55049-48-4	US 4400535	Urological	
urapidil	2,4-(1H,3H)-Pyrimidinedione, 6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl- [CAS]	34661-75-1	GB 1309324	Antihypertensive, adrenergic	Hypertension, general
urea	Urea [CAS]	57-13-6		Antipsoriasis	
Uredepa		302-49-8			
Urethan		51-79-6			
Uridine 5'-Triphosphate		63-39-8			
Urinastatin		80449-31-6			
ursodeoxycholic acid	3Alpha,7beta-dihydroxy-5beta-cholan-24-olic acid [CAS]	128-13-2		Formulation, other, Cirrhosis, primary biliary, hepatic dysfunction, biliary calculus	Cirrhosis, primary biliary
Ursodiol		128-13-2			
Ushercell			US 6063773	Formulation, mucosal, topical	Contraceptive, female
Uzarin		20231-81-6			
valaciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester [CAS]	124832-26-4	EP 308065	Antiviral, other	Infection, herpes simplex virus
Valacyclovir		124832-26-4			
valdecoxib	Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- [CAS]	181695-72-7	US 5859257	Antiarthritic, other	Arthritis, rheumatoid
Valdetamide		512-48-1			
Valethamate		90-22-2			
valganciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester [CAS]	175865-59-5 175865-60-8	EP 694547	Antiviral, other	Infection, cytomegalovirus
Valnoctamide		4171-13-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
valomaciclovir	L-Valine (3R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl)-4-((1-oxooctadecyl)oxy)butyl ester [CAS]	195156-77-5		Antiviral, other	Infection, herpes simplex virus
valproate	Pentanoic acid, 2-propyl-, [CAS]	76584-70-8 1069-66-5	US 4988731	Antiepileptic	Epilepsy, generalized, tonic-clonic
Valproic Acid		99-66-1			
Valpromide		2430-27-5			
valroceamide	Pentanamide, N-(2-amino-2-oxoethyl)-2-propyl- [CAS]	92262-58-3	US 5585358	Antiepileptic	Epilepsy, general
valrubicin	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(trifluoroacetyl)amino)-Alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl ester (2S-cis)-[CAS]	56124-62-0	US 4035566	Anticancer, antibiotic	Cancer, bladder
valsartan	L-Valine, N-(1-oxopentyl)-N-[[2-(1H-tetrazol-5-yl)](1,1'-biphenyl)-4-yl]methyl]-[CAS]	137862-53-4	EP 443983	Antihypertensive, renin system	Hypertension, general
Valspodar		121584-18-7			
wardenafil	Piperazine, 1-(3-(1,4-dihydro-5-methyl-(4-oxo-7-propylimidazo(5,1-f)(1,2,4)-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl- [CAS]	224785-90-4		Male sexual dysfunction	Sexual dysfunction, male, general
varespladib	Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- [CAS]	172732-68-2 172733-42-5	EP 675110	Septic shock treatment	Sepsis
<i>Varicella Virus Vaccine</i>					
vatandipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(4-(diphenylmethyl)-1-piperazinyl)phenyl]ethyl methyl ester, [CAS]	116308-55-5 133743-71-2	EP 257616	Neuroprotective	Hypertension, general
VEA			US 6007817	Radio/chemosensitizer	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
vecuronium	Piperidinium, 1- [(2R,3Alpha,5Alpha,16S,17S)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methyl-, [CAS]	50700-72-6	US 4237126	Muscle relaxant	Anaesthesia, adjunct
Velnacrine		104675-29-8			
venlafaxine	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]	93413-69-5 99300-78-4	GB 2227743	Antidepressant	Depression, general
Veralipride		66644-81-3			
verapamil	Benzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)- [CAS]	52-53-9		Formulation, modified-release, other	Hypertension, general
verteporfin	23H,25H-Benzob[porphine-9,13-dipropionic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans- [CAS]	129497-78-5	US 5238940	Ophthalmological	Macular degeneration
vesnarinone	Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinoliny)- [CAS]	81840-15-5	GB 2086896	Cardio stimulant	Heart failure
Vetrabutine		3735-45-3			
VF-233	Benzene carboximidamide, N,3,4,5-tetrahydroxy- [CAS]	95933-74-7	US 4623659	Cardiovascular	Reperfusion injury
VI-0134			US 6403597	Male sexual dysfunction	Premature ejaculation
vidarabine	9H-Purin-6-amine, 9-β-D-arabinofuranosyl- [CAS]	24356-66-9 5536-17-4	GB 1159290	Antiviral, other	Infection, herpes virus, general
vigabatrin	5-Hexenoic acid, 4-amino- [CAS]	68506-86-5 60643-86-9	GB 1472525	Antiepileptic	Epilepsy, partial (focal, local)
vilazodone	2-Benzofurancarboxamide, 5-[4-[5-cyano-1H-indol-3-yl]butyl]-1-piperazinyl- [CAS]	163521-12-8	EP 648767	Antidepressant	Depression, general
Viloxazine		46817-91-8			
Viminol		21363-18-8			
Vinbarbital		125-44-0			
Vinblastine		865-21-4			
vinburnine	Eburnamenin-14(15H)-one, (3Alpha,16Alpha)- [CAS]	474-00-0 4880-88-0	DE 1932245	Cognition enhancer	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Vincamine		1617-90-9			
Vinconate		70704-03-9			
vincristine	Vincalukoblastine, 22-oxo-, sulfate (1:1) (salt) [CAS]	2068-78-2 57-22-7	EP 207831	Formulation, parenteral, other	Cancer, general
vindesine	Vincalukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)- [CAS]	53643-48-4 59917-39-4	GB 1463575	Anticancer, other	Cancer, leukaemia, acute lymphocytic
vinflunine	Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2S,3S,4S,5Apha,12S,19Apha) - [CAS]	162652-95-1	FR 2707988	Anticancer, other	Cancer, general
vinorelbine	C'-Norvincalukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1	EP 10458	Anticancer, other	Cancer, lung, non-small cell
vinpocetine	Eburnamenine-14-carboxylic acid, ethyl ester, (3Apha,16Apha)- [CAS]	42971-09-5	GB 1405127	Cognition enhancer	Cognitive disorder, general
Vinyl Ether		109-93-3			
Vinylbital		2430-49-1			
Viquidil		84-55-9			
Viridin		3306-52-3			
Visnadine		477-32-7			
Vitamin A		68-26-8			
vitamin B12	Vitamin B12 [CAS]	68-19-9		Formulation, transmucosal, nasal	Anaemia, general
vitamin C	L-Ascorbic acid [CAS]	50-81-7		Formulation, modified-release, <=24hr	Nutrition
Vitamin D ₂		50-14-6			
Vitamin D ₃		67-97-0			
Vitamin K ₅		83-70-5			
Vitamins, Prenatal					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
VLA-4 antagonists	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-((4-biphenyl)-methyl)-4-methyl-2,5-dioximidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP 842943	Antiasthma	Asthma
VNP-40101M	1,2-Bis((methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine		US 6040338	Anticancer, alkylating	Cancer, general
voglbose	D-epi-Inositol, 3,4-dideoxy-4-[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C- [CAS]	83480-29-9	EP 56194	Antidiabetic	Diabetes, Type II
voriconazole	4-Pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-β-methyl-Alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-[CAS]	137234-62-9	EP 440372	Antifungal	Infection, fungal, general
Vorozole		129731-10-8			
VUF-K-8788	7-[3-[4-(2-Quinolinylmethyl)-1-piperazinyl]propoxy]-3,4-dihydro-2H-1,4-benzothiazine-3-one			Antiasthma	Asthma
Warfarin		81-81-2			
WF-10	Tetrachlorodecaoxide [CAS]	92047-76-2		Radiochemoprotective	Chemotherapy-induced injury, bone marrow, general
WMC-79	2-(3-[4-[3-(6-oxo-6H-2,10b-diazaaceanthrenyl)-5-ylamino]propyl]-piperazin-1-yl]propyl)-5-nitro-2-azaphenylene-1,3-dione			Anticancer, other	Cancer, colorectal
wound healing matrix			US 5897880	Formulation, transdermal, patch	Ulcer, diabetic
WP-170			US 6531121	Cytokine	Unspecified
xaliprodin	Pyridine, 1,2,3,6-tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-, [CAS]	90494-79-4 135354-020-8	EP 101381	Neuroprotective	Amyotrophic lateral sclerosis
xamoterol	4-Morpholinecarboxamide, N-[2-[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-, (+/-)-[CAS]	73210-73-8 81801-12-9	GB 2002748	Cardio stimulant	Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Xanomeline		131986-45-3			
Xanthinol Niacinate		437-74-1			
Xemilofiban		149820-74-6			
Xenbucin		959-10-4			
Xibenolol		81584-06-7			
xibornol	Phenol, 4,5-dimethyl-2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-, exo-[CAS]	13741-18-9	GB 1206774	Antibacterial, other	Infection, general
ximelegatran	Glycine, N-((R)-cyclohexyl-2-((2S)-2-(((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidiny)2-oxoethyl ethyl ester [CAS]	192939-46-1		Antithrombotic	Thrombosis, venous
Ximoprofen		56187-89-4			
xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US 3567777	Antihypertensive, diuretic	
xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-8-methyl-6-methylene-, (8S)- [CAS]	77287-89-9		Analgesic, other	Pain, cancer
XR-5118	2,5-Piperazinedione, 3-[[5-[2-(dimethylamino)ethyl]thio]-2-thienyl]methylene]-6-(phenylmethylene)-, monohydrochloride, (3Z,6Z)- [CAS]	174766-49-5	WO 9532190	Anticancer, other	Cancer, general
XR-5944	N,N'-(1,2-Ethanediy)bis(imino-2,1-ethanediy)bis(9-methylphenazine-1-carboxamide)				
Xylometazoline		526-36-3	EP 934278	Anticancer, other	Cancer, general
Xylose		58-86-6			
YH-1885	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	178307-42-1	WO 9605177	Antitumor	Ulcer, GI, general
YM-511	Benzonitrile, 4-[[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]- [CAS]	148869-05-0	WO 9305027	Anticancer, hormonal	Cancer, breast

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
YM-598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethanesulfonamide			Anticancer, other	Cancer, prostate
Yohimbine		146-48-5			
YT-146	Adenosine, 2-(1-octynyl)- [CAS]	90596-75-1	US 5270304	Anti-inflammatory	Inflammation, general
Z-321	Thiazolidine, 3-((2,3-dihydro-1H-inden-2-yl)acetyl)-4-(1-pyrrolidinylcarbonyl)-, (R)- [CAS]	130849-58-0	EP 372484	Cognition enhancer	Dementia, senile, general
Z-335	(1H-Indene-5-acetic acid, 2[[[(4-chlorophenyl)sulfonyl]amino]methyl]-2,3-dihydro, monosodium salt] [CAS]	146731-14-8	JP 92506077	Antithrombotic	Peripheral vascular disease
zafirlukast	Carbamic acid, [3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-, cyclopentyl ester [CAS]	107753-78-6	EP 199543	Antiasthma	Asthma
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	7481-89-2	US 4879277	Antiviral, anti-HIV	Infection, HIV/AIDS
Zaldaride		109826-26-8			
zaleplon	Acetamide, N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl- [CAS]	151319-34-5	EP 776898	Hypnotic/Sedative	Insomnia
zaltoprofen	Dibenzo[b,f]thiepin-2-acetic acid, 10,11-dihydro-Alpha-methyl-10-oxo- [CAS]	74711-43-6	JP 55053282	Anti-inflammatory	
zanamivir	5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid [CAS]	139110-80-8	WO 9116320	Antiviral, other	Infection, influenza virus
zanapazil	1-Propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- [CAS]	142852-50-4	EP 487071	Cognition enhancer	Alzheimer's disease
Zatebradine		85175-67-3			
ZD-0473	Platinum, amminedichloro(2-methylpyridine)- (SP-4-3)- [CAS]	181630-15-9	EP 727430	Anticancer, alkylating	Cancer, ovarian
ZD-0947			WO 9528388	Urological	Overactive bladder
ZD-6126	N-acetylcolchicol-O-phosphate			Anticancer, other	Cancer, general
ZD-9331	1H-Tetrazole-5-butanolic acid, Alpha-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl]amino (S)- [CAS]	153537-73-6	GB 2264946	Anticancer, antimetabolite	Cancer, pancreatic

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zebularine	2(1H)-Pyrimidinone, 1-β-D-ribofuranosyl- [CAS]	3690-10-6		Anticancer, other	Cancer, general
zelandopam	7,8-Isoquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-, [CAS]	138086-00-7	JP 03190818	Vasodilator, renal	Hypertension, general
Zenarestat		112733-06-9			
Ziconotide		107452-89-1			
zidovudine	Thymidine, 3'-azido-3'-deoxy- [CAS]	30516-87-1	US 4724232	Antiviral, anti-HIV	Infection, HIV/AIDS
zileuton	Urea, N-(1-benzo[b]thien-2-ylethyl)-N-hydroxy- [CAS]	111406-87-2	EP 279263	Antiasthma	Asthma
Zimeldine		56775-88-3			
zinc acetate	hexakis(Im-acetato)-Im4-oxotetrazinc	12129-82-7		Antiviral, other	Infection, herpes simplex virus prophylaxis
zinc acexamate	Hexanoic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS]	70020-71-2	EP 369088	Antitumor	Ulcer, duodenal
zinc ibuprofenate		78416-80-5		Anti-inflammatory, topical	Inflammation, dermal
Zinc p-Phenolsulfonate		127-82-2			
Zinc Salicylate		16283-36-6			
Zinostatin		9014-2-2			
zinostatin stimalamer		123760-07-6	EP 136791	Anticancer, antibiotic	Cancer, liver
Zipeprol		34758-83-3			
ziprasidone	2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	122883-93-6 146939-27-7	EP 281309	Neuroleptic	Schizophrenia
zofenopril	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, [1(R'), 2Alpha, 4Alpha]- [CAS]	75176-37-3 81872-10-8 81938-43-4	GB 2028327	Antihypertensive, renin system	Hypertension, general
zofenopril + HCTZ	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, [1(R'), 2Alpha, 4Alpha]- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide [CAS]				
zoledronic acid	Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- [CAS]	118072-93-8 165800-06-6	EP 531253	Formulation, fixed-dose combinations Osteoporosis treatment	Hypertension, general Hypercalcaemia of malignancy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zolimidine	2-(p-methylsulfonylphenyl)imidazo[1,2-a]pyridine	1222-57-7	US 3318880	Anticancer	Gastritis
zolmitriptan	2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)- [CAS]	139264-17-8	WO 9118897	Antimigraine	Migraine
zolpidem	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R-(R*))-(2,3-dihydroxybutanedioate (2:1) [CAS]	99294-93-6 82626-48-0	EP 50563	Hypnotic/Sedative	Insomnia
Zomepirac		33369-31-2			
zonampanel	1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-[CAS]	210245-80-0		Neuroprotective	Ischaemia, cerebral
zoniporide	1H-pyrazole-4-carboxamide, N-(aminomino methyl)-5-cyclopropyl-1-(5-quinolinyl)-, [CAS]	249296-45-5			
zonisamide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	68291-97-4 68291-98-5	GB 2025931	Cardiovascular Antiepileptic	Unspecified Epilepsy, generalized, tonic-clonic
zopiclone	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2	GB 1358680	Hypnotic/Sedative	Insomnia
Zopolrestat		110703-94-1			
Zorubicin		54083-22-6			
zosuquidar	1-Piperazineethanol, 4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzof[a,e]cyclopropa[c]cyclohepten-6-yl)-Alpha-[(5-quinolinyl)oxy)methyl]-, [6(R)-(1aAlpha,6Alpha,10bAlpha)]- [CAS]	167465-36-3		Radio/chemosensitizer	Cancer, leukaemia, acute myelogenous
zotepine	Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethyl- [CAS]	26615-21-4	GB 1247067	Neuroleptic	Schizophrenia
ZP-123			WO 0162775	Antiarrhythmic	Arrhythmia, general
Z-tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	10540-29-1		Anticancer, hormonal	Cancer, colorectal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zuclopenthixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-, (Z)-[CAS]	53772-83-1	EP 270282	Neuroleptic	Psychosis, general
		982-24-1			
		85721-05-7			
		64053-00-5			

CLAIMS:

1. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and co-crystal former are hydrogen bonded to each other.
2. The pharmaceutical co-crystal composition according to claim 1, wherein:
 - (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
 - (b) the API is selected from an API of Table IV;
 - (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
 - (d) the API is a liquid at room temperature;
 - (e) the API is a solid at room temperature;
 - (f) the API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (g) the co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring,

- thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (h) the difference in pK_a between the API and the co-crystal former does not exceed 2;
 - (i) the solubility of the co-crystal is increased as compared to the API;
 - (j) the dose response of the co-crystal is increased as compared to the API;
 - (k) the dissolution of the co-crystal is increased as compared to the API;
 - (l) the bioavailability of the co-crystal is increased as compared to the API;
 - (m) the stability of the co-crystal is increased as compared to the API;
 - (n) a difficult to salt or unsaltable API is incorporated into the co-crystal;
 - (o) the hygroscopicity of the co-crystal is decreased as compared to the API;
 - (p) an amorphous API is crystallized as a component of the co-crystal;
 - (q) the form diversity of the co-crystal is decreased as compared to the API; or
 - (r) the morphology of the co-crystal is modulated as compared to the API.

3. A pharmaceutical co-crystal composition, comprising: an API, a co-crystal former, and a third molecule; wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.

4. The pharmaceutical co-crystal composition according to claim 3, wherein:

- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (b) the API is selected from an API of Table IV;
- (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (d) the API is a liquid at room temperature;

- (e) the API is a solid at room temperature;
- (f) the API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (g) the co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
- (h) the difference in pK_a between the API and the co-crystal former does not exceed 2;
- (i) the solubility of the co-crystal is increased as compared to the API;
- (j) the dose response of the co-crystal is increased as compared to the API;
- (k) the dissolution of the co-crystal is increased as compared to the API;
- (l) the bioavailability of the co-crystal is increased as compared to the API;
- (m) the stability of the co-crystal is increased as compared to the API;
- (n) a difficult to salt or unsaltable API is incorporated into the co-crystal;
- (o) the hygroscopicity of the co-crystal is decreased as compared to the API;

- (p) an amorphous API is crystallized as a component of the co-crystal;
- (q) the form diversity of the co-crystal is decreased as compared to the API; or
- (r) the morphology of the co-crystal is modulated as compared to the API.

5. A pharmaceutical co-crystal composition, comprising: a first and a second API, wherein each API is either a liquid or a solid at room temperature, and wherein the APIs are hydrogen bonded to a molecule.

6. The pharmaceutical co-crystal composition according to claim 5, wherein:

- (a) the first API is hydrogen bonded to the second API;
- (b) an API is selected from an API of Table IV;
- (c) each API is selected from an API of Table IV;
- (d) an API is a liquid at room temperature and the other API is a solid at room temperature;
- (e) each API is a solid at room temperature;
- (f) an API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (g) each API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo,

organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (h) the difference in pK_a between the first API and the second API does not exceed 2;
- (i) the solubility of the co-crystal is increased as compared to an API;
- (j) the dose response of the co-crystal is increased as compared to an API;
- (k) the dissolution of the co-crystal is increased as compared to an API;
- (l) the bioavailability of the co-crystal is increased as compared to an API;
- (m) the stability of the co-crystal is increased as compared to an API;
- (n) a difficult to salt or unsaltable API is incorporated into the co-crystal;
- (o) the hygroscopicity of the co-crystal is decreased as compared to an API;
- (p) an amorphous API is crystallized as a component of the co-crystal;
- (q) the form diversity of the co-crystal is decreased as compared to an API; or
- (r) the morphology of the co-crystal is modulated as compared to an API.

7. A pharmaceutical co-crystal composition, comprising: a first and a second co-crystal former, wherein each co-crystal former is a solid at room temperature, and wherein both co-crystal formers are hydrogen bonded to a molecule.

8. The pharmaceutical co-crystal composition according to claim 7, wherein:

- (a) the first co-crystal former is hydrogen bonded to the second co-crystal former;
- (b) a co-crystal former is selected from a co-crystal former of Table I or Table II;
- (c) each co-crystal former is selected from a co-crystal former of Table I or Table II;

- (d) a co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (e) each co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (f) the difference in pK_a between the first co-crystal former and the second co-crystal former does not exceed 2;
- (g) the solubility of the co-crystal is increased as compared to a co-crystal former;
- (h) the dose response of the co-crystal is increased as compared to a co-crystal former;
- (i) the dissolution of the co-crystal is increased as compared to a co-crystal former;
- (j) the bioavailability of the co-crystal is increased as compared to a co-crystal former;
- (k) the stability of the co-crystal is increased as compared to a co-crystal former;
- (l) a difficult to salt or unsaltable API is incorporated into the co-crystal;

- (m) the hygroscopicity of the co-crystal is decreased as compared to a co-crystal former;
- (n) an amorphous API is crystallized as a component of the co-crystal;
- (o) the form diversity of the co-crystal is decreased as compared to a co-crystal former; or
- (p) the morphology of the co-crystal is modulated as compared to a co-crystal former.

9. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, or ibuprofen.

10. The pharmaceutical co-crystal composition according to claim 1, 3, 5, or 7, further comprising a pharmaceutically acceptable diluent, excipient, or carrier.

11. A co-crystal comprising an API and a co-crystal former selected from the group consisting of:

- (a) carbamazepine and saccharin;
- (b) carbamazepine and nicotinamide;
- (c) carbamazepine and trimesic acid;
- (d) celecoxib and nicotinamide;
- (e) olanzapine and nicotinamide;
- (f) celecoxib and 18-crown-6;
- (g) itraconazole and succinic acid;
- (h) itraconazole and fumaric acid;
- (i) itraconazole and L-tartaric acid;
- (j) itraconazole and L-malic acid;
- (k) itraconazoleHCl and DL-tartaric acid;
- (l) modafinil and malonic acid;

- (m) modafinil and glycolic acid;
- (n) modafinil and maleic acid;
- (o) topiramate and 18-crown-6;
- (p) 5-fluorouracil and urea;
- (q) hydrochlorothiazide and nicotinic acid;
- (r) hydrochlorothiazide and 18-crown-6;
- (s) hydrochlorothiazide and piperazine;
- (t) acetaminophen and 4,4'-bipyridine;
- (u) phenytoin and pyridone;
- (v) aspirin and 4,4'-bipyridine;
- (w) ibuprofen and 4,4'-bipyridine;
- (x) flurbiprofen and 4,4'-bipyridine;
- (y) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;
- (z) carbamazepine and p-phthalaldehyde;
- (aa) carbamazepine and 2,6-pyridinecarboxylic acid;
- (bb) carbamazepine and 5-nitroisophthalic acid;
- (cc) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; and
- (dd) carbamazepine and benzoquinone.

12. A process for preparing a pharmaceutical co-crystal composition comprising an API and a co-crystal former, comprising:

- (a) providing an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature;
- (b) grinding, heating, co-subliming, co-melting, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase, wherein the API and co-crystal former are hydrogen bonded to each other;
- (c) isolating co-crystals formed thereby; and

- (d) incorporating the co-crystals into a pharmaceutical composition.
13. The process of claim 12, wherein:
- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
 - (b) the API is selected from an API of Table IV;
 - (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
 - (d) the API is a liquid at room temperature;
 - (e) the API is a solid at room temperature;
 - (f) the API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (g) the co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
 - (h) the difference in pK_a between the API and the co-crystal former does not exceed 2.

14. A process for preparing a pharmaceutical co-crystal composition comprising an API, a co-crystal former, and a third molecule, comprising:
- (a) providing an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature;
 - (b) grinding, heating, co-subliming, co-melting, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase, wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other;
 - (c) isolating co-crystals formed thereby; and
 - (d) incorporating the co-crystals into a pharmaceutical composition.
15. The process of claim 14, wherein:
- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
 - (b) the API is selected from an API of Table IV;
 - (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
 - (d) the API is a liquid at room temperature;
 - (e) the API is a solid at room temperature;
 - (f) the API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (g) the co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
 - (h) the difference in pK_a between the API and the co-crystal former does not exceed 2.
16. A process for preparing a pharmaceutical co-crystal composition comprising a first and a second API, comprising:
- (a) providing a first and a second API, wherein each API is either a liquid or a solid at room temperature;
 - (b) grinding, heating, co-subliming, co-melting, or contacting in solution the APIs under crystallization conditions, so as to form a solid phase, wherein the APIs are hydrogen bonded to a molecule;
 - (c) isolating co-crystals formed thereby; and
 - (d) incorporating the co-crystals into a pharmaceutical composition.
17. The process of claim 16, wherein:
- (a) the first API is hydrogen bonded to the second API;
 - (b) an API is selected from an API of Table IV;
 - (c) each API is selected from an API of Table IV;
 - (d) an API is a liquid at room temperature and the other API is a solid at room temperature;
 - (e) each API is a solid at room temperature;
 - (f) an API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone,

thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (g) each API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
- (h) the difference in pK_a between the first API and the second API does not exceed 2.

18. A process for preparing a pharmaceutical co-crystal composition comprising a first and a second co-crystal former, comprising:

- (a) providing a first and a second co-crystal former, wherein each co-crystal former is a solid at room temperature;
- (b) grinding, heating, co-subliming, co-melting, or contacting in solution the co-crystal formers under crystallization conditions, so as to form a solid phase, wherein both co-crystal formers are hydrogen bonded to a molecule;
- (c) isolating co-crystals formed thereby; and
- (d) incorporating the co-crystals into a pharmaceutical composition.

19. The process of claim 18, wherein:

- (a) the first co-crystal former is hydrogen bonded to the second co-crystal former;
- (b) a co-crystal former is selected from a co-crystal former of Table I or Table II;
- (c) each co-crystal former is selected from a co-crystal former of Table I or Table II;
- (d) a co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (e) each co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
- (f) the difference in pK_a between the first co-crystal former and the second co-crystal former does not exceed 2.

20. The process of claim 12, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, or ibuprofen.

21. The process of claim 12, further comprising: incorporating a pharmaceutically acceptable diluent, excipient, or carrier.

22. A process of preparing a co-crystal comprising an API and a co-crystal former, comprising:

- (a) providing an API and a co-crystal former;
- (b) grinding, heating, co-subliming, co-melting, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase; and
- (c) isolating co-crystals formed thereby;

wherein the API and the co-crystal former, respectively, are selected from the group consisting of: carbamazepine and saccharin, carbamazepine and nicotinamide, carbamazepine and trimesic acid, celecoxib and nicotinamide, olanzapine and nicotinamide, celecoxib and 18-crown-6, itraconazole and succinic acid, itraconazole and fumaric acid, itraconazole and tartaric acid, itraconazole and malic acid, itraconazoleHCl and tartaric acid, modafinil and malonic acid, modafinil and glycolic acid, modafinil and maleic acid, topiramate and 18-crown-6, 5-fluorouracil and urea, hydrochlorothiazide and nicotinic acid, hydrochlorothiazide and 18-crown-6, hydrochlorothiazide and piperazine, acetaminophen and 4,4'-bipyridine, phenytoin and pyridone, aspirin and 4,4'-bipyridine, ibuprofen and 4,4'-bipyridine, flurbiprofen and 4,4'-bipyridine, flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene, carbamazepine and p-phthalaldehyde, carbamazepine and 2,6-pyridinecarboxylic acid, carbamazepine and 5-nitroisophthalic acid, carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid, and carbamazepine and benzoquinone.

23. A process for modulating the solubility of an API for use in a pharmaceutical composition, which process comprises:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

- (b) isolating the co-crystal, wherein the co-crystal has a modulated solubility as compared to the API; and
- (c) incorporating the co-crystal having modulated solubility into a pharmaceutical composition.

24. The process of claim 23, wherein the solubility of the co-crystal is increased as compared to the API.

25. A process for modulating the dose response of an API for use in a pharmaceutical composition, which process comprises:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has a modulated dose response as compared to the API; and
- (c) incorporating the co-crystal having modulated dose response into a pharmaceutical composition.

26. The process of claim 25, wherein the dose response of the co-crystal is increased as compared to the API.

27. A process for modulating the dissolution of an API for use in a pharmaceutical composition, which process comprises:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has a modulated dissolution as compared to the API; and

- (c) incorporating the co-crystal having modulated dissolution into a pharmaceutical composition.

28. The process of claim 27, wherein the dissolution of the co-crystal is increased as compared to the API.

29. A process for modulating the bioavailability of an API for use in a pharmaceutical composition, which process comprises:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has a modulated bioavailability as compared to the API; and
- (c) incorporating the co-crystal having modulated bioavailability into a pharmaceutical composition.

30. The process of claim 29, wherein the bioavailability of the co-crystal is increased as compared to the API.

31. A process for increasing the stability of an API for use in a pharmaceutical composition, which process comprises:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has increased stability as compared to the API; and
- (c) incorporating the co-crystal having increased stability into a pharmaceutical composition.

32. A process for the incorporation of a difficult to salt or unsaltable API for use in a pharmaceutical composition, which process comprises:
- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
 - (b) isolating the co-crystal;
 - (c) incorporating the co-crystal having a difficult to salt or unsaltable API into a pharmaceutical composition.
33. A process for decreasing the hygroscopicity of an API for use in a pharmaceutical composition, which process comprises:
- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
 - (b) isolating the co-crystal, wherein the co-crystal has decreased hygroscopicity as compared to the API; and
 - (c) incorporating the co-crystal having decreased hygroscopicity into a pharmaceutical composition.
34. A process for crystallizing an amorphous API for use in a pharmaceutical composition, which process comprises:
- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
 - (b) isolating the co-crystal;
 - (c) incorporating the co-crystal into a pharmaceutical composition.

35. A process for decreasing the form diversity of an API for use in a pharmaceutical composition, which process includes:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has decreased form diversity as compared to the API; and
- (c) incorporating the co-crystal having decreased form diversity into a pharmaceutical composition.

36. A process for modulating the morphology of an API for use in a pharmaceutical composition, which process includes:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has a different morphology as compared to the API; and
- (c) incorporating the co-crystal having modulated morphology into a pharmaceutical composition.

37. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an amino-pyridine functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) water;
- (e) an alcohol;
- (f) a primary amine;

- (g) a secondary amine;
- (h) a carbonyl;
- (i) a sulfoxo moiety;
- (j) an ether;
- (k) an ester;
- (l) an aromatic N;
- (m) a cyano moiety;
- (n) a nitro moiety;
- (o) a chloride moiety;
- (p) a bromide moiety;
- (q) a primary amide where the interaction distance is between about 2.97 and about 3.07 angstroms;
- (r) a secondary amide where the interaction distance is between about 2.70 and about 3.20 angstroms;
- (s) a secondary amide where the interaction distance is between about 2.75 and about 3.17 angstroms;
- (t) a carboxylic acid where the interaction distance is between about 2.72 and about 3.07 angstroms;
- (u) a carboxylic acid where the interaction distance is between about 2.54 and about 2.82 angstroms;
- (v) water where the interaction distance is between about 2.72 and about 3.15 angstroms;
- (w) water where the interaction distance is between about 2.65 and about 3.15 angstroms;
- (x) an alcohol where the interaction distance is between about 2.78 and about 3.14 angstroms;
- (y) an alcohol where the interaction distance is between about 2.63 and about 3.06 angstroms;
- (z) a primary amine where the interaction distance is between about 2.85 and about 3.25 angstroms;

- (aa) a secondary amine where the interaction distance is between about 2.83 and about 3.25 angstroms;
- (bb) a carbonyl where the interaction distance is between about 2.87 and about 3.10 angstroms;
- (cc) a sulfoxo moiety where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (dd) an ether where the interaction distance is between about 2.84 and about 3.20 angstroms;
- (ee) an ester where the interaction distance is about 3.09 angstroms;
- (ff) an ester where the interaction distance is between about 2.85 and about 3.16 angstroms;
- (gg) an aromatic N where the interaction distance is between about 2.78 and about 3.25 angstroms;
- (hh) a cyano moiety where the interaction distance is between about 2.83 and about 3.30 angstroms;
- (ii) a nitro moiety where the interaction distance is between about 2.85 and about 3.28 angstroms;
- (jj) a chloride moiety where the interaction distance is between about 3.10 and about 3.45 angstroms; or
- (kk) a bromide moiety where the interaction distance is between about 3.27 and about 3.48 angstroms.

38. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a primary amine functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;

- (g) an alcohol;
- (h) a carbonyl;
- (i) a sulfoxo moiety;
- (j) a sulfonyl;
- (k) an ether;
- (l) an ester;
- (m) an aromatic N;
- (n) a cyano moiety;
- (o) a nitro moiety;
- (p) a chloride moiety;
- (q) a bromide moiety;
- (r) a primary amide where the interaction distance is between about 2.73 and about 3.20 angstroms;
- (s) a secondary amide where the interaction distance is between about 2.65 and about 3.20 angstroms;
- (t) a carboxylic acid where the interaction distance is between about 2.74 and about 3.15 angstroms;
- (u) a carboxylic acid where the interaction distance is between about 2.72 and about 3.12 angstroms;
- (v) an amino-pyridine where the interaction distance is between about 3.10 and about 3.24 angstroms;
- (w) a sulfonamide where the interaction distance is between about 2.86 and about 3.17 angstroms;
- (x) water where the interaction distance is between about 2.65 and about 3.17 angstroms;
- (y) an alcohol where the interaction distance is between about 2.63 and about 3.26 angstroms;
- (z) a carbonyl where the interaction distance is between about 2.64 and about 3.15 angstroms;
- (aa) a sulfoxo moiety where the interaction distance is between about 2.70 and about 3.10 angstroms;

- (bb) a sulfonyl where the interaction distance is between about 2.93 and about 3.12 angstroms;
- (cc) an ether where the interaction distance is between about 2.75 and about 3.25 angstroms;
- (dd) an ester where the interaction distance is between about 2.90 and about 3.20 angstroms;
- (ee) an ester where the interaction distance is between about 2.74 and about 3.27 angstroms;
- (ff) an aromatic N where the interaction distance is between about 2.92 and about 3.26 angstroms;
- (gg) a cyano moiety where the interaction distance is between about 2.83 and about 3.30 angstroms;
- (hh) a nitro moiety where the interaction distance is between about 2.75 and about 3.17 angstroms;
- (ii) a chloride moiety where the interaction distance is between about 3.07 and about 3.50 angstroms; or
- (jj) a bromide moiety where the interaction distance is between about 3.23 and about 3.60 angstroms.

39. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a primary sulfonamide functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) water;
- (b) an alcohol;
- (c) a primary amine;
- (d) a secondary amine;
- (e) a sulfonyl;
- (f) an ether;
- (g) an ester;
- (h) a cyano moiety;
- (i) a nitro moiety;

- (j) a chloride moiety;
- (k) water where the interaction distance is about 2.87 angstroms;
- (l) an alcohol where the interaction distance is between about 2.85 and about 3.07 angstroms;
- (m) a primary amine where the interaction distance is between about 2.85 and about 3.20 angstroms;
- (n) a secondary amine where the interaction distance is between about 2.85 and about 3.20 angstroms;
- (o) a sulfonyl where the interaction distance is between about 2.85 and about 3.20 angstroms;
- (p) an ether where the interaction distance is between about 2.90 and about 3.20 angstroms;
- (q) an ester where the interaction distance is between about 2.85 and about 3.12 angstroms;
- (r) a cyano moiety where the interaction distance is about 3.00 angstroms;
- (s) a nitro moiety where the interaction distance is between about 3.00 and about 3.20 angstroms; or
- (t) a chloride moiety where the interaction distance is between about 3.20 and about 3.32 angstroms.

40. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a primary amide functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a secondary amide;
- (b) a carboxylic acid;
- (c) an amino-pyridine;
- (d) an aromatic N;
- (e) water;
- (f) an alcohol;
- (g) a secondary amine;
- (h) a carbonyl;

- (i) a sulfonyl;
- (j) an ether;
- (k) an ester;
- (l) a cyano moiety;
- (m) a nitro moiety;
- (n) a chloride moiety;
- (o) a bromide moiety;
- (p) a secondary amide where the interaction distance is between about 2.70 and about 3.15 angstroms;
- (q) a carboxylic acid where the interaction distance is between about 2.40 and about 2.80 angstroms;
- (r) a carboxylic acid where the interaction distance is between about 2.80 and about 3.25 angstroms;
- (s) an amino-pyridine where the interaction distance is between about 2.90 and about 3.20 angstroms;
- (t) an amino-pyridine where the interaction distance is between about 2.80 and about 3.10 angstroms;
- (u) an aromatic N where the interaction distance is between about 2.90 and about 3.21 angstroms;
- (v) water where the interaction distance is between about 2.60 and about 3.00 angstroms;
- (w) water where the interaction distance is between about 2.70 and about 3.07 angstroms;
- (x) an alcohol where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (y) an alcohol where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (z) a secondary amine where the interaction distance is between about 2.80 and about 3.10 angstroms;
- (aa) a secondary amine where the interaction distance is between about 3.00 and about 3.15 angstroms;

- (bb) a carbonyl where the interaction distance is between about 2.80 and about 3.15 angstroms;
- (cc) a sulfonyl where the interaction distance is between about 2.90 and about 3.00 angstroms;
- (dd) an ether where the interaction distance is between about 2.80 and about 3.10 angstroms;
- (ee) an ester where the interaction distance is between about 2.70 and about 3.05 angstroms;
- (ff) a cyano moiety where the interaction distance is between about 3.00 and about 3.30 angstroms;
- (gg) a nitro moiety where the interaction distance is between about 2.90 and about 3.07 angstroms;
- (hh) a chloride moiety where the interaction distance is between about 3.10 and about 3.60 angstroms; or
- (ii) a bromide moiety where the interaction distance is between about 3.30 and about 3.80 angstroms.

41. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a secondary amide functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a carboxylic acid;
- (c) an amino-pyridine;
- (d) a sulfonamide;
- (e) an aromatic N;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a carbonyl;
- (k) a sulfonyl;

- (l) an ether;
- (m) an ester;
- (n) a cyano moiety;
- (o) a nitro moiety;
- (p) a chloride moiety;
- (q) a bromide moiety;
- (r) a primary amide where the interaction distance is between about 2.70 and about 3.15 angstroms;
- (s) a carboxylic acid where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (t) a carboxylic acid where the interaction distance is between about 2.40 and about 3.05 angstroms;
- (u) an amino-pyridine where the interaction distance is between about 2.70 and about 3.20 angstroms;
- (v) an amino-pyridine where the interaction distance is between about 2.75 and about 3.17 angstroms;
- (w) a sulfonamide where the interaction distance is between about 2.70 and about 3.00 angstroms;
- (x) an aromatic N where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (y) water where the interaction distance is between about 2.40 and about 3.10 angstroms;
- (z) water where the interaction distance is between about 2.60 and about 3.10 angstroms;
- (aa) an alcohol where the interaction distance is between about 2.50 and about 3.04 angstroms;
- (bb) an alcohol where the interaction distance is between about 2.50 and about 3.20 angstroms;
- (cc) a primary amine where the interaction distance is between about 2.65 and about 3.20 angstroms;

- /
- (dd) a secondary amine where the interaction distance is between about 2.60 and about 3.15 angstroms;
 - (ee) a carbonyl where the interaction distance is between about 2.70 and about 3.07 angstroms;
 - (ff) a sulfonyl where the interaction distance is between about 2.60 and about 3.25 angstroms;
 - (gg) an ether where the interaction distance is between about 2.70 and about 3.16 angstroms;
 - (hh) an ester where the interaction distance is between about 2.80 and about 3.16 angstroms;
 - (ii) a cyano moiety where the interaction distance is between about 2.90 and about 3.30 angstroms;
 - (jj) a nitro moiety where the interaction distance is between about 2.80 and about 3.10 angstroms;
 - (kk) a chloride moiety where the interaction distance is between about 2.90 and about 3.40 angstroms; or
 - (ll) a bromide moiety where the interaction distance is between about 3.10 and about 3.50 angstroms.

42. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an alcohol functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) an aromatic N;
- (g) water;
- (h) a primary amine;
- (i) a secondary amine;

- (j) a carbonyl;
- (k) a sulfonyl;
- (l) an ether;
- (m) an ester;
- (n) a cyano moiety;
- (o) a nitro moiety;
- (p) a chloride moiety;
- (q) a bromide moiety;
- (r) a primary amide where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (s) a primary amide where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (t) a secondary amide where the interaction distance is between about 2.50 and about 3.04 angstroms;
- (u) a secondary amide where the interaction distance is between about 2.50 and about 3.20 angstroms;
- (v) a carboxylic acid where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (w) a carboxylic acid where the interaction distance is between about 2.40 and about 2.90 angstroms;
- (x) an amino-pyridine where the interaction distance is between about 2.60 and about 3.06 angstroms;
- (y) an amino-pyridine where the interaction distance is between about 2.75 and about 3.15 angstroms;
- (z) a sulfonamide where the interaction distance is between about 2.80 and about 3.07 angstroms;
- (aa) an aromatic N where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (bb) water where the interaction distance is between about 2.40 and about 3.03 angstroms;

- (cc) a primary amine where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (dd) a secondary amine where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (ee) a carbonyl where the interaction distance is between about 2.40 and about 3.05 angstroms;
- (ff) a sulfonyl where the interaction distance is between about 2.40 and about 3.15 angstroms;
- (gg) an ether where the interaction distance is between about 2.40 and about 3.00 angstroms;
- (hh) an ester where the interaction distance is between about 2.50 and about 3.10 angstroms;
- (ii) a cyano moiety where the interaction distance is between about 2.40 and about 3.10 angstroms;
- (jj) a nitro moiety where the interaction distance is between about 2.45 and about 3.05 angstroms;
- (kk) a chloride moiety where the interaction distance is between about 2.60 and about 3.30 angstroms; or
- (ll) a bromide moiety where the interaction distance is between about 3.00 and about 3.50 angstroms.

43. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a carboxylic acid functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) an amino-pyridine;
- (d) an aromatic N;
- (e) water;
- (f) an alcohol;
- (g) a primary amine;

- (h) a secondary amine;
- (i) a carbonyl;
- (j) an ether;
- (k) an ester;
- (l) a cyano moiety;
- (m) a nitro moiety;
- (n) a chloride moiety;
- (o) a bromide moiety;
- (p) a primary amide where the interaction distance is between about 2.80 and about 3.25 angstroms;
- (q) a primary amide where the interaction distance is between about 2.40 and about 2.80 angstroms;
- (r) a secondary amide where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (s) a secondary amide where the interaction distance is between about 2.40 and about 3.05 angstroms;
- (t) an amino-pyridine where the interaction distance is between about 2.50 and about 2.80 angstroms;
- (u) an amino-pyridine where the interaction distance is between about 2.70 and about 3.00 angstroms;
- (v) an aromatic N where the interaction distance is between about 2.54 and about 2.94 angstroms;
- (w) water where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (x) water where the interaction distance is between about 2.40 and about 3.00 angstroms;
- (y) an alcohol where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (z) an alcohol where the interaction distance is between about 2.50 and about 2.90 angstroms;

- (aa) a primary amine where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (bb) a secondary amine where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (cc) a carbonyl where the interaction distance is between about 2.40 and about 3.00 angstroms;
- (dd) an ether where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (ee) an ester where the interaction distance is between about 2.40 and about 3.05 angstroms;
- (ff) an ester where the interaction distance is between about 2.40 and about 3.10 angstroms;
- (gg) a cyano moiety where the interaction distance is between about 2.50 and about 2.80 angstroms;
- (hh) a nitro moiety where the interaction distance is between about 2.70 and about 3.05 angstroms;
- (ii) a chloride moiety where the interaction distance is between about 2.80 and about 3.20 angstroms; or
- (jj) a bromide moiety where the interaction distance is between about 3.00 and about 3.30 angstroms.

44. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a carbonyl functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a secondary sulfonamide;
- (f) water;
- (g) an alcohol;

- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is between about 2.83 and about 3.15 angstroms;
- (k) a secondary amide where the interaction distance is between about 2.70 and about 3.07 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 2.40 and about 3.00 angstroms;
- (m) an amino-pyridine where the interaction distance is between about 2.87 and about 3.10 angstroms;
- (n) a secondary sulfonamide where the interaction distance is between about 2.76 and about 3.22 angstroms;
- (o) water where the interaction distance is between about 2.55 and about 3.05 angstroms;
- (p) an alcohol where the interaction distance is between about 2.40 and about 3.05 angstroms;
- (q) a primary amine where the interaction distance is between about 2.64 and about 3.15 angstroms; or
- (r) a secondary amine where the interaction distance is between about 2.64 and about 3.15 angstroms.

45. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a cyano group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a primary sulfonamide;
- (f) a secondary sulfonamide;
- (g) water;

- (h) an alcohol;
- (i) a primary amine;
- (j) a secondary amine;
- (k) a primary amide where the interaction distance is between about 3.01 and about 3.30 angstroms;
- (l) a secondary amide where the interaction distance is between about 2.90 and about 3.30 angstroms;
- (m) a carboxylic acid where the interaction distance is between about 2.57 and about 3.00 angstroms;
- (n) an amino-pyridine where the interaction distance is between about 2.84 and about 3.33 angstroms;
- (o) a primary sulfonamide where the interaction distance is about 2.99 angstroms;
- (p) a secondary sulfonamide where the interaction distance is between about 2.83 and about 3.00 angstroms;
- (q) water where the interaction distance is between about 2.78 and about 3.20 angstroms;
- (r) an alcohol where the interaction distance is between about 2.72 and about 3.13 angstroms;
- (s) a primary amine where the interaction distance is between about 2.84 and about 3.27 angstroms; or
- (t) a secondary amine where the interaction distance is between about 2.84 and about 3.30 angstroms.

46. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a sulfonyl group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a primary sulfonamide;
- (d) a secondary sulfonamide;

- (e) water;
- (f) an alcohol;
- (g) a primary amine;
- (h) a secondary amine;
- (i) a primary amide where the interaction distance is about 2.92 angstroms;
- (j) a secondary amide where the interaction distance is between about 2.95 and about 3.25 angstroms;
- (k) a primary sulfonamide where the interaction distance is between about 2.85 and about 3.10 angstroms;
- (l) a secondary sulfonamide where the interaction distance is between about 2.85 and about 3.20 angstroms;
- (m) water where the interaction distance is between about 2.84 and about 3.00 angstroms;
- (n) an alcohol where the interaction distance is between about 2.65 and about 3.15 angstroms;
- (o) a primary amine where the interaction distance is between about 2.93 and about 3.32 angstroms; or
- (p) a secondary amide where the interaction distance is between about 2.75 and about 3.32 angstroms.

47. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an aromatic N as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) water;
- (f) an alcohol;
- (g) a primary amine;
- (h) a secondary amine;

- (i) a primary amide where the interaction distance is between about 2.90 and about 3.21 angstroms;
- (j) a secondary amide where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (k) a carboxylic acid where the interaction distance is between about 2.54 and about 2.94 angstroms;
- (l) an amino-pyridine where the interaction distance is between about 2.70 and about 3.20 angstroms;
- (m) water where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (n) an alcohol where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (o) a primary amine where the interaction distance is between about 2.92 and about 3.26 angstroms; or
- (p) a secondary amine where the interaction distance is between about 2.73 and about 3.25 angstroms.

48. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an ether functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is between about 2.80 and about 3.10 angstroms;

- (k) a secondary amide where the interaction distance is between about 2.70 and about 3.16 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 2.50 and about 3.02 angstroms;
- (m) an amino-pyridine where the interaction distance is between about 2.80 and about 3.20 angstroms;
- (n) a sulfonamide where the interaction distance is less than about 3.20 angstroms;
- (o) water where the interaction distance is between about 2.40 and about 3.15 angstroms;
- (p) an alcohol where the interaction distance is between about 2.40 and about 3.00 angstroms;
- (q) a primary amine where the interaction distance is between about 2.75 and about 3.25 angstroms; or
- (r) a secondary amine where the interaction distance is between about 2.60 and about 3.25 angstroms.

49. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a chloride moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is between about 3.10 and about 3.60 angstroms;

- (k) a secondary amide where the interaction distance is between about 2.90 and about 3.30 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 2.80 and about 3.30 angstroms;
- (m) an amino-pyridine where the interaction distance is between about 3.10 and about 3.45 angstroms;
- (n) a sulfonamide where the interaction distance is less than about 3.35 angstroms;
- (o) water where the interaction distance is between about 2.70 and about 3.30 angstroms;
- (p) an alcohol where the interaction distance is between about 2.50 and about 3.30 angstroms;
- (q) a primary amine where the interaction distance is between about 3.00 and about 3.50 angstroms; or
- (r) a secondary amine where the interaction distance is between about 2.90 and about 3.40 angstroms.

50. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an organochloride moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is between about 3.18 and about 3.21 angstroms;

- (k) a secondary amide where the interaction distance is between about 3.20 and about 3.27 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 2.90 and about 3.23 angstroms;
- (m) an amino-pyridine where the interaction distance is between about 3.28 and about 3.33 angstroms;
- (n) a sulfonamide where the interaction distance is less than about 3.50 angstroms;
- (o) water where the interaction distance is between about 2.79 and about 3.26 angstroms;
- (p) an alcohol where the interaction distance is between about 2.90 and about 3.29 angstroms;
- (q) a primary amine where the interaction distance is between about 3.21 and about 3.29 angstroms; or
- (r) a secondary amine where the interaction distance is between about 3.26 and about 3.30 angstroms.

51. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a bromide moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) an alcohol;
- (f) a primary amine;
- (g) a secondary amine;
- (h) a primary amide where the interaction distance is between about 3.30 and about 3.80 angstroms;
- (i) a secondary amide where the interaction distance is between about 3.10 and about 3.80 angstroms;

- (j) a carboxylic acid where the interaction distance is between about 3.00 and about 3.30 angstroms;
- (k) an amino-pyridine where the interaction distance is between about 3.20 and about 3.50 angstroms;
- (l) an alcohol where the interaction distance is between about 3.00 and about 3.50 angstroms;
- (m) a primary amine where the interaction distance is between about 3.20 and about 3.60 angstroms; or
- (n) a secondary amine where the interaction distance is between about 3.10 and about 3.60 angstroms.

52. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an organobromide moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is less than about 3.50 angstroms;
- (k) a secondary amide where the interaction distance is less than about 3.50 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 3.01 and about 3.31 angstroms;
- (m) an amino-pyridine where the interaction distance is less than about 3.50 angstroms;

- (n) a sulfonamide where the interaction distance is less than about 3.50 angstroms;
- (o) water where the interaction distance is between about 3.14 and about 3.27 angstroms;
- (p) an alcohol where the interaction distance is between about 2.90 and about 3.36 angstroms;
- (q) a primary amine where the interaction distance is less than about 3.50 angstroms; or
- (r) a secondary amine where the interaction distance is between about 3.20 and about 3.39 angstroms.

53. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an organoiodide moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) an aromatic N;
- (f) an alcohol;
- (g) a primary amine;
- (h) a secondary amine;
- (i) a primary amide where the interaction distance is less than about 3.80 angstroms;
- (j) a secondary amide where the interaction distance is less than about 3.80 angstroms;
- (k) a carboxylic acid where the interaction distance is less than about 3.80 angstroms;
- (l) an amino-pyridine where the interaction distance is less than about 3.80 angstroms;

- (m) an aromatic N where the interaction distance is between about 2.70 and about 3.23 angstroms;
- (n) an alcohol where the interaction distance is between about 2.90 and about 3.48 angstroms;
- (o) a primary amine where the interaction distance is between about 3.25 and about 3.42 angstroms; or
- (p) a secondary amine where the interaction distance is between about 2.71 and about 2.87 angstroms.

54. The pharmaceutical co-crystal composition according to claims 1 or 3, wherein the API forms a dimeric primary amide structure via hydrogen bonds with an R^2_2 (8) motif, and further wherein the composition comprises:

- (a) at least one hydrogen bond donor;
- (b) at least two hydrogen bond donors;
- (c) at least three hydrogen bond donors;
- (d) at least four hydrogen bond donors;
- (e) at least one hydrogen bond acceptor;
- (f) at least two hydrogen bond acceptors;
- (g) at least one hydrogen bond donor and one hydrogen bond acceptor;
- (h) at least two hydrogen bond donors and one hydrogen bond acceptor;
- (i) at least one hydrogen bond donor and two hydrogen bond acceptors;
- (j) at least two hydrogen bond donors and two hydrogen bond acceptors; or
- (k) at least three hydrogen bond donors and one hydrogen bond acceptor.

55. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 3.77, 9.63, and 17.78 degrees;

- (ii) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 9.63, 20.44, and 22.10 degrees;
- (iii) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 14.76 and 21.19 degrees;
- (iv) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 3.77 and 19.31 degrees;
- (v) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 17.78 and 20.44 degrees;
- (vi) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises a peak at 3.77 degrees; or
- (vii) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises a peak at 17.78 degrees;
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a celecoxib:nicotinamide co-crystal and said DSC thermogram comprises an endothermic transition at about 130 degrees C; or
- (c) the co-crystal is characterized by a Raman spectrum comprising peaks expressed in terms of cm^{-1} , wherein:
 - (i) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises peaks at 1599, 1162, and 1044;
 - (ii) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises peaks at 1618, 1044, and 796;
 - (iii) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises peaks at 1599 and 1044;
 - (iv) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises a peak at 1044;
 - (v) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises a peak at 1618; or
 - (vi) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises a peak at 1599.

56. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 8.73, 13.13, and 18.45 degrees;
 - (ii) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 8.73, 11.89, and 17.75 degrees;
 - (iii) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 16.37, 18.45, and 23.11 degrees;
 - (iv) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 17.75 and 20.75 degrees;
 - (v) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 8.73 and 13.13 degrees;
 - (vi) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 11.89 and 22.37 degrees;
 - (vii) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 8.73 degrees;
 - (viii) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 11.89 degrees; or
 - (ix) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 17.75 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a celecoxib:18-crown-6 co-crystal and said DSC thermogram comprises an endothermic transition at about 190 degrees C.

57. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (i) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 11.07, 13.83, and 18.03 degrees;
- (ii) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 10.79, 16.13, and 18.51 degrees;
- (iii) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 12.17, 18.03, and 21.43 degrees;
- (iv) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 11.07 and 18.03 degrees;
- (v) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 12.17 and 18.51 degrees;
- (vi) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 16.13 and 21.43 degrees;
- (vii) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 11.07 degrees; or
- (viii) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 13.83 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a topiramate:18-crown-6 co-crystal and said DSC thermogram comprises an endothermic transition at about 135 degrees C.

58. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 4.89, 8.65, and 17.15 degrees;

- (ii) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 17.15, 23.95, and 25.53 degrees;
- (iii) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 8.65, 19.71, and 26.71 degrees;
- (iv) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 4.89 and 17.15 degrees;
- (v) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 8.65 and 23.95 degrees;
- (vi) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 23.95 and 25.53 degrees;
- (vii) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises a peak at 4.89 degrees; or
- (viii) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises a peak at 17.15 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is an olanzapine:nicotinamide form I co-crystal and said DSC thermogram comprises an endothermic transition at about 126 degrees C.

59. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 8.65, 17.53, and 24.19 degrees;

- (b) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 11.87, 14.53, and 19.69 degrees;
- (c) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 8.65, 17.53, and 18.09 degrees;
- (d) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 11.87 and 17.53 degrees;
- (e) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 8.65 and 14.53 degrees;
- (f) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 11.87 and 24.19 degrees;
- (g) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises a peak at 8.65 degrees;
- (h) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises a peak at 17.53 degrees; or
- (i) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises a peak at 11.87 degrees.

60. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 6.41, 12.85, and 18.67 degrees;
- (b) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 12.85, 21.85, and 24.37 degrees;

- (c) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 14.91, 18.67, and 21.85 degrees;
- (d) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 6.41 and 12.85 degrees;
- (e) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 6.41 and 18.67 degrees;
- (f) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 12.85 and 18.67 degrees;
- (g) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises a peak at 6.41 degrees;
- (h) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises a peak at 12.85 degrees; or
- (i) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises a peak at 18.67 degrees.

61. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 3.01, 16.17, and 17.29 degrees;
 - (ii) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.01, 15.87, and 24.47 degrees;

- (iii) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.05, 20.41, and 22.27 degrees;
- (iv) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 3.01 and 17.29 degrees;
- (v) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.01 and 16.17 degrees;
- (vi) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.05 and 22.27 degrees;
- (vii) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 3.01 degrees;
- (viii) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 16.17 degrees; or
- (ix) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 17.29 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said DSC thermogram comprises an endothermic transition at about 160 degrees C.

62. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.61, 5.89, and 10.57 degrees;
 - (ii) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.23, 19.05, and 20.79 degrees;

- (iii) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.51, 16.23, and 16.93 degrees;
- (iv) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.61 and 20.79 degrees;
- (v) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 5.89 and 19.05 degrees;
- (vi) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.57 and 16.23 degrees;
- (vii) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 4.61 degrees;
- (viii) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 5.89 degrees;
- (ix) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 10.57 degrees; or
- (x) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 19.05 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said DSC thermogram comprises an endothermic transition at about 180 degrees C.

63. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.13, 6.19, and 8.49 degrees;

- (ii) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.19, 16.13, and 17.23 degrees;
- (iii) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.49, 18.07, and 20.79 degrees;
- (iv) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.13 and 8.49 degrees;
- (v) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.19 and 20.79 degrees;
- (vi) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 16.13 and 17.23 degrees;
- (vii) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 4.13 degrees;
- (viii) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 6.19 degrees; or
- (ix) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 8.49 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said DSC thermogram comprises an endothermic transition at about 181 degrees C.

64. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.07, 8.85, and 17.05 degrees;

- (ii) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.93, 20.49, and 22.85 degrees;
- (iii) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.85, 15.93 and 26.17 degrees;
- (iv) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.07 and 17.05 degrees;
- (v) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.85 and 21.27 degrees;
- (vi) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.07 and 8.85 degrees;
- (vii) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises a peak at 6.07 degrees;
- (viii) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises a peak at 8.85 degrees; or
- (ix) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises a peak at 17.05 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said DSC thermogram comprises an endothermic transition at about 154 degrees C.

65. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 3.73, 10.95, and 13.83 degrees;

- (ii) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 16.53, 17.75, and 19.65 degrees;
 - (iii) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.95, 16.53, and 21.11 degrees;
 - (iv) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 3.73 and 10.95 degrees;
 - (v) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 13.83 and 17.75 degrees;
 - (vi) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 16.53 and 19.65 degrees;
 - (vii) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 3.73 degrees;
 - (viii) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 10.95 degrees; or
 - (ix) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 17.75 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said DSC thermogram comprises an endothermic transition at about 162 degrees C.

66. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (i) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 5.11, 9.35, and 16.87 degrees;
- (ii) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 16.87, 18.33, and 19.53 degrees;
- (iii) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 9.35, 19.53, and 22.89 degrees;
- (iv) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 5.11 and 9.35 degrees;
- (v) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 16.87 and 19.53 degrees;
- (vi) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 18.33 and 22.89 degrees;
- (vii) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises a peak at 5.11 degrees;
- (viii) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises a peak at 9.35 degrees; or
- (ix) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises a peak at 16.87 degrees;
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a modafinil:malonic acid form I co-crystal and said DSC thermogram comprises an endothermic transition at about 106 degrees C; or
- (c) the co-crystal is characterized by a Raman spectrum comprising peaks expressed in terms of cm^{-1} , wherein:
 - (i) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1004, 633, and 265;

- (ii) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1032, 1601, and 767;
- (iii) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1004 and 633;
- (iv) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1183 and 767; or
- (v) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1601 and 718.

67. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 5.90, 9.54, and 20.01 degrees;
- (b) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 15.79, 18.02, and 21.66 degrees;
- (c) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 9.54, 20.01, and 25.30 degrees;
- (d) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 5.90 and 9.54 degrees;
- (e) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 5.90 and 20.01 degrees;
- (f) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 9.54 and 20.01 degrees;

- (g) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 5.90 degrees; or
- (h) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 9.54 degrees.

68. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.51, 15.97, and 20.03 degrees;
- (b) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 14.91, 19.01, and 22.75 degrees;
- (c) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.97, 25.03, and 25.71 degrees;
- (d) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.51 and 15.97 degrees;
- (e) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 20.03 and 25.03 degrees;
- (f) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.97 and 25.03 degrees;
- (g) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises a peak at 9.51 degrees;
- (h) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises a peak at 15.97 degrees; or
- (i) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises a peak at 20.03 degrees.

69. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.69, 6.15, and 9.61 degrees;
- (b) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.23, 19.97, and 21.83 degrees;
- (c) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.69, 10.23, and 21.83 degrees;
- (d) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.69 and 19.97 degrees;
- (e) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.15 and 9.61 degrees;
- (f) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.69 and 6.15 degrees;
- (g) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises a peak at 4.69 degrees;
- (h) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises a peak at 9.61 degrees; or
- (i) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises a peak at 19.97 degrees.

70. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a 5-fluorouracil: urea co-crystal and said X-ray diffraction pattern comprises peaks at 11.23, 13.27, and 16.93 degrees;
 - (ii) said co-crystal is a 5-fluorouracil: urea co-crystal and said X-ray diffraction pattern comprises peaks at 12.69, 20.37, and 25.55 degrees;
 - (iii) said co-crystal is a 5-fluorouracil: urea co-crystal and said X-ray diffraction pattern comprises peaks at 17.93, 23.65, and 26.87 degrees;

- (iv) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises peaks at 11.23 and 16.93 degrees;
- (v) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises peaks at 23.65 and 32.49 degrees;
- (vi) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises peaks at 13.27 and 25.55 degrees;
- (vii) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises a peak at 11.23 degrees;
- (viii) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises a peak at 16.93 degrees; or
- (ix) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises a peak at 25.55 degrees;
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a 5-fluorouracil:urea co-crystal and said DSC thermogram comprises an endothermic transition at about 208 degrees C; or
- (c) the co-crystal is characterized by a Raman spectrum comprising peaks expressed in terms of cm^{-1} , wherein:
 - (i) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 1347, 1024, and 757;
 - (ii) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 644, 545, and 472;
 - (iii) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 1680 and 1347;
 - (iv) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 1347 and 757; or
 - (v) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 1024 and 757.

71. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.57, 13.23, and 21.13 degrees;
- (b) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 14.31, 17.89, and 26.57 degrees;
- (c) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.57, 21.13, and 25.73 degrees;
- (d) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.57 and 21.13 degrees;
- (e) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 13.23 and 26.57 degrees;
- (f) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 17.89 and 24.41 degrees;
- (g) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 8.57 degrees;
- (h) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 13.23 degrees; or
- (i) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 21.13 degrees.

72. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 9.97, 11.57, and 15.67 degrees;
- (b) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 14.53, 19.05, and 20.31 degrees;
- (c) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 16.61, 20.65, and 23.63 degrees;

- (d) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 9.97 and 10.43 degrees;
- (e) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 12.83 and 15.67 degrees;
- (f) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 14.53 and 20.31 degrees;
- (g) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 10.43 degrees;
- (h) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 12.83 degrees; or
- (i) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 20.31 degrees.

73. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 6.85, 13.75, and 18.71 degrees;
- (b) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 15.93, 23.27, and 24.17 degrees;
- (c) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 18.17, 20.93, and 27.75 degrees;
- (d) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 6.85 and 18.71 degrees;
- (e) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 13.75 and 23.27 degrees;
- (f) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 15.93 and 24.17 degrees;
- (g) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises a peak at 6.85 degrees;

- (h) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises a peak at 13.75 degrees; or
- (i) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises a peak at 18.71 degrees.

74. The co-crystal according to claim 11, wherein the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is an acetaminophen:4,4-bipyridine:water co-crystal and said DSC thermogram comprises an endothermic transition at about 58 degrees C.

75. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises peaks at 5.2, 15.1, and 16.7 degrees;
 - (ii) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises peaks at 11.1, 16.2, and 17.8 degrees;
 - (iii) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises peaks at 5.2 and 15.1 degrees;
 - (iv) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises peaks at 15.1 and 19.4 degrees;
 - (v) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises a peak at 5.2 degrees; or
 - (vi) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises a peak at 15.1 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a phenytoin:pyridone co-crystal and said DSC thermogram comprises an endothermic transition at about 233 degrees C.

76. The co-crystal according to claim 11, wherein the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is an aspirin:4,4-bipyridine co-crystal and said DSC thermogram comprises an endothermic transition at about 95 degrees C.

77. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 3.4 and 6.9 degrees;
 - (ii) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 3.4 and 10.4 degrees;
 - (iii) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 10.4 and 17.3 degrees;
 - (iv) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises a peak at 3.4 degrees; or
 - (v) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises a peak at 10.4 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said DSC thermogram comprises an endothermic transition at about 119 degrees C.

78. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 16.8, 18.1, and 20.0 degrees;
 - (ii) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 18.1, 21.3, and 25.0 degrees;

- (iii) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 16.8 and 19.0 degrees;
- (iv) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 17.1 and 21.3 degrees;
- (v) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises a peak at 16.8 degrees; or
- (vi) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises a peak at 19.0 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said DSC thermogram comprises an endothermic transition at about 163 degrees C.

79. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises peaks at 3.6, 17.3, and 18.4 degrees;
 - (ii) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises peaks at 17.3, 19.1, and 23.8 degrees;
 - (iii) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises peaks at 18.1 and 22.3 degrees;
 - (iv) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises peaks at 3.6 and 18.4 degrees;
 - (v) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises a peak at 3.6 degrees; or

- (vi) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises a peak at 19.1 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said DSC thermogram comprises an endothermic transition at about 164 degrees C.

80. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises peaks at 8.5, 11.9, and 15.1 degrees;
 - (ii) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises peaks at 10.6, 14.4, and 18.0 degrees;
 - (iii) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises peaks at 11.9 and 23.7 degrees;
 - (iv) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises peaks at 8.5 and 14.4 degrees;
 - (v) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises a peak at 8.5 degrees; or
 - (vi) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises a peak at 11.9 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said DSC thermogram comprises an endothermic transition at about 128 degrees C.

81. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 8.8, 13.2, and 15.6 degrees;
 - (ii) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 13.2, 15.6, and 20.4 degrees;
 - (iii) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 8.8 and 26.4 degrees;
 - (iv) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 13.2 and 15.6 degrees;
 - (v) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises a peak at 8.8 degrees; or
 - (vi) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises a peak at 15.6 degrees; or
 - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:nicotinamide co-crystal and said DSC thermogram comprises an endothermic transition at about 157 degrees C.
82. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises peaks at 6.9, 13.6, and 15.3 degrees;
 - (ii) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises peaks at 14.0, 20.2, and 28.3 degrees;

- (iii) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises peaks at 12.2 and 21.3 degrees;
 - (iv) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises peaks at 14.0 and 20.2 degrees;
 - (v) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises a peak at 14.0 degrees; or
 - (vi) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises a peak at 21.3 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:saccharin co-crystal and said DSC thermogram comprises an endothermic transition at about 177 degrees C.

83. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.14 and 17.44 degrees;
 - (ii) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.29 and 21.17 degrees;
 - (iii) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.14 and 15.29 degrees;
 - (iv) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises peaks at 21.17 and 31.41 degrees;
 - (v) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises a peak at 10.14 degrees; or

- (vi) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises a peak at 17.44 degrees; or
 - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said DSC thermogram comprises an endothermic transition at about 191 degrees C.
- 84. The co-crystal according to claim 11, wherein:
 - (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
 - (i) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.89, 12.23, and 16.25 degrees;
 - (ii) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.89, 17.05, and 18.47 degrees;
 - (iii) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises peaks at 12.23 and 17.05 degrees;
 - (iv) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.89 and 21.95 degrees;
 - (v) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises a peak at 10.89 degrees; or
 - (vi) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises a peak at 16.25 degrees; or
 - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:trimesic acid co-crystal and said DSC thermogram comprises an endothermic transition at about 273 degrees C.

85. The co-crystal of claim 1, specifically excluding a co-crystal selected from the group consisting of: nabumetone:2,3-naphthalenediol, fluoxetine HCl:benzoic acid, fluoxetine HCl:succinic acid, acetaminophen:piperazine, acetaminophen:theophylline, theophylline:salicylic acid, theophylline:p-hydroxybenzoic acid, theophylline:sorbic acid, theophylline:1-hydroxy-2-naphthoic acid, theophylline:glycolic acid, theophylline:2,5-dihydroxybenzoic acid, theophylline:chloroacetic acid, bis(diphenylhydantoin):9-ethyladenine acetylacetone solvate, bis(diphenylhydantoin):9-ethyladenine 2,4-pentanedione solvate, 5,5-diphenylbarbituric acid:9-ethyladenine, bis(diphenylhydantoin):9-ethyladenine, 4-aminobenzoic acid:4-aminobenzonitrile, sulfadimidine:salicylic acid, 8-hydroxyquinolinium 4-nitrobenzoate:4-nitrobenzoic acid, sulfaproxyline:caffeine, retro-inverso-isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-(N-((2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl)-L-histidylamino)butyrate:cinnamic acid monohydrate, benzoic acid:isonicotinamide, 3-(2-N',N'-(dimethylhydrazino)-4-thiazolylmethylthio)-N''-sulfamoylpropionamidine:maleic acid, diglycine hydrochloride ($C_2H_5NO_2:C_2H_6NO_2^+Cl^-$), octadecanoic acid:3-pyridinecarboxamide, cis-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide hydrochloride:oxalic acid, trans-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide oxalate:oxalic acid dihydrate, bis(1-(3-((4-(2-isopropoxyphenyl)-1-piperazinyl)methyl)benzoyl)piperidine)succinate:succinic acid, bis(p-cyanophenyl)imidazolylmethane:succinic acid, cis-1-((4-(1-imidazolylmethyl)cyclohexyl)methyl)imidazole:succinic acid, (+)-2-(5,6-dimethoxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline:(+)-dibenzoyl-D-tartaric acid, raclopride:tartaric acid, 2,6-diamino-9-ethylpurine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:bis(2-aminopyridine), 5,5-diethylbarbituric acid:acetamide, 5,5-diethylbarbituric acid:KI₃, 5,5-diethylbarbituric acid:urea, bis(barbital):hexamethylphosphoramide, 5,5-diethylbarbituric acid:imidazole, barbital:1-methylimidazole, 5,5-diethylbarbituric acid:N-methyl-2-pyridone, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine:5,5-diethylbarbituric acid, bis(barbital):caffeine, bis(barbital):1-methylimidazole, bis(beta-cyclodextrin):bis(barbital) hydrate, tetrakis(beta-cyclodextrin):tetrakis(barbital), 9-ethyladenine:5,5-diethylbarbituric acid,

barbital:N'-(*p*-cyanophenyl)-N-(*p*-iodophenyl)melamine, barbital:2-amino-4-(*m*-bromophenylamino)-6-chloro-1,3,5-triazine, 5,5-diethylbarbituric acid:N,N'-diphenylmelamine, 5,5-diethylbarbituric acid:N,N'-bis(*p*-chlorophenyl)melamine, N,N'-bis(*p*-bromophenyl)melamine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:N,N'-bis(*p*-iodophenyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(*p*-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(*m*-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(*m*-chlorophenyl)melamine, N,N'-Bis(*m*-methylphenyl)melamine:barbital, N,N'-bis(*m*-chlorophenyl)melamine:barbital tetrahydrofuran solvate, 5,5-diethylbarbituric acid:N,N'-bis(*tert*-butyl)melamine, 5,5-diethylbarbituric acid:N,N'-di(*tert*-butyl)melamine, 6,6'-diquinolyl ether:5,5-diethylbarbituric acid, 5-*tert*-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, N,N'-bis(4-carboxymethylphenyl)melamine:barbital ethanol solvate, N,N'-bis(4-*tert*-butylphenyl)melamine:barbital, tris(5,17-N,N'-bis(4-amino-6-(butylamino)-1,3,5-triazin-2-yl)diamino-11,23-dinitro-25,26,27,28-tetrapropoxycalix(4)arene):hexakis(diethylbarbituric acid) toluene solvate, N,N'-bis(*m*-fluorophenyl)melamine:barbital, N,N'-bis(*m*-bromophenyl)melamine:barbital acetone solvate, N,N'-bis(*m*-iodophenyl)melamine:barbital acetonitrile solvate, N,N'-bis(*m*-trifluoromethylphenyl)melamine:barbital acetonitrile solvate, aminopyrine:barbital, N,N'-bis(4-fluorophenyl)melamine:barbital, N,N'-bis(4-trifluoromethylphenyl)melamine:barbital, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine:barbital, hydroxybutyrate:hydroxyvalerate, 2-aminopyrimidine:succinic acid, 1,3-bis(((6-methylpyrid-2-yl)amino)carbonyl)benzene:glutaric acid, 5-*tert*-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, bis(dithiobiuret-S,S')nickel(II):diuracil, platinum 3,3'-dihydroxymethyl-2,2'-bipyridine dichloride:AgF₃CSO₃, 4,4'-bipyridyl:isophthalic acid, 4,4'-bipyridyl:1,4-naphthalenedicarboxylic acid, 4,4'-bipyridyl:1,3,5-cyclohexane-tricarboxylic acid, 4,4'-bipyridyl:tricarballic acid, urotropin:azelaic acid, insulin:C8-HI (octanoyl-N^c-LysB29-human insulin), isonicotinamide:cinnamic acid, isonicotinamide:3-hydroxybenzoic acid, isonicotinamide:3-N,N-dimethylaminobenzoic acid, isonicotinamide:3,5-bis(trifluoromethyl)-benzoic acid, isonicotinamide:d,l-mandelic acid,

isonicotinamide:chloroacetic acid, isonicotinamide:fumaric acid monoethyl ester, isonicotinamide:12-bromododecanoic acid, isonicotinamide:fumaric acid, isonicotinamide:succinic acid, isonicotinamide:4-ketopimelic acid, isonicotinamide:thiodiglycolic acid, 1,3,5-cyclohexane-tricarboxylic acid:hexamethyltetramine, 1,3,5-cyclohexane-tricarboxylic acid:4,7-phenanthroline, 4,7-phenanthroline:oxalic acid, 4,7-phenanthroline:terephthalic acid, 4,7-phenanthroline:1,3,5-cyclohexane-tricarboxylic acid, 4,7-phenanthroline:1,4-naphthalenedicarboxylic acid, pyrazine:methanoic acid, pyrazine:ethanoic acid, pyrazine:propanoic acid, pyrazine:butanoic acid, pyrazine:pentanoic acid, pyrazine:hexanoic acid, pyrazine:heptanoic acid, pyrazine:octanoic acid, pyrazine:nonanoic acid, pyrazine:decanoic acid, diammine-(deoxy-quanyl-quanyl-N⁷,N⁷)-platinum:tris(glycine) hydrate, 2-aminopyrimidine:p-phenylenediacetic acid, bis(2-aminopyrimidin-1-ium)fumarate:fumaric acid, 2-aminopyrimidine:indole-3-acetic acid, 2-aminopyrimidine:N-methylpyrrole-2-carboxylic acid, 2-aminopyrimidine:thiophen-2-carboxylic acid, 2-aminopyrimidine:(+)-camphoric acid, 2,4,6-Trinitrobenzoic acid:2-aminopyrimidine, 2-aminopyrimidine:4-aminobenzoic acid, 2-aminopyrimidine:bis(phenoxyacetic acid), 2-aminopyrimidine:(2,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:(3,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:indole-2-carboxylic acid, 2-aminopyrimidine:terephthalic acid, 2-aminopyrimidine:bis(2-nitrobenzoic acid), 2-aminopyrimidine:bis(2-aminobenzoic acid), 2-aminopyrimidine:3-aminobenzoic acid, 2-hexeneoic acid:isonicotinamide, 4-nitrobenzoic acid:isonicotinamide, 3,5-dinitrobenzoic acid:isonicotinamide:4-methylbenzoic acid, 2-amino-5-nitropyrimidine:2-amino-3-nitropyridine, 3,5-dinitrobenzoic acid:4-chlorobenzamide, 3-dimethylaminobenzoic acid:4-chlorobenzamide, fumaric acid:4-chlorobenzamide, oxine:4-nitrobenzoic acid, oxine:3,5-dinitrobenzoic acid, oxine:3,5-dinitrosalicylic acid, 3-[2-(N',N'-dimethylhydrazino)-4-thiazolylmethylthio]-N²-sulfamoylpropionamidine:maleic acid, 5-fluorouracil:9-ethylhypoxanthine, 5-fluorouracil:cytosine dihydrate, 5-fluorouracil:theophylline monohydrate, stearic acid:nicotinamide, cis-1-{[4-(1-imidazolylmethyl)cyclohexyl]methyl}imidazole:succinic acid, CGS18320B:succinic acid, sulfaproxyline:caffeine, 4-aminobenzoic acid:4-aminobenzonitrile, 3,5-

dinitrobenzoic acid:isonicotinamide:3-methylbenzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-(dimethylamino)benzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-hydroxy-3-methoxycinnamic acid, isonicotinamide:oxalic acid, isonicotinamide:malonic acid, isonicotinamide:succinic acid, isonicotinamide:glutaric acid, isonicotinamide:adipic acid, benzoic acid:isonicotinamide, mazapertine:succinate, betaine:dichloronitrophenol, betainepyridine:dichloronitrophenol, betainepyridine:pentachlorophenol, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:methyl 2,4-dihydroxybenzoate, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxypropiophenone, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxyacetophenone, squaric acid:4,4'-dipyridylacetylene, squaric acid:1,2-bis(4-pyridyl)ethylene, chloranilic acid:1,4-bis[(4-pyridyl)ethynyl]benzene, 4,4'-bipyridine:phthalic acid, 4,4'-dipyridylacetylene:phthalic acid, bis(pentamethylcyclopentadienyl)iron:bromanilic acid, bis(pentamethylcyclopentadienyl)iron:chloranilic acid, bis(pentamethylcyclopentadienyl)iron:cyananilic acid, pyrazinotetrathiafulvalene:chloranilic acid, phenol:pentafluorophenol, co-crystals of itraconazole, and co-crystals of topiramate.




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11




FIG. 12




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 38A




FIG. 38B




FIG. 39A




FIG. 39B




FIG. 40A




FIG. 40C




FIG. 40B




FIG. 40D




FIG. 41A




FIG. 41C




FIG. 41B




FIG. 41D




FIG. 42A




FIG. 42C




FIG. 42B




FIG. 42D




FIG. 43A




FIG. 43B




FIG. 44A




FIG. 44B




FIG. 45




FIG. 46




FIG. 47




FIG. 48




FIG. 49




FIG. 50




FIG. 51A




FIG. 51B




FIG. 52A




FIG. 52B




FIG. 53A




FIG. 53B




FIG. 54A




FIG. 54B




FIG. 55A




FIG. 55B




FIG. 56





FIG. 57



Dissolution profiles into 0.1 N HCl at 25 °C

Sporanox Beads (amorphous freebase) (Rectangle)

I-Malate (Inverted triangle)

I-Tartrate (Oval)

Succinate (Triangle)

Crystalline Freebase (Diamond)

FIG. 58






FIG. 59


1. One-dimensional (linear) hydrogen-bonded chains:



2. Isolated rings:



3. Extended Networks:



4. Isolated triads:




FIG. 60




FIG. 61